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Abstract 
Dendritic cells (DC) play a pivotal role in the initiation of T cell responses and earlier studies 
have shown that their survival is important for the generation of effective immune responses. 
Cytotoxic T lymphocytes (CTL) and natural killer T (NKT) cells have been proposed to 
regulate the survival of antigen presenting DC through their ability to kill cells expressing 
specific antigen via secretion of perforin, a protein contained in cytotoxic granules. Perforin 
knockout (PKO) mice generate amplified immune responses to DC immunization, suggesting 
a link between defective cytotoxicity and increased T cell responses. The studies in this thesis 
used PKO mice and in vivo models of CD8+ T cells and NKT cell immune responses to 
determine whether CTL and NKT cells eliminate DC in a perforin-dependent manner, and 
whether DC elimination is a mechanism to regulate T cell responses.  
 
During a primary influenza infection C57BL/6 and PKO mice generated a similar influenza 
specific CD8+ immune response. No significant difference in the percentage of influenza 
epitope PA224-233 specific T cells was observed between C57BL/6 and PKO mice during a 
secondary influenza infection, but PKO mice had a significantly reduced T cell response 
directed towards the dominant influenza epitope, NP366-374. The reduced T cell response in 
PKO mice was not due to differences in activation or differentiation status of specific T cells 
compared to C57BL/6 mice. Therefore, the extended DC survival in PKO after secondary 
influenza viral infection, recently reported by other authors, does not appear to correlate with 
increased expansion of virus specific CD8+ T cells in infected mice.  
 
The role of NKT cells in DC elimination was assessed in vivo using the NKT cell ligand α-
Galactosylceramide (α-GalCer). Injection of α-GalCer in C57BL/6 mice induced a dramatic 
decline in the number of splenic CD8+ DC. A similar decrease in CD8+ DC numbers was 
observed in PKO mice, suggesting that the mechanism of DC loss did not involve perforin-
mediated killing. In contrast, treatment with a TNF-α neutralizing antibody substantially 
reduced the decline in CD8+ DC numbers. This reduction in splenic CD8+ DC occurred as 
early as 15 hr after α-GalCer treatment, and did not affect generation of CD8+ T cell responses 
or the ability of α-GalCer treatment to provide tumour protection. 
 
 iii 
Taken together, these results suggest that multiple cells and mechanisms can regulate DC 
survival in vivo. CTL regulate DC survival in vivo in a perforin-dependent manner, but this 
does not necessarily affect the magnitude of the resulting immune responses. NKT cells also 
affect the survival of DC in vivo, but in a perforin-independent, cytokine-dependent manner. 
These findings provide additional knowledge about the in vivo involvement of perforin in 
regulating DC survival by CTL and NKT cells and the effects this has on T cell responses.  
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The main role of the immune system is to protect the host from foreign pathogens, 
including viral, bacterial, fungal and parasitic infections. Two branches of the immune 
system exist: innate and adaptive immunity. The innate immune system provides the first 
line of defense against environmental organisms and is essential for the control of common 
infections. Neutrophils and macrophages eliminate invading pathogens by phagocytosis, 
while natural killer (NK) cells directly kill infected cells. In addition, natural killer T 
(NKT) cells are rapidly activated upon recognition of bacterial lipids and enhance immune 
responses. Dendritic cells (DC) take up foreign antigen and present parts of these antigens 
on their cell surface for recognition by other cells of the immune system. In contrast, the 
adaptive immune response is activated in response to specific antigens and employs 
antigen specific T and B lymphocytes for efficient pathogen elimination. Furthermore, the 
adaptive immune response also provides protection against subsequent re-infection with 
the same pathogen, a phenomenon known as immunological memory.  
 
DC play a central role in immune responses because they interact with cells from both the 
innate and adaptive branches of the immune system. DC can directly encounter pathogens 
that induce the secretion of cytokines, which in turn can activate cells of the innate 
immune system, such as neutrophils, macrophages, NK and NKT cells, ultimately 
resulting in pathogen clearance. In addition, DC can directly interact with T and NKT cells 
resulting in their activation, leading to the eradication of the invading pathogens. DC-NKT 
cell interactions also result in the activation of NK cells, T and B cells, further amplifying 
the immune response. Thus, through several different interactions, DC provide an 
important link between innate and adaptive immunity leading to the generation of an 
effective immune response. 
 
Since DC are important in eliciting effective T cell responses, which are necessary for anti-
tumour immunity, DC presenting tumour antigens have been used as an anti-cancer 
immunotherapeutic treatment. However, after multiple clinical trials only a small number 
of patients have benefited from DC treatment. The survival and regulation of DC is vital 
for generating an effective T cell response, and hence an effective anti-cancer treatment. 
Thus, the overall goal of this thesis was to evaluate DC survival in two different in vivo 
models and assess whether CD8+ T cells and NKT cells, which both have cytolytic 
potential, eliminate DC through the use of perforin, a molecule important for target cell 
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lysis. By gaining a better understanding of the regulation of DC survival, it will be possible 
to generate more effective anti-cancer treatments.  
 
This introductory chapter summaries the functions of DC and their importance in 
activating naïve T cells. It also reviews the current literature addressing the regulation of 
DC survival and outlines the effect this has on T cell responses. In addition, as this thesis 
focuses on the role of CD8+ T cells and NKT cells in DC elimination, an overview of these 
cells and their ability to eliminate DC is presented.  
 
 
1.1 Dendritic cells  
DC are sentinels of the immune system (1); they are highly efficient antigen presenting 
cells (APCs) and play a central role in the induction and regulation of most adaptive 
immune responses. DC reside in most peripheral tissues in an ‘immature’ state where they 
are continuously sampling the antigenic environment. In the steady state, DC 
spontaneously ‘mature’ and constitutively migrate to the lymph nodes (LN) where they 
present self-antigen to T cells. In the absence of pro-inflammatory cytokines this 
presentation results in peripheral tolerance. However, upon encountering microbial 
products DC become ‘activated’ and present the captured antigen to T cells in the presence 
of pro-inflammatory cytokines, resulting in T cell activation, and culminating in an 
immune response.  
 
DC are a heterogenous cell population and are comprised of two main subpopulations: 
plasmacytoid DC (pDC) and so called “conventional” DC (cDC). Based on phenotypic 
markers and localisation, these two main categories can be further subdivided into 
functionally distinct subsets. These DC subsets will be discussed further in section 1.1.3. 
 
1.1.1 DC development 
DC are continuously produced from bone marrow (BM) hemopoietic stem cells (HSC) (2). 
All HSC-derived cells develop along either the lymphoid or myeloid pathway, through a 
committed but lineage restricted common lymphoid precursor (CLP) or common myeloid 
precursor (CMP) ((3, 4), Figure 1.1). Studies of DC development provide evidence that 
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DC subsets can originate through both myeloid and lymphoid pathways, from a CMP or 
CLP (5-7). FMS-related tyrosine kinase 3 (Flt3), a member of the class III receptor 
tyrosine kinase family, is expressed on early progenitor cells from the BM (8). Both CMP 
and CLP are heterogeneous for Flt3 expression, with most CLP expressing Flt3, whereas 
only a minor fraction of CMP expresses Flt3 (3, 9, 10). Flt3 ligand (Flt3L) has been shown 
to act as a growth factor for hemopoietic progenitors (8, 11, 12). Early DC precursors are 
found only among the Flt3+ fractions of both CMP and CLP subpopulations (9, 10), 
demonstrating that DC can be of either myeloid or lymphoid origin (Figure 1.1). 
 
 
 
CMPs CLPs
HSC
B cells T cellsConventional DC
Plasmacytoid DC
NK cellsErythrocytes
Megakaryocytes
Granulocytes
Macrophages
Multipotent HSC
Flt3- Flt3+ Flt3+ Flt3-
 
Figure 1.1 DC Development from haematopoietic precursors  
Both conventional and plasmacytoid DC can be generated from the Flt3+ expressing early myeloid 
and lymphoid progenitors. HSC: Hemopoietic stem cell, CMPs: Common myeloid progenitors and 
CLPs: Common lymphoid progenitors. Adapted from Shortman and Naik (13).  
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1.1.1.1 Development of DC from myeloid precursors 
DC were originally considered to be of myeloid origin because early studies demonstrated 
that cultured mouse BM myeloid precursors had the capacity to produce macrophages, 
granulocytes and DC in the presence of granulocyte macrophage colony stimulating factor 
(GM-CSF, (14)). Similar results were seen in studies of human cells (15-17). Direct 
evidence for a myeloid origin of DC was obtained when transplantation of mouse CMPs 
into irradiated recipients led to the reconstitution of all the major DC populations found in 
mouse lymphoid tissues (6, 7, 18). Further studies demonstrated that the capability of 
CMPs to produce all cDC and pDC subsets found in the mouse spleen and thymus was 
restricted to the Flt3+ fraction ((9), Figure 1.1). 
 
1.1.1.2 Development of DC from lymphoid precursors 
The first suggestion of a possible lymphoid origin of DC came when mouse thymic DC 
and a subset of splenic DC were found to express a number of cell surface markers 
normally expressed on lymphoid cells (19). However, the first direct evidence was 
obtained when transfer of thymic lymphoid precursors into irradiated mice gave rise to 
both T cells and CD8+ thymic cDC (20). Recent studies have shown that BM CLPs can 
generate all DC populations identified in lymphoid tissues (Figure 1.1), but with a strong 
bias towards the development of the CD8+ DC subset (5, 7).  
 
Based on the finding that pDC express many lymphoid markers, some authors have 
suggested that pDC may be exclusively of lymphoid origin. Human thymic pDCs were 
found to express the pre-T cell receptor α (pTα) (21, 22). In addition, murine pDC were 
found to carry a rearranged immunoglobulin heavy chain (IgH) D-J and express the Rag 
gene but lack TCRβ gene D-J rearrangements (23, 24). Further support for a lymphoid 
origin came from a study where over-expression of the dominant-negative transcription 
factors Id2 or Id3 in human hematopoietic progenitor cells blocked development of pDC, T 
cells and B cells but not myeloid DC (25). However, later studies have revealed that Flt3+ 
cells within either CLPs or CMPs can differentiate into both cDC and pDC in culture and 
in vivo ((9, 24, 26), Figure 1.1). In support of this, pDC derived from CMPs were shown to 
carry D-J rearrangement of IgH genes (24). Thus, recent studies have established that pDC 
can arise from both myeloid and lymphoid precursors.  
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1.1.2 DC maturation stages 
In the absence of inflammation (steady state), DC continually patrol peripheral tissues in 
an immature state, poised to capture and process antigen. The immature state is 
characterised by low surface expression of major histocompatibility complex II (MHC II) 
molecules and co-stimulatory molecules along with a high capacity to capture antigen ((1), 
Figure 1.2). Immature DC can capture antigen by receptor mediated endocytosis through 
DEC 205 (CD205) (27) or the mannose receptor, CD206 (28). DC have also been reported 
to take up antigen by phagocytosis (29), pinocytosis (28) and they can take up immune 
complexes, consisting of antigens bound to IgG, though immunoglobulin Fcγ receptors 
(FcγR) (30). The large array of antigen capture mechanisms partly accounts for DC being 
the most efficient APCs in the immune system.  
 
Steady state immature DC can spontaneously mature, upregulating expression of MHC and 
co-stimulatory molecules along with lymph node (LN) homing receptors, thus allowing 
migration to the LN (31). Mature DC migrate in small numbers to the LN, where they 
present self antigens to resting CD8+ T cells, leading to the induction of tolerance ((32-34), 
Figure 1.2). Directly targeting steady state DC with a monoclonal antibody (mAb) directed 
towards DEC 205 can cause tolerance in peripheral CD8+ and CD4+ T cells, by inducing T 
cell deletion or anergy (35, 36). Peripheral tolerance is thought to be responsible for 
elimination of auto-reactive T cells that have escaped thymic deletion (37). Thus, DC are 
also important for protecting the body from autoimmune diseases, by the induction of 
tolerance.  
 
Activation of immature DC into a mature phenotype also occurs in response to microbial 
and viral products, such as lipopolysaccharide (LPS) and double stranded RNA, these DC 
will be termed “activated” DC. DC recognise these products via signalling through Toll-
like receptors (TLRs) or other pattern recognition receptors (PRRs) (38, 39). Upon sensing 
these signals from pathogens, DC undergo a number of phenotypic changes, such as 
upregulation of expression of MHC molecules and the co-stimulatory molecules CD80, 
CD86 and CD40 ((1, 40), Figure 1.2). They also down regulate the expression of receptors 
involved in antigen uptake. Changes in the expression of chemokine receptors such as 
CCR7 and CXCR4 allow migration of DC from the peripheral tissues towards the T cell 
areas of the LN and spleen (41). Similar phenotypic changes are also observed in 
tolerogenic DC making it hard to distinguish between these two DC states. However, one 
Chapter 1: General Introduction 
 
25 
important functional difference is the secretion of IL-12 and other cytokines by activated 
DC (1, 42-44), which is necessary for differentiation of CD8+ T cells into effector cells and 
the subsequent initiation of cell mediated immunity. Thus, changes in phenotype and 
cytokine secretion allow activated DC to become efficient APCs and initiators of CD8+ T 
cell mediated immunity (31, 45).  
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Figure 1.2 Maturation states of DC 
Immature DC patrol the peripheral tissues where they have high endocytic activity. In the steady 
state (in the absence of inflammation) DC can mature and migrate to the LN where they present 
self-antigens and induce T cells anergy or tolerance. In the presence of ‘danger signals’ such as 
microbial products, DC become activated and upregulate expression of co-stimulatory molecules, 
inducing naïve T cell activation.  
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1.1.3 DC subsets 
There are many distinct DC subsets, each with a particular location and specialized 
function in the immune system (46). The two main types of DC, pDC and cDC, can be 
further subdivided, based on their location and the expression of a number of phenotypic 
markers. The different DC subsets are discussed in detail below.  
 
1.1.3.1 Plasmacytoid DC (pDC) 
Human pDC are identified as being CD4+CD45RA+IL-3Rα+ILT3+ILt1-CD11c-lineage- 
cells, whereas mouse pDC are identified as B220+ly6C+CD11clo. pDC circulate through 
the blood and lymphoid tissues and only acquire the typical DC morphology after 
activation (47, 48). pDC become activated after recognising viral RNA and DNA via 
signalling through TLR7 and TLR9 (49). Following activation, pDC release large 
quantities of type I interferons (IFNs), which inhibit viral replication and activate NK cells, 
macrophages and cDC. Activation of cDC leads to increased antigen presentation to T 
cells resulting in more effective viral clearance. Once activated, pDC can also present 
antigens and induce T cell expansion, although not as efficiently as cDC. This is thought to 
be due to the reduced ability of pDC to endocytose antigens as well as their lower cell 
surface expression of MHC II molecules and co-stimulatory molecules (50). Thus, pDC 
play an important role in many immune responses, particularly antiviral responses and 
provide a link between innate and adaptive immunity (47, 48).  
 
1.1.3.2 Conventional DC (cDC) 
Conventional DC can be either migratory or reside in lymphoid tissue. The migratory cDC 
can be grouped based on the peripheral tissue of origin. Langerhans cells (LC) of the 
epidermis are the model migratory DC. They patrol the peripheral tissue and, upon 
recognition of microbial products differentiate into activated LC, migrating to the skin 
draining LN and presenting captured antigen. Until recently, LC were thought to differ 
from dermally derived DC, which also migrate to skin draining LN, by expression of 
Langerin (51, 52). However, recent data indicate that a large proportion of Langerin+ cells 
in the LN originate from the dermis (53-55). These dermal Langerin+ DC are 
indistinguishable from LC based on the expression levels of MHC II, CD11c and 
Langerin, but can be separated based on CD103 and CD11b expression (53, 56). LC and 
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dermal DC also differ in their localisation within the LN, with LC primarily found in the T 
cell zone and dermal DC present near the B cell follicles (57). This distinct localisation 
may allow these different DC subsets to carry out non-overlapping roles in immune 
responses.  
 
Lymphoid tissue-resident DC can be further subdivided based on their cell surface 
expression profile. The T cell markers, CD4 and CD8, are expressed on mouse DC (58) 
and are useful for segregating subsets. CD8 on DC is expressed as a CD8αα homodimer, 
unlike the CD8αβ heterodimer found on T cells (19). To date, there is no evidence that 
either CD4 or CD8 markers are functionally significant on mouse DC (46). Three DC 
subsets have been described in the spleen of mice: the CD4-CD8+ (CD8+ DC), the CD4+ 
CD8- (CD8- DC) and the CD4-CD8- (double negative [DN] DC) (58). Two additional 
markers used to segregate mouse DC subsets are CD11b (the integrin αM chain of Mac-1) 
and c-type lectin DEC 205 (59). DEC 205 is expressed on CD8+ DC, whereas CD11b is 
present on CD8- DC and DN DC (60). Thus, expression of surface markers distinguishes 
clearly between different DC subsets.  
 
The CD8+ and CD8- DC subsets in the spleen differ in immune functions and location. 
CD8+ DC are concentrated in the T cell areas and CD8- DC are located in the marginal 
zones, however, the CD8- DC migrate into the T cell zones upon stimulation with 
microbial products (44, 61, 62). DC subsets also differ in function, with CD8+ DC 
producing the largest amount of IL-12 after stimulation (44, 63). DC subsets also differ in 
their ability to present antigen on MHC class I molecules (60), which will be discussed in 
more detail in section 1.1.4.2.3. These differences in immune functions correlate with a 
variant gene profile based on a global gene analysis by Affymetrix microarray (64). Taken 
together, these results show that the distinct lymphoid tissue resident DC may play diverse 
roles in immune responses.  
 
Sensing invading pathogens is essential to induce an adaptive immune response in the host. 
DC express multiple TLRs which enables them to detect a range of microbial derived 
products. Studies of DC subsets isolated from humans and mice have reported a distinct 
repertoire of TLR. Freshly isolated human pDC express TLR7 and TLR9, whereas human 
cDC express TLR1, TLR2, TLR3, TLR5, TLR6 and TLR8, with the exception of human 
LC which do not express TLR3 (49). In mice, all splenic DC subsets express TLRs 1, 2, 4, 
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6, 8 and 9 (65). However, TLR3 is only expressed by the splenic CD8+ and DN DC (65, 
66). High expression of TLR3 on CD8+ DC has been linked to their ability to present 
exogenous antigens on MHC I molecules (66). Moreover, mouse CD8+ DC lack TLR5 and 
TLR7 expression and fail to respond to TLR7 agonists (65, 67). Distinct TLR expression 
profiles on DC subsets suggest that they will respond differently to certain types of 
pathogens and are functionally diverse.  
 
The presence of a heterogenous DC population with defined locations and cytokine 
profiles allows for tailoring of the immune response to specific pathogens, while 
successfully combating foreign pathogens.  
 
1.1.4 DC function 
DC play a central role in initiating immune responses due to their ability to present antigen 
and their expression of co-stimulatory molecules, both of which are necessary for an 
effective T cell response to be elicited. However, for this to occur DC must interact with T 
cells within secondary lymphoid organs. Migration of DC to the T cell zones in secondary 
lymphoid organs is therefore critical to the function of DC. The molecules involved in DC 
migration, antigen presentation, and co-stimulation are discussed in detail below.  
 
1.1.4.1 Migration of DC to secondary lymphoid organs 
Spontaneous maturation or activation through sensing of microbial products results in 
upregulation of the CC-chemokine receptor 7 (CCR7), which is essential for DC migration 
from peripheral tissue to secondary lymphoid organs (41, 68-71). CCR7 deficient mice 
were shown to have markedly defective DC and lymphocyte migration to LN (72). 
Evidence that DC themselves need to express CCR7 to migrate to LN, rather than other 
cell types indirectly affecting DC trafficking, came from murine adoptive transfer studies 
of CCR7-/- DC into CCR7+/+ hosts. Transfer of CCR7-/- DC resulted in reduced recovery of 
DC from LN compared to transfer of CCR7+/+ DC (73). However, expression of CCR7 
alone is not sufficient for DC migration. A number of additional signals are required to 
sensitise CCR7 to its ligands, although the signalling mechanisms by which these other 
mediators alter CCR7 functionality have not been elucidated (74, 75). In addition to CCR7, 
expression of another chemokine receptor, CXCR4, is also upregulated on human DC after 
Chapter 1: General Introduction 
 
29 
stimulation (41) and was recently reported to be important in DC migration (76). Taken 
together these data illustrate that the expression of particular chemokine receptors is 
important for DC to migrate from the periphery to the T cell areas of secondary lymphoid 
organs, and present antigen to resident T cells.  
 
CCR7 has two ligands: CCL21 and CCL19. CCL21 is produced by endothelial cells in 
lymphatics and high endothelial venules (HEVs) as well as by stromal cells present in the 
T cell zone of LN. CCL19 is produced by stromal cells and activated DC in the T cell zone 
(77-80). The current model proposes that CCR7+ DC arrive at peripheral lymphatic vessels 
by responding to a chemotactic gradient of CCL21 and CCL19, originating from the 
lymphatic vessel. However, there is currently no direct evidence that this is correct, 
although it is clear that the migration of DC from the periphery to LN depends on CCR7 
and its ligands (74).  
 
The classical view is that DC migrate to LN constitutively from peripheral tissues through 
afferent lymph vessels (74). However, similar to naïve lymphocytes, some DC enter the 
LN through specialised HEVs. Although CD8+ DC have been proposed to use the 
hematogenous route (81), attempts to demonstrate directly that CD8+ DC traverse HEV to 
enter LN have so far failed (82) but there is evidence indicating that pre-cDCs enter the LN 
through HEVs, though not specifically CD8+ DC (83). pDC have been reported to enter 
LN through HEVs. Initially, pDC were shown to accumulate in human inflamed LN just 
beneath HEVs, suggesting that they may enter LN through this route (84). More recently, 
intravital microscopy of mouse LN clearly established pDC entered through HEVs (85). It 
appears that perhaps pDC and CD8+ DC can travel to LN using different routes, which 
may contribute to their distinct functional roles.  
 
1.1.4.2 Antigen presentation 
Immature DC effectively capture and present self and non-self antigens. The molecules 
involved in the processing and presentation of antigen are discussed in detail below. 
 
1.1.4.2.1 Major histocompatibility complex (MHC) expression 
There are two main types of MHC molecules: MHC class I (MHC I) and MHC class II 
(MHC II). All nucleated cells express MHC I molecules, including DC. MHC I is a 
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heterodimer consisting of a membrane spanning α chain that associates with a β2-
microglobulin (β2m) molecule. MHC I molecules bind peptides that are usually 8-10 
amino acids in length. In contrast, MHC II molecules are expressed only on DC, B cells, 
macrophages and thymic epithelial cells (86). MHC II molecules consist of α and β 
transmembrane glycoprotein chains and unlike MHC I molecules, MHC II molecules are 
less restricted by peptide size and bind peptides that are longer than 13 amino acids. 
 
There are two major T cell subsets that are distinguished by expression of the cell surface 
proteins CD4 and CD8. These two T cell subsets differ in the class of MHC they 
recognise, with MHC II and MHC I molecules being recognised by CD4+ and CD8+ T 
cells respectively. Upon recognition of the corresponding MHC/peptide complex and co-
stimulatory molecules (see section 1.1.4.3) on activated DC, CD4+ T cells differentiate into 
either activated T helper 1 (Th1), Th2, Th17 cells, T follicular helper cells or T regulatory  
(T reg) cells (87-89), whereas CD8+ T cells become effector cytotoxic T lymphocytes 
(CTL) (90).  
 
1.1.4.2.2 CD1 expression 
In addition to MHC I and II, DC express a third class of molecules involved in antigen 
presentation, the CD1 proteins. Five CD1 genes have been identified in humans that 
correspond to five proteins, designated CD1a, b, c, d, and e. In contrast, only CD1d has 
been identified in mice (91). In humans and mice, CD1d is not only expressed on DC, but 
also macrophages, B cells, thymocytes and peripheral T cells (91-93). The CD1 proteins 
share sequence homology and overall domain structure with MHC I molecules, being 
comprised of a heavy chain that is associated with β2m (94). However, in contrast to MHC 
I molecules that present peptide antigen, the CD1 family has evolved to present lipids as 
cognate antigens to NKT cells (95).  
 
1.1.4.2.3 Presentation on MHC molecules 
The classical model of antigen presentation is based on strict compartmentalization of 
MHC I and II biogenesis. Peptides generated from the degradation of endogenous proteins 
are translocated into the endoplasmic reticulum by the transmembrane transporter 
associated with antigen processing and loaded onto new MHC I molecules. Once 
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associated with peptides, MHC I molecules are rapidly transferred through the Golgi 
apparatus to the cell surface for recognition by CD8+ T cells (45, 90). By contrast, 
exogenous antigen is taken up by DC into endosomes and degraded into polypeptides. 
Peptides are targeted to lysosome related cellular compartments, which are rich in MHC II 
molecules, and loaded onto new MHC II molecules, which are then translocated to the cell 
surface for recognition by CD4+ T cells. Therefore, MHC I and MHC II present antigen 
from different intracellular compartments. However, this is not the only mechanism of 
antigen presentation. Over 30 years ago, work by Bevan demonstrated that priming of 
CD8+ T cell immune responses in vivo can also occur after presentation of exogenous 
antigens by MHC I, a phenomenon that he called cross priming (96). Subsequently, the 
term ‘cross presentation’ has been used to describe exogenous antigen presentation on 
MHC I, resulting in activation (cross priming) or tolerisation (cross tolerance) of CD8+ T 
cells (97).  
 
It is necessary for DC to present exogenous antigens on MHC I to enable efficient T cell 
activation during a viral infection, in which the DCs themselves are not infected (98). 
Many studies have shown that DC and macrophages are capable of cross presentation in 
vitro (reviewed in (97)). However, DC are the main players in cross presentation in vivo 
(99). Studies using transgenic mice selectively expressing the diphtheria toxin receptor in 
CD11c+ cells showed that selective depletion of CD11c+ DC prevented CD8+ T cell 
responses to cell associated antigens from Plasmodium yoelii and Listeria monocytogenes 
(99). Even though DC seem to be the main cell type involved in cross presentation, not all 
DC subsets have equal capacity to cross present antigens to CD8+ T cells. Bevan’s group 
was the first to report functional differences in the ability to cross present cell associated 
antigens between the various DC subsets (100). Later studies using fluorescently labelled 
chicken ovalbumin (ova) as a model antigen, or ova-conjugated fluorescent microspheres 
to track internalised antigen, revealed that all subsets were capable of antigen uptake, but 
only the CD8+ DC subset could achieve cross priming in vivo (100). CD8+ DC were also 
shown more efficient at cross presenting soluble (101) or latex bead associated antigens 
(102), and antigens captured by C-type lectin receptors (103, 104). In contrast the CD8- 
DC subset appeared more efficient at presenting antigen on MHC II molecules (103, 104).  
 
Cross presentation is an important mechanism for eliciting CD8+ T cell responses against 
viruses that do not infect APC. However, as reviewed by Lin et al, the mechanism by 
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which the exogenous antigen accesses the MHC I presentation pathway is not fully 
elucidated, although several mechanisms have been proposed (97). Recently, the cross 
presentation of ova protein was shown to require the mannose receptor selectively 
expressed on CD8+ DC (105). Furthermore, CD8+ DC have been found to express higher 
levels of MHC I processing associated proteins than CD8- DC (104). But further studies 
are necessary to confirm why the CD8+ DC subset is more efficient at cross presentation 
than other DC subsets (60). 
 
1.1.4.3 Co-stimulatory molecules 
By itself, recognition of peptide/MHC complexes expressed on DC is not sufficient for an 
effective T cell response. Additional signals from co-stimulatory molecules are required to 
fully activate naïve T cells. DC express many co-stimulatory molecules on their cell 
surface, which can be divided into two main groups on the basis of their structural 
configuration, co-stimulatory molecules the immunoglobulin superfamily, and co-
stimulatory molecules of the tumour necrosis factor receptor (TNFR) superfamily.  
 
The most well characterised co-stimulatory molecules are B7-1 (CD80) and B7-2 (CD86), 
which belong to the immunoglobulin superfamily and are expressed on the cell surface of 
DC, macrophages and B cells (106). CD86 is constitutively expressed at low levels and 
rapidly upregulated following activation of DC, whereas CD80 is inducibly expressed and 
upregulated more slowly than CD86 following activation. Both CD80 and CD86 bind 
CD28, which is constitutively expressed on mouse T cells (107). Signalling through CD28 
lowers the threshold for the activation of naïve T cells, enhances T cell proliferation, 
promotes T cell survival and increases the secretion of cytokines (108-111).  
 
Both CD80 and CD86 can also bind the inhibitory receptor, cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) (112). CTLA-4 expression is rapidly upregulated following 
T cell activation and has a higher affinity for both CD80 and CD86 than CD28 (113-116). 
Signalling through CTLA-4 blocks T cell proliferation and cytokine production (109, 112, 
117). T cell responses go unchecked in the absence of CTLA-4, resulting in fatal 
lymphoproliferative diseases (118, 119). This suggests that CTLA-4 plays an important 
negative regulatory role in T cell activation and in maintaining homeostasis.  
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The TNFR superfamily co-stimulatory molecule CD40 is expressed on B cells, 
macrophages, DC (120) and some T cells (121). CD40 on DC binds to CD40L, which is 
expressed on activated T, NK, NKT cells, platelets, eosinophils and mast cells (120, 122, 
123). Engagement of CD40 activates DC leading to IL-12 production and the upregulation 
of co-stimulatory molecules required for T cell activation and differentiation (124). In 
particular, CD40 ligation drives increased expression of B7 co-stimulatory molecules. 
Furthermore, ligation of CD40 on DC is reported to be sufficient to provide CD4+ T cell 
mediated help for CD8+ T cell responses (125-127). Additionally ligation of CD40 has also 
been shown to enhance DC survival by the upregulation of anti-apoptotic molecules and 
expression of serine protease inhibitor (SPI)-6 (128, 129).  
 
Another TNFR superfamily co-stimulatory molecule, Tumour necrosis factor (TNF)-
related activation-induced cytokine (TRANCE), expressed by activated T cells, also 
enhances the survival of DC and stimulates the secretion of cytokines required for T cell 
differentiation when it binds its receptor, TRANCE-R on activated DC (130-132).  
 
Additional co-stimulatory molecules of the immunoglobulin superfamily, such as inducible 
co-stimulator ligand (ICOS-L) and programmed death-1 ligand (PD-L1), along with 
OX40L, 4-1BBL and CD70 of the TNFR super family are also present on DC. These co-
stimulatory molecules enhance T cell clonal expansion, cytokine production and survival 
upon binding their respective receptors on T cells (133-141). However, as these molecules 
are not the focus of this thesis they will not be discussed in any further detail.  
 
1.1.5 Regulation of DC survival 
The central role played by DC in initiating adaptive immune responses means their 
survival is critical in the generation of an effective adaptive immune response and hence 
the outcome of the immune response. There are a number of mechanisms that regulate DC 
survival, and this DC survival affects the T cell response in either a positive or negative 
way. These are discussed below.  
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1.1.5.1 Mechanisms of DC survival and regulation 
Survival of DC may be intrinsically determined or it may be regulated by external factors 
such as signals from pathogens. Several studies have investigated the lifespan of steady 
state DC subsets in vivo by using bromodeoxyuridine (BrdU) labelling. Mouse splenic DC 
subsets had a rapid turn over (half-life 1.5-2.9 days), with CD8+ DC turning over more 
rapidly than the CD8- DC subset (81, 142, 143). This suggests that DC survival may be 
intrinsically controlled to some extent. However, engagement of TLRs has been shown to 
affect the survival of DC. Treatment of BMDC with a range of TLR ligands led to an 
altered DC lifespan depending on the TLR ligand (144). Unmethylated CpG motifs, the 
ligands for TLR9, enhanced DC survival and increased expression of the anti-apoptotic 
molecules Bcl-2 and Bc1-xL. LPS and lipoteichoic acid, which are TLR4 and TLR2 
ligands respectively, initially enhanced DC survival. However, after 3 days the cells 
underwent increased cell death associated with decreased expression of Bcl-2 and Bc1-xL 
(144). In vivo administration of LPS led to DC maturation and migration from the spleen 
marginal zone to the T cell zone, resulting in an increased DC turnover rate (61, 81, 145). 
Ligation of certain TLR has been proposed to set a ‘molecular timer’ that limits the 
lifespan of DC and controls the homeostasis and immunogenicity of these cells (144). 
These results suggest that both intrinsic and extrinsic factors play a role in the regulation of 
DC survival.  
 
The co-stimulatory molecules, CD40L and TRANCE, expressed by activated T cells (124, 
130-132) can also enhance DC survival. Upon engagement of its receptor on mature DC, 
TRANCE has been shown to inhibit apoptosis of both mouse and human DC in vitro (131, 
132). Ligation of CD40 on human DC also enhances DC survival due to resistance to Fas-
induced and spontaneous apoptosis (128, 146). Furthermore, DC lacking CD40 expression 
or treatment of mice with an anti-CD40L mAb resulted in the decline of total DC overtime, 
whereas treatment with a CD40 agonist resulted in prolonged longevity in vivo (147). It 
has been suggested that the enhanced survival of DC after either ligation of TRANCE or 
CD40 is due to the upregulated expression of the anti-apoptotic molecules Bcl-xL and Bcl-
2 (128, 132).  
 
CTL, NK and NKT cells have been proposed to play a role in regulating DC survival. As 
reviewed by Degli-Esposti, a number of studies have found that immature DC are 
susceptible to NK cell mediated cytolysis (148), via signalling through TNF-related 
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apoptosis-inducing ligand (TRAIL) (149). NKT cells have also been shown to kill DC in 
vitro by a number of mechanisms (150-152), which will be discussed further in section 1.4. 
CTL have been shown to eliminate antigen loaded DC (153-155) in a perforin-dependent 
manner (155, 156), which will also be discussed further in section 1.4.  
 
1.1.5.2 Effect of DC survival on T cell responses 
T cell activation involves extended contact between T cell and DC, therefore increased DC 
survival may affect T cell responses in a positive or negative way. Positive effects have 
been observed when DC survival was improved by manipulating the expression of anti- or 
pro-apoptotic molecules. Altering the expression of Bcl-2 and Bcl-xL (144, 157-161) or 
using small interfering RNA (siRNA) to silence gene expression of the pro-apoptotic 
molecules, Bak and Bax, in DC in vivo (162), resulted in enhanced antigen-specific CD4+ 
and CD8+ T cell responses and anti-tumour effects. In contrast, negative effects have also 
arisen with increased DC survival. Humans with a defect in caspase 10 (163) or transgenic 
mice with a targeted inhibition of apoptosis in DC by expression of a caspase inhibitor 
(164) have an accumulation of DC in LN, and also show spontaneous T cell activation but 
this is correlated with systemic autoimmunity. 
 
In summary, several mechanisms exist that regulate DC survival. Increased DC survival 
enhances T cell responses, which has been associated with both positive and negative 
immune responses. Thus the regulation of DC survival plays a critical role in establishing 
an effective and desirable immune response.  
 
1.1.6 DC-based cancer vaccines 
DC can be used as a tool for increasing anti-cancer immune responses. Early studies 
demonstrated that DC could be cultured in large numbers from bone marrow precursors 
(165, 166). A common approach is to inject cancer patients with their own DC loaded ex 
vivo with tumour antigens. A number of mouse studies (167) and early clinical trials 
testing vaccination with ex vivo generated DC loaded with tumour antigens provided proof 
of principle that therapeutic immunity can be achieved (168). Mouse studies in our group 
have also shown that DC loaded with tumour antigen can induce protective anti-tumour 
immunity (169). Yet, after multiple clinical trials, the clinical benefit measured by 
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regression of established tumours has been observed in only a fraction of patients (167, 
168, 170). Thus, a better understanding of DC biology and the requirements for a 
protective DC-mediated anti-tumour immune response will enable the generation of more 
efficient DC-based cancer vaccines.  
 
 
1.2 CD8+ T cells 
 
1.2.1 CD8+ T cell development 
CD8+ T cells are generated in the thymus from lymphoid precursor cells that have 
migrated from the BM. Two distinct lineages of T cells, αβ and γδ, are identified based on 
the type of T cell receptor (TCR) expressed. The CD8+ T cells develop from the αβ 
lineage. CD8+ T cells undergo a developmental selection process within the thymus (171). 
They are first positively selected by thymic cortical epithelial cells, and then negatively 
selected by APC such as DC and macrophages, based on their ability to recognise self-
antigens presented in the context of MHC I molecules. T cells are deleted either when they 
fail to be positively selected if their TCR has a very low affinity for MHC-self antigen 
complexes, or when they undergo negative selection if they have a very high affinity for 
self-antigen (172). Once the CD8+ T cells have completed the developmental process 
within the thymus they leave the thymus and traffic through the lymphatic system to 
populate the secondary lymphoid organs.  
 
1.2.2 Activation and differentiation of naïve CD8+ T cells 
Upon activation by DC expressing MHC I and peptide, naïve CD8+ T cells go through 3 
phases of differentiation: expansion, contraction and memory development ((173, 174), 
Figure 1.3). The first stage, expansion, is initiated in the secondary lymphoid tissues where 
CD8+ T cells encounter their specific antigen. CD8+ T cells clonally expand and 
differentiate into CTL, leading to a substantial increase (~1000-fold) in the precursor 
frequency of antigen specific T cells in immune animals compared with naïve animals 
(175-178). Clonal expansion ensures that there are enough antigen specific T cells to clear 
the invading pathogen. The second stage is the contraction phase in which the number of 
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cells declines and typically only 5-10 % of the antigen specific T cells remain. During the 
memory phase, long-lived antigen specific cells are present and survive long-term, ready to 
elicit a faster and stronger immune response upon pathogen re-challenge. 
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Figure 1.3 The 3 phases of naïve T cell differentiation 
A schematic diagram of naïve CD8+ T cell differentiation following host infection with a pathogen 
such as influenza A virus. After a small lag period naïve precursor T cells undergo many rounds of 
cell division and generate millions of effector cytotoxic T lymphocytes (CTL) by about 7-8 days 
post-infection. Then, most effectors die, leaving behind a pool of memory CD8+ T cells. Upon re-
infection, memory CD8+ T cells are able to proliferate more rapidly than the naïve precursors but 
still undergo a contraction phase where a large majority of cells die.  
 
 
 
1.2.2.1 Expansion phase of naïve CD8+ T cells 
As mentioned in section 1.1.4.3, two distinct signals are required for optimal expansion 
and differentiation of resting CD8+ T cells into cytotoxic T lymphocytes (CTL). The first 
signal is delivered via stimulation of the T cell receptor (TCR) by peptide-MHC 
complexes displayed on the surface of APCs. The second signal is co-stimulatory, such as 
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CD80/CD86-CD28 interactions and serves to amplify or modify the first signal. The most 
potent activators of naïve CD8+ T cells are DC, because they provide both signals to T 
cells.  
 
In addition to signal 1 and 2, there is evidence that optimal clonal expansion and 
development of effector function require a third signal (179). A study using artificial APC 
showed that IL-12 was necessary for activating naïve T cells (180). In vivo studies using 
transgenic T cells also demonstrate that IL-12 acts as a third signal directly on naïve T 
cells (181, 182). IL-12 has been found to regulate the survival of activated CD8+ T cells 
through altering the expression of the anti-apoptotic molecule, Bcl-3 (183). Type I 
interferons (IFNs) were also shown to provide the third signal (184) by directly signalling 
to CD8+ T cells to promote their survival and effector differentiation during expansion 
(184-186). DC produce both IL-12 and type I IFNs upon stimulation with TLR ligands 
(63) and in response to CD40-CD40L interactions with CD4+ T cells and NKT cells (125-
127, 187). Taken together these data indicate that the presence of IL-12 and type I IFNs are 
important in providing a third signal for optimal development of effector CD8+ T cells.  
 
Other studies have focussed on determining the length of antigenic stimulation required for 
activating naïve T cells. Only a brief period of antigenic stimulation (2-24 hr) was shown 
to be enough for naïve CD8+ T cells to commit to 7-10 cell divisions and differentiate into 
CTL (188-191). Moreover, once naïve T cells received an activation signal they continued 
to divide and differentiate in the absence of further antigenic stimulation, suggesting that 
activated T cells are programmed to clonally expand and differentiate into effector cells 
(188). Therefore it would appear that after only a short period of antigenic stimulation 
naïve CD8+ T cells can clonally expand and generate an effective CTL response.  
 
Interactions between naïve T cells and DC in vivo have been the subject of several studies 
in recent years. This has been made possible by two-photon laser scanning microscopy 
which allows real time imaging of T cell-DC interactions within a LN (192). Von Andrian 
and colleagues were the first to carefully examine the evolution of CD8+ T cell-DC contact 
dynamics over time (193). They found that peptide-loaded DC primarily established 
transient interactions during the first 8 hr in the LN. It was only after this initial phase that 
stable T cell-DC contacts were detected (193). Other studies have also observed initial 
short-lived interactions, whereas other authors failed to observe this initial phase of 
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transient interactions (reviewed in (194)). It is thought that the differences observed could 
be explained by the diversity of experimental conditions used in the different studies. 
Nevertheless, the emerging consensus is that strong signals induce rapid and stable 
interactions, while weaker signals lead to transient T cell-DC interactions. Differences in T 
cell-DC contacts might contribute to creating a heterogeneous T cell response (194). Thus, 
improvements in technology have helped gain a better understanding into the in vivo 
interactions that occur between the T cell and DC.  
 
1.2.2.2 Contraction of CD8+ T cells 
After extensive proliferation of antigen specific CD8+ T cells following an infection or 
vaccination, a contraction phase occurs (Figure 1.3). In general, the contraction phase 
eliminates ~90-95 % of antigen-specific effector CD8+ T cells (195, 196). Despite this 
massive elimination, the antigen-specific T cell population is maintained at a higher 
frequency than they were in the initial naïve precursor population. These surviving cells 
are memory CD8+ T cells. Originally it was thought that the onset of the contraction phase 
correlated with the kinetics of pathogen clearance (173). However, experiments 
investigating the kinetics of the contraction phase have found it to be programmed early 
during infection (188, 190, 195). In experiments where the duration of infection was 
limited by antibiotic treatment or allowed to persist through the use of PKO mice, 
contraction kinetics were not affected (195). The same contraction kinetics were also 
observed regardless of differences in the initial expansion and were independent of the 
duration of infection and antigen persistence (188, 190). These results suggest that 
contraction of antigen-specific CD8+ T cells occurs independently of pathogen clearance 
and is a programmed event.  
 
1.2.2.3 Memory CD8+ T cells. 
Memory CD8+ T cells are long-lived cells that persist in a resting state after the resolution 
of infection and serve to protect against a secondary challenge. Memory CD8+ T cells are 
heterogeneous in their phenotype, location and effector functions.  
 
In the late 1990s, two subsets of memory cells from human peripheral blood were defined: 
effector memory (Tem) cells and central memory (Tcm) cells (197). Tcm and Tem can be 
distinguished based on expression of the LN homing receptors, CD62L and CCR7, effector 
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functions and proliferative ability. Tem cells are defined as CD62Llo and CCR7lo, possess 
immediate effector function and are found in the peripheral tissues poised to rapidly clear 
pathogens. In contrast, Tcm cells are CD62Lhi and CCR7hi, exist mainly in LN and express 
effector function upon restimulation (197). These memory cell subsets have been 
characterised in mice as well as in humans, (198-200). However, it is now evident that 
memory T cell heterogeneity is more complex than simply Tcm and Tem cells (201).   
 
Currently, there is ongoing debate in the literature about the development and lineage 
relationships of memory CD8+ T cell subsets. A number of models have been proposed 
including the linear and divergent models (202). However, these models may not be 
mutually exclusive and multiple pathways may exist depending on the T cell priming 
conditions (201). The main difference between the proposed models is whether memory 
cells are required to pass through an effector phase. There is some indication that memory 
cells are direct descendents of effector cells (203-205), while other evidence supports a 
divergent lineage, whereby memory cells directly differentiate from naïve cells without 
passing through an effector phase (206-210).  
 
Whilst the differentiation pathway of memory CD8+ T cells has not been completely 
elucidated, memory cells are required for long-term protective immunity. Memory CD8+ T 
cells rapidly respond to re-infection and can clear a second infection faster than naïve 
CD8+ T cells can. This is due to the increased precursor frequency of antigen specific T 
cells in immune animals (175-178, 211) and the capacity to produce larger amounts of 
interferon-gamma (IFN-γ), and faster production of perforin compared to naïve CD8+ T 
cells (177, 188, 212-217). In addition, unlike naïve CD8+ T cells which are found in LN, 
effector or certain memory CD8+ T cell subsets are able to patrol the peripheral tissues, 
enabling earlier encounter with pathogens (218). These features of memory CD8+ T cells 
make them distinct from naïve CD8+ T cells and enable them to mediate long-term 
protective immunity.  
 
1.2.3 Effector functions of activated CD8+ T cells 
Upon activation, CD8+ T cells differentiate into CTL and develop effector functions, 
including the ability to produce cytokines to recruit other cells to the site of infection and 
the ability to directly interfere with pathogen replication (196). CTL are able to induce 
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killing of infected cells by two distinct pathways: death receptor-mediated apoptosis and 
cytotoxic granule exocytosis (219).  
 
1.2.3.1 Cytokine production 
Upon activation, CTL secrete cytokines that can have both local and systemic 
consequences. CTL secrete IFN-γ and tumour necrosis factor alpha (TNF-α), which both 
contribute to their cytotoxic function. TNF-α can bind to its receptor, TNFR, which is 
present on the cell surface of target cells to induce programmed cell death (220). The 
presence of TNF-α, along with IFN-γ, can lead to macrophage activation and recruitment 
to sites of infection. Experiments have also shown that direct exposure to IFN-γ and TNF-
α induces cellular proteins that can decrease transcription and/or replication of several 
viruses (221, 222). IFN-γ also induces the expression of MHC I on infected cells, which 
increases the chance that infected cells will be recognised as target cells for cytotoxic 
attack (221, 222). In addition, activated CD8+ T cells secrete IL-2, which helps drive their 
proliferation and differentiation.  
 
1.2.3.2 Fas-FasL 
One mechanism of cell lysis utilised by CTL is via cell death receptors such as Fas 
(CD95), TNFR-1 and TRAIL receptor (TRAIL-R) (223). Expression of death receptors on 
the target cell can lead to cell destruction by CTL expressing the corresponding ligand. 
The best-characterised death receptor pathway is Fas-FasL. Fas is expressed on many cells, 
whereas FasL is expressed predominantly on activated CD8+ T cells due to its upregulation 
upon TCR stimulation (224). Engagement of Fas with FasL results in classical caspase-
dependent apoptosis. The Fas-FasL pathway is involved not only in cell-mediated 
cytotoxicity but also in T cell homeostasis (225, 226).  
 
1.2.3.3 Perforin and the perforin/granzyme cytotoxic pathway 
In addition to death receptor mediated apoptosis, the main pathway that is utilised by CTL 
to kill target cells is the perforin/granzyme pathway. Perforin was first described in 1985 
and was characterised as a calcium-dependent, pore-forming cytolytic protein (227-229). 
Perforin is a ~67 kDa multidomain protein with some similarity to the pore forming 
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component of complement, C9 (230, 231). However, until recently the perforin domains 
were largely undefined and the protein structure was not solved, due to the lack of a 
recombinant form of perforin (232). Detailed mutational and structure-function analysis 
has revealed that the highly conserved amphipathic α helical region, formerly thought to 
constitute the membrane-spanning domain (233), is involved in the assembly of perforin 
monomers into a pore complex (234). It is anticipated that future studies will completely 
solve the protein structure and define the domains of perforin, which will provide insights 
into its function.  
 
Perforin is primarily expressed in NK cells and antigen-experienced CD8+ T cells, but it 
can also be expressed in subpopulations of CD4+ T cells and NKT cells (235-237). 
Perforin, along with granzymes that are complexed with the proteoglycan serglycin, are 
sequestered into specialised secretory cytotoxic granules (238). Granzymes are highly 
specific proteases; granzyme A and in particular granzyme B are the most abundant 
granzymes in mice and humans. The granzymes are redundant, each capable of 
proteolytically activating independent cell death pathways (239). In CTL, the cytotoxic 
granules are synthesised only after the cell has encountered specific antigen and becomes 
activated (240, 241), whereas in NK cells, cytotoxic granules are formed during 
development (237, 242). Recognition of a target cell by a CTL triggers rapid polarisation 
of the microtubule organising centre towards the immunological synapse, followed by the 
granules moving along the microtubules in the direction of the plasma membrane. After 
the cytotoxic granules have been polarised at the cell membrane, they are secreted into the 
immunological synapse in an ordered set of events. This results in the rapid delivery of the 
contents of cytotoxic granules to a precisely defined point between the CTL and target cell 
(243). Subsequently, the granzymes are delivered to the target cell resulting in cell death. 
The mechanism of how perforin delivers the granzymes to the target cell is still not fully 
understood. However, the generation of PKO mice has demonstrated the absolute 
requirement of perforin for granzyme-dependent killing (244-248).  
 
1.2.3.4 Proposed models for perforin-mediated delivery of granzymes into target 
cells  
A number of models have been proposed to explain how perforin facilitates the delivery of 
granzymes to the target cell. A series of experiments where perforin and granzymes were 
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over-expressed in the mast cell line RBL demonstrated that both perforin and granzymes 
were required for the DNA damage observed during CTL killing (249, 250). These results 
formed the basis for the first proposed mechanism of perforin/granzyme-mediated 
cytotoxicity. Perforin was proposed to form a plasma membrane pore to act as a channel, 
through which the granzymes could pass (Figure 1.4 A). However, perforin pores may be 
too small to allow passage of molecules as large as granzymes because small dyes that 
ought to be able to pass through perforin sized pores are unable to enter perforin treated 
cells (251, 252). However, a later study, using sublytic doses of perforin, demonstrated that 
perforin does form cell membrane pores and small amounts of molecular dyes were able to 
enter the cell (253). The earlier experiments may have failed to observe the dye present in 
the cytosol because not much dye enters and it does not diffuse throughout the cytoplasm 
(254). This original model of pore-forming perforin was further questioned after studies 
showed that granzyme B was taken up into target cells in a perforin-independent manner, 
via the mannose-6-phosphate receptor (255). This mechanism of granzyme uptake has 
been contested by a number of groups (256-258) and therefore the exact mechanism of 
perforin action remains to be elucidated.  
 
A modification to the original pore forming model has been proposed by Froelich and 
colleagues, in which perforin forms pores in the endosomal membrane rather than in the 
plasma membrane, releasing granzymes from endosomes into the cytosol ((251, 252), 
Figure 1.4 B). This idea is supported by the fact that transfer of granzyme B into target cell 
endosomes occurred in a perforin-independent manner, but that perforin was required for 
endosomal disruption, leading to apoptosis (251, 259). However, there was no evidence of 
perforin in the target cell cytosol.  
 
More recently, another modification to the original model by Lieberman and colleagues 
proposes that perforin forms small pores in the cell membrane that trigger a Ca2+ influx 
leading to a membrane repair response and endocytosis of granzymes and perforin into 
giant endosomes, followed by perforin mediated release of granzymes into the cytosol 
((253), Figure 1.4 C). However, further evidence is still required to fully validate this latest 
model. Regardless of which model is correct, all point to perforin forming a membrane 
pore. Nevertheless, further investigations ought to elucidate its precise mechanism of 
action. 
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Figure 1.4 Models of perforin-dependent delivery of granzymes to the target cell  
(A) The original pore model proposed that perforin formed a pore in the plasma membrane, 
through which granzymes could diffuse and access key substrates leading to apoptotic death. (B) 
The endosomolysis model proposes that granzymes can be taken up in a perforin-independent 
manner but that perforin is required for endosomal disruption. (C) The most recent model proposes 
that perforin forms small pores in the plasma cell membrane that trigger a Ca2+ influx, which 
activates a membrane repair response in which internal vesicles such as lysosomes donate their 
membranes to patch the holes. The next step involves endocytosis of granzymes and perforin into 
endosomes, followed by perforin mediated release of granzymes in to the cytosol leading to cell 
death. Adapted from Trapani and Smyth (260) and Keefe et al (253). 
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1.3 Natural Killer T (NKT) cells 
The term ‘NKT cells’ was first coined in 1995 to define a novel subset of mouse T cells 
characterised by cell surface expression of NK1.1 and an αβ TCR, with Vα14 incorporated in 
the α chain ((261), Figure 1.5). More recently, murine NKT cells have been defined as cells 
expressing an invariant Vα14 Jα18 TCR. These ‘invariant’ type I NKT cells are reactive to 
the glycosphingolipid α-Galactosyleramide (α-GalCer) presented on MHC I-like CD1d 
molecules (262). In humans CD1d-restricted, α-GalCer reactive cells are also found and 
express a Vα24 Jα18 TCR (263). The CD1d restriction can be used to identify NKT cells by 
using α-GalCer loaded CD1d tetramers that specifically bind the TCR of NKT cells (264-
266), these cells are referred to as “iNKT”. A second subset of CD1d-restricted, type II NKT 
cells has been identified, however, they are not reactive to α-GalCer and have a diverse TCRα 
repertoire (267). These NKT cells are less well characterised, mainly because they cannot be 
identified using α-GalCer loaded CD1d tetramers. From here on in the term NKT cell will 
refer to the ‘invariant’ type I NKT cells. 
 
An important feature of NKT cells is their ability to rapidly produce of a wide range of 
cytokines; within hours of stimulation NKT cells produce IL-4, IFN-γ and TNF-α (268, 269). 
The ability of NKT cells from naïve mice to rapidly produce cytokines, may be due to the 
presence of high levels of preformed IL-4 and IFN-γ mRNAs expressed even in a resting state 
(270, 271). To date, NKT cells have been shown to produce IFN-γ and IL-4, as well as 
interleukins -2, -5, -6, -10, -13, -17, -21, TNF-α, Transforming growth factor β (TGFβ) and 
GM-CSF in addition to a range of chemokines (272). It is through their production of this 
diverse array of cytokines and chemokines that NKT cells have been implicated in many 
different immune responses, from autoimmune diseases to asthma and infectious diseases 
along with tumour protection (263, 273-276). 
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Figure 1.5 Mouse NKT cells share some characteristics of NK and T cells 
This Venn diagram shows the key features of NKT, T and NK cells. Characteristics that are unique to 
each lineage are shown in the non-overlapping sections, whilst common characteristics are indicated in 
the overlapping areas. The central white area indicates the characteristics exhibited by all three 
lineages. * NK1.1 is not present in all mouse strains. Reproduced from Godfrey et al (273). 
 
 
 
1.3.1 NKT cell development 
NKT cells are a thymus-derived T cell subset, but are developmentally and functionally 
distinct from conventional CD4+ and CD8+ T cells (277-280). NKT cells separate from 
conventional T cell development at the double positive (DP; CD4+CD8+) thymocyte stage 
(280-283). In contrast to conventional T cells, which are positively selected by thymic cortical 
epithelial cells, NKT cells are positively selected by CD1d expressing DP cortical thymocytes 
(277, 284, 285). Whether NKT cells are subjected to negative selection is not yet clear. There 
is some evidence that negative selection does occur; however, no study has directly 
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demonstrated the deletion of pre-formed NKT cells (277, 284-286). Thus, although much has 
been learnt about NKT cell development over the last few years there are still areas that 
require further investigation to elucidate the full developmental pathway of NKT cells.  
 
Within the thymus, NKT cell precursors undergo a series of differentiation steps that have 
been defined by the differential expression of CD24, CD44, DX5 and NK1.1 (286, 287). The 
final maturation step, which results in the expression of NK1.1, can occur in both the thymus 
and periphery. Most of the NKT cells that emigrate from the thymus are immature, and 
complete their maturation in the periphery (280, 288, 289). Some mature thymic NKT cells do 
migrate to the periphery, while others remain as long-term thymus resident cells (289). Mature 
NKT cells in the periphery are widely distributed throughout the body; they are most abundant 
in liver, BM and thymus, while they represent a smaller proportion of T cells in the spleen, 
LN, blood and lung (263, 264, 266, 273, 276). In the periphery, mature NKT cells have a 
semi-activated phenotype, resembling activated CD8+ T cells (290, 291). This semi-activated 
phenotype could be responsible for the rapid activation of NKT cells that results in the 
production of a large array of cytokines.  
 
1.3.2 NKT cell subsets 
NKT cells can be divided into subsets based on the expression of the co-receptor CD4. In mice 
they can be either CD4+ or double negative (DN; CD4-CD8-) (264, 266), whereas in humans 
an additional subset exists that is positive for the co-receptor CD8 (235). It has been proposed 
that these subsets are functionally distinct and play different roles in immune responses (235, 
292, 293). The strongest evidence is provided by a study by Crowe et al (292) showing that 
the CD4- liver NKT cells elicit superior tumour protection compared to CD4+ NKT cells. In 
addition, many cytokines are differentially expressed by NKT cell subsets (294). Particularly 
in humans, there is strong evidence that the CD4+ NKT cells are enriched for Th2 cytokines 
(235, 293, 295). Additionally, human NKT cell subsets have been found to differentially 
regulate DC activity (296). CD4+ NKT cells induced IL-12 production by DC, while CD4- 
NKT cells were found to eliminate DC by cytolysis and cause down regulation of IL-12 
production. This study did not investigate the mechanism of DC killing by NKT cells but an 
earlier study did demonstrate that human NKT cell subsets differentially express molecules 
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involved in cytotoxicity (235). Human CD4- NKT cells expressed more perforin compared to 
the CD4+ NKT cells, which expressed a greater amount of intracellular FasL than the CD4- 
NKT cells (235). Taken together, these results from both human and mouse studies provide 
evidence that functionally distinct subsets of NKT cells may play different immunoregulatory 
roles.  
 
1.3.3 NKT cell ligands 
 
1.3.3.1 α-Galactosylceramide (α-GalCer) 
Kirin Pharmaceuticals identified the first NKT cell agonist during screenings for natural anti-
cancer medicines. Extracts from Agelas mauritianus, a marine sponge, prolonged survival of 
mice bearing B16 melanoma (297). The active component was identified as an α-branched 
galactosylceramide. This was modified slightly for optimal efficacy to produce a compound 
termed KRN7000, commonly referred to as α-GalCer ((298), Figure 1.6). It was not until a 
few years later that α-GalCer was identified as an NKT cell ligand (299), binding to CD1d. 
The CD1d-α-GalCer complex is recognised by both human and mouse NKT cells (300). To 
date, α-GalCer is the best-characterised NKT cell ligand, with proven capacity to stimulate 
strongly both murine and human NKT cells to produce both IFNγ and IL-4 (299, 301).  
  
It is unlikely that this antigen recognition system has been conserved to defend us from marine 
sponges; thus it is assumed that α-GalCer is only a mimic of the natural ligand that NKT cells 
recognise. In support of this, it has been found that glycosphingolipids from the bacteria wall 
of Sphingomonas were also able to activate NKT cells (302-304). A. mauritianus is known to 
be colonised by Sphingomonas; therefore, rather than being derived from marine sponges, α-
GalCer may in fact have originated from bacterial symbionts (274).  
 
1.3.3.2 OCH is an analogue of α-GalCer 
Many synthetic analogues of α-GalCer have been produced to determine structure-function 
relationships. One of these analogues that is also used in this thesis is OCH. OCH has a 
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substantially shorter phytosphingosine chain and unlike α-GalCer preferentially induces NKT 
cells to produce IL-4 ((305-307), Figure 1.6). Biased IL-4 production by NKT cells stimulated 
with OCH resulted in the suppression of experimental autoimmune encephalomyelitis in mice 
(305). OCH is a weaker NKT cell agonist than α-GalCer because stimulation of a NKT cell 
hybridoma with OCH resulted in reduced IL-2 production compared to α-GalCer (307). In 
addition, OCH stimulation led to reduced proliferation of splenocytes compared with α-
GalCer stimulation (305). This correlated with the finding that OCH has a less stable 
association with CD1d compared with α-GalCer. It has been proposed that this less stable 
binding of OCH leads to the preferential production of IL-4 (306). 
 
1.3.3.3 Endogenous NKT cell ligands 
To date, the endogenous ligand for positive selection of NKT cells remains to be identified. It 
is thought that the self-ligand is likely to be a glycolipid similar to α-GalCer. The endogenous 
glycosphingolipid, isoglobotrihexosylceramide (iGb3) can activate mouse and human NKT 
cells ((308), Figure 1.6), although iGb3 is a much weaker agonist than α-GalCer, requiring 
~30-100 fold higher concentrations to achieve the same level of NKT cell stimulation. Studies 
have implicated iGb3 as the natural antigen involved in NKT cell positive selection in the 
thymus (308), although this is currently highly controversial (286). In addition, humans lack 
the functional iGb3 synthase found in mouse; thus iGb3 may not be a physiological antigen 
for human NKT cells. Nevertheless, an alternative synthesis pathway might exist (309). Future 
studies hope to reveal the natural ligand for NKT cells and this may provide further insights 
into NKT cell development.  
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Figure 1.6 Structures of some NKT cell ligands 
The strong NKT cell ligand α-GalCer is composed of a galactose head group that is linked to a 
ceramide lipid with an α-linkage. The ceramide lipid is made up of an unfunctionalised lipid chain and 
a shorter phytosphingosine lipid chain. The synthetic analogue OCH has a truncated phytosphingosine 
lipid chain. A potential natural ligand for NKT cells is isoglobotrihexosylceramide (iGb3). In contrast 
to α-GalCer and OCH, iGb3 has three sugar residues connected to the ceramide lipid via a β-linkage. 
The ceramide of iGb3 contains a sphingosine lipid rather than the phytosphingosine found in α-GalCer 
and OCH. The lengths of the lipid chains are indicated.  
 
 
 
1.3.4 Cytolytic functions of NKT cells 
Mouse and human NKT cells have been shown to express perforin (235, 310-313) and 
granzyme B (310). Through the use of either NKT cells from PKO mice, or concanamycin A 
to block perforin secretion from WT NKT cells, perforin has been shown to be important for 
lysis of a number of tumour cell lines by NKT cells (312-315). By contrast, in an in vivo 
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tumour model, perforin production from NKT cells was not essential for controlling tumour 
growth (316). These results indicate that in some situations perforin mediated killing by NKT 
cells could play a role in regulating immune responses. Further in vivo investigations of 
perforin mediated killing by NKT cells needs to be undertaken to fully elucidate its role.  
 
Upon stimulation, human NKT cells also express the ligands FasL and TRAIL on their cell 
surface (152, 317, 318), which can bind their respective receptors to induce cell death. Co-
culturing of myeloid leukaemia cells with NKT cells led to apoptosis of the leukaemia cells. 
However, blocking TRAIL with a neutralising antibody almost completely reduced apoptosis 
in these cells (318). Furthermore, reduced NKT cell cytotoxicity against certain tumour cell 
lines was observed upon the addition of TRAIL and FasL neutralising antibodies (315), 
indicating that both TRAIL and FasL are important for NKT cell anti-tumour activity. In 
addition to killing of tumour cells, FasL expression is also crucial for lysis of DP thymocytes 
by mouse thymic NKT cells (317). Taken together, these results indicate that NKT cells can 
directly lyse a number of tumour cells as well as control NKT cell development through the 
lysis of DP thymocytes. Thus, in addition to the extensive array of cytokines rapidly produced 
by NKT cells, their cytolytic functions also appear to be valuable in immune responses.  
 
1.3.5 Immunoregulatory functions of NKT cells 
Following NKT cell stimulation, many other cell types are directly or indirectly activated. The 
interaction between NKT cells and DC plays a central role in these responses (Figure 1.7). 
After α-GalCer treatment, DC upregulate expression of the co-stimulatory molecules CD40, 
CD80, CD86 and MHC II (319, 320) as well as producing cytokines such as TNF-α and IL-12 
(187). Production of IL-12 by DC has been shown to be important for IFN-γ production by 
NKT cells (122). IL-12 in combination with increased production of IFN-γ by NKT cells leads 
to the activation of NK cells, which in turn produce more IFN-γ and have lytic functions (321, 
322). In addition to IFN-γ, the production of IL-2 by NKT cells has also been found to be 
important for NK cell cytotoxicity (323). It has been proposed that NKT cells themselves do 
not directly kill tumour cells by cytolytic activity but instead rapidly activate NK cells via 
IFN-γ and IL-2, which then results in NK-mediated cell lysis (321-324). However, this does 
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not account for the CD1d-dependent NKT cell killing observed in vitro (323) or the direct 
cytotoxicity against many tumour cell lines (312-315, 317). Thus it is possible that both 
mechanisms, NKT cell mediated cytotoxicity and cytotoxicity mediated by IFN-γ-activated 
NK cells, can occur. Regardless of the cell type mediating the cytotoxicity, NKT cell 
stimulation enhances cytotoxic responses in vivo.  
 
Activated NKT cells can also influence the behaviour of cells of the adaptive immune 
response (Figure 1.7). As discussed above, cognate NKT cell-DC interactions result in DC 
activation, which is important for T cell activation. Following administration of α-GalCer 
together with the protein antigen ova, ova-specific CD4+ and CD8+ T cell responses were 
elicited (319, 320, 325, 326). The development of ova-specific T cells resulted in protection 
against ova-expressing tumours (319, 320, 325). Simultaneous injection of α-GalCer and ova 
protein was required for the development of T cell responses (320), indicating that α-GalCer 
and ova protein may need to be presented by the same DC. Further investigation into NKT-
DC interactions in vivo demonstrated that TNF-α and IFN-γ were important for the 
upregulation of co-stimulatory molecules on DC and the T cell response to protein antigen 
(187). Additional studies demonstrated that the CD40-CD40L mediated signals between DC 
and NKT cell were essential for the interaction to result in T cell immunity (187, 320). Thus 
the NKT cell-DC interaction is important not only for the activation of NK cells but also 
conventional T cells which are crucial for certain immune responses such as tumour 
immunity.  
 
NKT cell activation can also provide help to B cells (Figure 1.7). After α-GalCer treatment B 
cells were shown to upregulate activation markers CD86, CD69 and MHC II, in a CD1d NKT 
cell-dependent manner, leading to proliferation and antibody secretion (327-332). 
Furthermore, B cell receptor internalisation of CD1d-restricted antigens was reported to be 
effective at stimulating B cell proliferation and the development of early specific antibody 
responses in vivo (333, 334). Additionally, NKT cells were shown to play a role in sustaining 
specific B cell responses and memory (335). Therefore, through activation of NKT cells both 
B and T cells of the adaptive immune response are affected. Consequently, the DC-NKT cell 
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interaction is pivotal to the effector function of the NKT cell and enables the NKT cell to skew 
the immune response towards different outcomes.  
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Figure 1.7 NKT cells interact with and activate many different cell types 
Recognition of α-GalCer presented on CD1d molecule on DC by NKT cells results in the reciprocal 
activation of both NKT cells and DC. This, in turn, results in the activation of T cells, NK cells and B 
cells. NK and CD8+ T cells then may have a cytotoxic effect on DC. There is some evidence that NKT 
cells can also have a direct cytotoxic effect on DC. 
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1.4 DC killing by CD8+ T cells and NKT cells 
Because of their pivotal role in the immune system, it is important that DC survival and 
regulation is under tight control. Therefore the mechanisms and cells involved in regulating 
DC survival are of great interest. This topic has been reviewed in section 1.1.5.  
 
Several authors have proposed the presence of a regulatory feedback network, whereby CTL 
eliminate DC to control the magnitude of the immune response (153, 155, 336). In support of 
this, rapid elimination of antigen-loaded DC was observed after immunisation of CD8+ TCR 
transgenic and immune non-transgenic mice (169, 337). Additionally, elimination of antigen-
loaded DC by effector CD8+ T cells was shown to limit the induction of tumour immunity 
following immunisation of mice with peptide-loaded DC (169), and prevented boosting of 
existing immune responses (169, 337), thus illustrating the importance of DC survival during 
certain immune responses. Early studies demonstrated a link between perforin and enhanced 
immune responses. In the absence of perforin, an enhanced CD8+ T cell response was 
observed following infection with L. monocytogenes, Lymphocytic Choriomeningitis Virus 
(LCMV), or during mixed lymphocyte reactions (338-340). These results suggest that, in the 
absence of perforin, DC may survive longer and induce better CD8+ T cell responses. More 
recently, a direct link has been established between CTL mediated killing of DC and 
expression of perforin by CTL. DC injected into immune PKO mice were not eliminated, in 
contrast to those injected into immune WT mice (155). This lead to a progressive increase in 
the number of antigen-specific CD8+ T cells in PKO mice after repeated immunisation with 
the antigen-loaded DC (155). Also, during a secondary influenza infection, DC in mediastinal 
LN have been found to be killed in a perforin-dependent manner (156). Furthermore, patients 
with familial hemophagocytic lymphohistiocytosis (FHL), who have mutations in the perforin 
gene, have uncontrolled T cell activation, resulting in a fatal outcome (341). This uncontrolled 
T cell activation in FHL patients is thought be to due to increased DC survival since CTL are 
unable to eliminate DC as they lack the expression of perforin (342). Overall these data 
suggest that CTL can eliminate DC in a perforin-dependent manner, and that this mechanism 
may contribute to regulation of immune responses. 
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Other studies have endeavoured to determine if effector CTL and memory CD8+ T cells can 
both eliminate DC. Recently, in vitro work demonstrated that only CTL kill DC, while 
memory CD8+ T cells cause DC to enhance IL-12 production and increase the expression of 
SPI-6 (343). This is in contrast to previously published work by our laboratory where in a 
memory setting, DC were also eliminated, although with slower kinetics compared to DC 
elimination by CTL (169). Furthermore, both memory CD8+ T cells and CTL eliminated DC 
in vivo even though DC had upregulated SPI-6 (344). Thus, the in vivo evidence points 
towards the ability of both CTL and memory CD8+ T cells to eliminate DC.  
 
Investigations have also been undertaken to determine where CTL eliminate DC. DC 
elimination by CTL was shown to occur only in peripheral tissues in experiments that altered 
the injection timing of antigen-loaded DC and specific CTL (155). Sallusto and colleagues, 
using two-photon microscopy to visualise DC-T cell interactions within the LN, found that 
after a stable T cell-DC interaction, DC displayed prominent blebbing and fragmentation 
consistent with the induction of apoptotic cell death (345). The authors therefore proposed that 
DC elimination by CTL can also occur within the LN. The question still remains as to how 
significant the DC killing in the LN is compared to that observed outside the LN. Therefore 
this aspect of DC elimination by CTL remains controversial.  
 
NKT cells also have cytolytic ability and could kill DC in a similar manner to CD8+ T cells. It 
has been proposed that DC killing is one of the immune regulatory functions of NKT cells, to 
prevent excessive antigen stimulation (151, 152) and regulate the Th1/Th2 balance (310). 
Human NKT cells can lyse DC in vitro in an α-GalCer, CD1d-dependent manner (150, 151, 
310). DC cytolysis by NKT cells was shown to be abrogated by calcium chelation. As the 
perforin mediated pathway is calcium dependent, this would suggest that perforin is involved 
in the elimination of DC by NKT cells (310). Additionally, treatment with a neutralising 
antibody against FasL reduced apoptosis of DC cultured with human NKT cells, indicating 
that the FasL pathway could also be a mechanism that NKT cells utilise to kill DC (152). 
Recently, a study found that human DN NKT cells cultured with DC induced increased death 
of the DC compared to CD4+ NKT cells (296). However, the mechanism of the DC death by 
the NKT cells was not investigated, but was consistent with the differential expression of 
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perforin in the NKT cell subsets (235). Therefore, these in vitro studies suggest that in 
addition to CTL, NKT cells could also regulate immune responses by eliminating DC.  
 
 
1.5 Aims 
Regulation of DC survival and activity is critical to the outcome of immune responses. The 
evidence presented in recent literature supports a regulatory role for CTL in DC survival, 
which occurs by a perforin-dependent mechanism. In addition, there is evidence to suggest 
that NKT cells have an immunoregulatory role in eliminating DC. At the start of this project, 
the strongest evidence for DC elimination by CTL had been generated in a model using 
BMDC loaded with peptide antigen and TCR transgenic CD8+ T cells (155). No in vivo data 
had been generated at that time, to demonstrate a direct role of NKT cells in regulating DC 
survival. Therefore, significant questions yet to be answered were whether CTL eliminate DC 
in a perforin-dependent manner during a physiologically relevant immune response, and 
whether NKT cell eliminate DC in an in vivo setting. The aim of this thesis was to answer 
these questions.  
 
1.5.1 Specific Aims 
• The first aim of this thesis was to use the murine influenza A virus model to determine 
whether the virus specific CD8+ T cell response was enhanced in PKO mice compared 
to C57BL/6 mice, and to correlate the magnitude of the CD8+ T cell response to DC 
survival in the two mouse strains. More DC survival was expected to correlate with 
increased CD8+ T cell response.  
 
• The second aim was to use the potent NKT cell ligand α-GalCer and the model protein 
antigen ova to determine whether either ova-specific CTL or NKT cells regulated DC 
survival in a perforin-dependent manner.  
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• During investigations into the second aim a decrease in the splenic CD8+ DC subset 
was identified during treatment with α-GalCer. The third and final aim was to further 
characterise the kinetics of this decrease, and determine the mechanism by which the 
splenic CD8+ DC were lost after treatment with the NKT cell ligand α-GalCer.  
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2.1 Materials 
 
2.1.1 Labware 
A list of plasticware and suppliers is given below.  
Product Supplier/Distributor 
ABI Prism® 96 well optical reaction (PCR) 
plates 
Applied Biosystems, Foster City, CA, 
USA 
Acrodisc® 32 mm syringe filters with 0.2 µm 
Supor® membrane 
PALL LifeSciences, Cornwall, U.K 
Axygen Micro Tubes 1.7 mL Axygen Scientific Inc., Union City, 
CA, USA 
BD 10 mL syringes & BD 1 mL tuberculin 
syringes 
BD BioSciences, Bedford, MA, USA 
BD Insyte I.V. Catheter BD BioSciences 
BD Falon sterile nylon cell strainer (70 
µM)  
BD BioSciences 
BD Falcon Polystyrene tissue culture 
plates: 6 well plates, Multiwell plates & 
Microtest U-bottom 96 well plates 
BD BioSciences 
BD Falcon Polystyrene tissue culture 
flasks: 200 mL & 600 mL 
BD BioSciences 
BD FalconPolystyrene conical tubes: Blue 
Max 50 mL & Blue Max Jr 15 mL 
BD BioSciences 
BD Falcon Polystyrene serological pipettes BD BioSciences 
Nunc-Immuno Plate, MaxiSorpSurface  Nunc Brand Products, Denmark 
Nylon Gauze (70 µm) NZ Filter Specialists Ltd., Onehunga, 
Auckland, NZ 
PrecisionGlide Needles (18, 21 & 25 
gauge)  
BD BioSciences 
RNAse free Pestle Disp with 1.5 mL 
microtube  
Kontes glass company, Vineland New 
Jersey, USA 
TitreTubes® Micro Tubes BioRad, Hercules, CA, USA 
Transfer pipettes (1 mL) Samco Scientific, Mexico 
Ultra-Fine™ needle Insulin syringes (29 BD BioSciences 
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gauge)  
2.1.2 Reagents and Buffers 
 
2.1.2.1 General Buffers and Solutions 
Ammonium Chloride Tris (ACT) Lysis buffer 
Immediately before use, 9 parts NH4Cl (Sigma, St Louis, MO, USA), pH 7.4, was combined 
with 1 part Tris-HCl (Merck, Darmstadt, Germany), pH 7.4, to give a final concentration of 
0.144 M NH4Cl and 0.017 M HCl. 
 
Alsever’s Solution 
Dextrose (BDH Laboratory supplies, Poole, England), NaCl (BDH Laboratory supplies), and 
Sodium citrate.2H2O (BDH Laboratory supplies) were dissolved in 1 L dH2O to give final 
concentration of 20.5 mg/mL dextrose, 4.2 mg/mL NaCl and 8.0 mg/mL sodium citrate.2H2O. 
The pH was adjusted to 6.1 with 1 M citric acid (BDH Laboratory supplies) and the solution 
stored at room temperature (RT).  
 
Anaesthetic 
A 10 x concentration of anaesthetic was made by combining 10 mL ketamine (100 mg/mL, 
Phoenix, Auckland, New Zealand) with 1.5 mL of xylazine (20 mg/mL, Phoenix) and stored 
in the dark at RT. Immediately before use the 10 X stock solution was diluted to a 1 X 
solution using sterile phosphate buffered saline (PBS, GIBCO, Invitrogen, Auckland, NZ).  
 
Bio-Plex assay buffer 
Bovine serum albumin (BSA, Henderson, Auckland, NZ), Tween 20 (Sigma), NaN3 (Sigma), 
and ethylenediaminetetraacetic acid (EDTA, Sigma) were added to 1 L PBS, to give a final 
concentration of 0.1 % BSA, 0.05 % Tween 20, 0.005 % (w/vol) NaN3, and 2.5 mM EDTA. 
The buffer was stored at 4 °C.  
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Bovine Serum Albumin (BSA) 
BSA with low endotoxin content (≤ 1 EU/mg) and no IgG was purchased from ICPbio Ltd. 
(Henderson, Auckland, NZ) in powder form and stored at 4 °C.  
 
BSA was also purchased from Sigma in powder form and stored at 4 °C.  
 
5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) 
CFSE was purchased as a powder from Molecular Probes (Eugene, OR, USA) and dissolved 
in dimethyl sulfoxide (DMSO, Sigma) to a 10 mM solution and stored at -20 °C 
 
Cell Tracker Orange (5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine) 
(CTO) 
CTO was purchased as a powder from Molecular Probes (Eugene, OR, USA) and dissolved in 
DMSO (Sigma) to a 10 mM solution and stored at -20 °C.  
 
Collagenase II 
Collagenase II was purchased from Invitrogen. The lyophilised powder was stored at 4 °C and 
made up fresh in IMDM to a concentration of 2.4 mg/mL before use.  
 
DEPC/RNAse free dH2O  
DEPC/RNAse free dH2O was purchased from Ambion (Foster city, CA, USA) and stored at 
RT.  
 
DNase I 
DNase I was purchased from Roche (Mannheim, Germany). The lyophilised powder was 
dissolved to a concentration of 10 mg/mL in IMDM and stored at -20 °C.  
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Foetal Calf Serum (FCS) 
Mycoplasma and virus screened, and performance-tested FCS that contained less than 0.5 
EU/mL endotoxin, was purchased from Sigma (batch number 6C0413) and stored at -20 °C. 
 
Fluorescence Activated Cell Sorting (FACS) Buffer 
EDTA (Sigma), NaN3 (Sigma) and FCS were added to 1 L PBS, to give final concentrations 
of 10 mM EDTA, 0.01 % (w/vol) NaN3 and 2 % FCS. The buffer was stored at 4 °C.  
 
Geneticin (G418) 
The selective antibiotic Geneticin (G418, GIBCO) was made into aliquots and stored at -20 
°C.  
 
Iscove’s Modified Dulbecco’s Medium (IMDM) 
IMDM supplemented with GlutaMAX, 25 mM HEPES buffer plus 3.024 mg/L NaHCO3 
from GIBCO was purchased from Invitrogen.  
 
Complete IMDM (cIMDM) 
cIMDM was made by adding Penicillin-Streptomycin (GIBCO, Invitrogen), 2-ME and FCS to 
0.5 L IMDM to give final concentrations of 100 U/mL Penicillin, 100 µg/mL Streptomycin, 
55 µM 2-ME and 5 % FCS. cIMDM was stored for up to 1 month at 4 °C.  
 
Liberase CI 
Liberase CI was purchased from Roche. The lyophilised powder was diluted in injectable 
water (DEMO S.A Pharmaceutical Industry, Athens, Greece) to a final concentration of 16.4 
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mg/mL. Aliquots were stored at -20 °C and further diluted in IMDM just before use to a 
working concentration of 0.41 mg/mL.  
 
Lipopolysaccharide (LPS) 
LPS from Escherichia coli, serotype 0111:B4, was purchased from Sigma. The lyophilised 
powder was dissolved to a concentration of 1 mg/mL in IMDM and stored at 4 °C.  
 
2 Mercaptoethanol (2 ME) 
2 ME solution in PBS was purchased from Sigma as a 55 mM (1000x) and stored at 4 °C.  
 
Phosphate Buffered Saline (PBS) pH 7.2 
One 47.8 g bottle of Dulbecco’s PBS without CaCl2 and MgCl2 (Sigma Aldrich, Auckland, 
NZ) was dissolved in 5 L dH2O to make a 1 X solution for making FACS buffer. The pH was 
adjusted to 7.4 and the solution was stored at 4 °C.  
 
PBS used at other times was purchased from GIBCO in 500 mL bottles. Bottles were stored at 
RT until opened. Once opened bottles were stored at 4 °C.  
 
Trypsin/EDTA (Ethylenediaminetetraacetic acid) 
Trypsin/EDTA solution containing 0.25 % Trypsin and 1 mM EDTA in Hanks Balanced Salt 
Solution (GIBCO) were stored at -20 °C. Aliquots were thawed as required and kept at 4 °C.  
 
Würzburger Buffer 
EDTA (Sigma), DNAse I and FCS were added to 1 L PBS, to give final concentrations of 5 
mM EDTA, 0.02 mg/mL DNAse I and 1 % FCS. Buffer was stored at 4 °C.  
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2.1.2.2 Solutions for enzyme linked immunosorbent assay (ELISA)  
ELISA Buffer  
BSA (Sigma), 5 g and 0.1 g of Thimerosal (Sigma) was dissolved in 1 L of 1 X wash buffer. 
The pH was adjusted to 7.4 and the buffer stored at 4 °C for no longer than one month.  
 
ELISA Blocking Buffer  
BSA (Sigma), 5 g was added to 250 mL of PBS, to give a final concentration of 5 % BSA. 
The pH was adjusted to 7.4 and the buffer stored at 4 °C for no longer than 3 weeks. 
 
ELISA Coating Buffer  
Na2CO3 (BDH Laboratory Supplies), 1.59 g and 2.93 g of NaHCO3 were dissolved in 1 L of 
dH2O and the pH adjusted to 9.6. The solution was stored at 4 °C for no longer than 3 weeks.  
 
ELISA Stopping Solution (2 mM Sodium Azide solution) 
NaN3 (Sigma) was dissolve in 200 mL of dH2O, giving a final concentration of 2 mM. The 
solution was stored at RT.  
 
ELISA Substrate Buffer  
Citric acid (BDH Laboratory Supplies), 2.82 g and 2.92 g of NaH2PO4 were dissolved in 500 
mL of dH2O and pH adjusted to 4.2. The solution was stored at 4 °C. 
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ELISA Substrate Solution (ABTS-2,2’-azino-di (3-ethylbenzthiazolinesulfonic acid) in 
substrate buffer pH 4.2) 
ABTS (Sigma), 0.0548 g was dissolved in 100 mL Substrate Buffer. The solution was stored 
in aliquots at -20 °C protected from light. Immediately before use, 1 µl of 30 % H2O2 (BDH 
Laboratory Supplies) was added per 1 mL of substrate solution.  
 
ELISA Wash Buffer  
NaCl (BDH Laboratory Supplies) 32 g, 0.8 g of KH2PO4 (BDH Laboratory Supplies), 4.6 g of 
Na2HPO4 (anhydrous) (BDH Laboratory Supplies), 0.8 g of KCl (BDH Laboratory Supplies) 
and 2 mL of Tween 20 (Sigma Aldrich, St Louis, MO, USA) were dissolved in 400 mL of 
dH2O to make a 10 X solution. The pH was adjusted to 7.4 and stored at 4 °C.  
 
A 1 X solution was made by using 1 part of 10 X solution and 9 parts dH2O and stored at 4 °C.  
 
 
2.1.2.3 Cytokines 
Granulocyte-macrophage colony stimulating factor (GM-CSF) 
Recombinant murine GM-CSF was produced using stationary phase cultures of the murine 
X63 cell line, transfected to secrete the full length murine GM-CSF protein (kindly provided 
by Dr Antonius Rolink, Basel Institute for Immunology, Basel, Switzerland).  
 
Interleukin 4 (IL-4) 
Recombinant murine IL-4 was produced using stationary phase cultures of a Chinese Hamster 
Ovary cell line (CHO), transfected to secrete the full length murine IL-4 protein (346). 
 
To collect cytokines from producing cell lines, adherent cells were grown for approximately 2 
weeks in cIMDM and culture supernatants were harvested and filtered through a 0.2 µM 
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serum filter and stored at -80 °C. Culture supernatants were titrated and an optimal dose used 
for the growth of bone marrow derived DC (BMDC). 
 
2.1.2.4 Glycolipids 
The α-Galactosylceramide (α-GalCer) for loading of CD1d tetramer was obtained from 
Alexis (Sapphire Bioscience, Redfern, Australia) and used as described in section 2.2.5.1. In 
all remaining experiments, the NKT cell ligands α-GalCer and OCH were kindly provided by 
Gavin Painter (IRL, Lower Hutt, NZ) and were manufactured as described in Lee et al (347).  
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2.1.2.5 Antibodies, pentamers/multimers and secondary step reagents  
Antibodies used for flow cytometry 
Specificity Clone/Isotype Fluorophore Source 
FcγRII/III 
(CD32/CD16) 
2.4G2 - Purified from B cell hybridoma cell 
line 
B220 (CD45R) 6B2 PerCp BD Pharmingen (San Diego, CA, 
USA) 
CD1d 1B1 PE eBioscience (San Diego, CA, USA) 
CD3ε 145-2C11 PE-Cy7 eBioscience  
CD4 GK1.5 Pacific Blue Purified from B cell hybridoma cell 
line 
CD8 53-6.7  FITC BD Pharmingen   
2.43 FITC Purified from B cell hybridoma cell 
line 
CD11b M1/70 PE BD Pharmingen  
CD11c 
 
N418 APCy 
Alexa 647 
Purified from B cell hybridoma cell 
line 
HL3 APCy BD Pharmingen  
CD24 M1/69 PE BD Pharmingen  
CD62L MEL-14 APCy BD Pharmingen  
CD86/B7-2 GL1 Biotin Purified from B cell hybridoma cell 
line 
GL1 PE eBioscience  
CD45.1  A20 PE eBioscience  
CD205/DEC 205 NLDC 145 Biotin  
FITC  
Purified from B cell hybridoma cell 
line 
IFN-γ XMG1.2 APCy BD Pharmingen  
 Rat IgG1a APCy BD Pharmingen  
MHC-II (I-Ab) M5/114.15 PE BD Pharmingen  
KLRG1 2F1 APCy eBioscience  
 Golden 
Hamster IgG 
APCy eBioscience  
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Antibody used for ELISA 
Specificity Clone/Isotype Source 
Rat anti-mouse IgG1 A85-1 BD Pharmingen  
 
Antibody used for neutralisation of TNF-α 
Specificity Clone/Isotype Source 
TNF-α TN3-19.12 Biolegend (San Diego, CA, 
USA) 
 
Multimers/Pentamers 
Name Peptide sequence Label Source 
NP366-374 H-2Db ASNENMETM Unlabelled  ProImmune Ltd 
(Oxford, England) 
PA224-233 H-2Db SSLENFRAYV Biotin ProImmune Ltd  
Ova257-264 H-2Kb SIINFEKL PE ProImmune Ltd  
LCMV GP33-41 H-2Db  KAVYNFATC Unlabelled  ProImmune Ltd  
CD1d tetramer Unloaded PE ProImmune Ltd  
 
Second step reagents  
Name Source 
R-PE Fluorotag ProImmune Ltd  
Streptavidin (SA)-FITC, PE, PerCP, APCy  BD Pharmingen  
SA- Horseradish peroxidase (HRP) BD Pharmingen  
 
Viability dyes used for flow cytometry  
Name Source 
4’,6-diamidino-2-phenylindole (DAPI) Invitrogen  
Propidium Iodide (PI) BD Pharmingen  
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2.1.2.6 Peptides 
The influenza A nucleoprotein (NP366-374, ASNENMETM) and influenza A Polymerase acidic 
protein (PA224-233, SSLENFRAYV) peptides were purchased from Mimotopes Pty Ltd. 
(Clayton, Victoria, Australia).  
 
 
2.1.2.7 Tumour cell line 
The B16.ova tumour cell line was generated by E.Lord and J.G. Frelinger (348). The tumour 
cell line was derived by transfection of the parental B16.F0 tumour cell line with cDNA 
encoding chicken ovalbumin.  
 
The tumour cell line was maintained in cIMDM containing 0.5 mg/mL Geneticin selective 
antibiotic. Adherent cells were detached by 1 min incubation at 37 °C with 2 ml 
Trypsin/EDTA. Proteolysis was stopped by adding an equal volume of FCS and cells were 
washed 3 times in IMDM before use.  
 
 
2.1.3 Mice 
 
2.1.3.1 Mouse ethics approval 
All experimental procedures were approved by and carried out with the ethical approval of the 
Victoria University Animal Ethics Committee and performed according the guidelines of 
Victoria University.  The ethics protocol numbers used throughout this thesis were: 
2003R23M, 2004R5, 2004R21M, 2006R19, 2007R3M, 2007R17M.   
 
2.1.3.2 Mouse maintenance  
All animals were maintained and bred in the Biomedical Research Unit, Malaghan Institute of 
Medical Research, based at Victoria University, Wellington, New Zealand.  
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2.1.3.3 Mouse strains 
C57BL/6, interferon gamma knockout (IFN-γ KO) (349), and perforin knockout (PKO) mice 
on a C57BL/6 background (244) were originally purchased from The Jackson Laboratory (Bar 
Harbour, ME, USA). PKO mice were genotyped and shown to contain the inactivated perforin 
allele as reported in Kagi et al (244). Furthermore, experiments carried out in the laboratory 
while this thesis work was being carried out consistently found that immune PKO mice lack 
the ability to eliminate DC in vivo, which is in contrast to immune C57BL/6 mice that rapidly 
eliminate DC (unpublished data and (155)). 
 
Mice deficient in CD1 (CD1 KO) on a C57BL/6 background were obtained from CR Wang 
(Department of Pathology, University of Chicago, IL, USA) and generated as described in 
Chen et al (350).  
 
Langerin-EGFP knockin mice, on a C57BL/6 background, expressing enhanced green 
fluorescent protein (EGFP) under the control of the Langerin promoter, as described in 
Kissenpfennig et al (57), were kindly provided by B. Malissen, Centre d’Immunologie 
Marseille-Luminy, France. 
 
Mice lacking Fas expression (B6.MRL.Faslpr or B6.lpr) were from breeding pairs obtained 
from The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.  
 
OT-IxB6.congenic mice were created onsite by breeding B6.SJL-PtprcaPep3b/BoyJARC mice, 
obtained from the Animal Resources Centre (Canning Vale, WA, Australia), with OT-I mice 
(351) provided by S. Hook (School of Pharmacy, Dunedin, NZ) with the permission of 
F.Carbone (Melbourne University, Melbourne, Australia), until homozygous for the transgenic 
TCR. 
 
All mice strains were maintained by brother x sister mating at the Malaghan Institute of 
Medical Research. At the commencement of each experiment, mice were aged 6-12 weeks and 
mice within each experiment were age- and sex-matched.  
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2.2 Methods 
 
2.2.1 General cell culture 
All cells were cultured in cIMDM at 37 °C, with 5 % CO2 and 95 % humidity.  
 
 
2.2.2 Culture of Dendritic Cells 
 
2.2.2.1 Culture from Bone marrow (BM) precursors 
Mice were first euthanised by asphyxiation in CO2, and the hind limbs were detached at the 
hip joints and placed into a 10 mL Falcon tube containing IMDM. The muscle and connective 
tissue were removed, knee joints were separated and the ends of the femurs and tibias were cut 
off to expose the BM. The marrow was flushed out into a 50 mL Falcon tube using a 25-gauge 
needle and a 10 mL syringe filled with IMDM. Clumps of cells were disrupted by vigorous 
pipetting and the suspension was passed through a 70 µm cell strainer. Cells were pelleted by 
centrifugation at 320 g for 4 min and resuspended in cIMDM. Live cells were identified by 
Trypan blue dye (Trypan Blue stain 0.4 %, GIBCO) exclusion and counted using a 
haemocytometer (Weber Scientific International Ltd, Middix, England). Cells were 
resuspended in cIMDM at 4 x 105 cells/mL and plated out in 6 well plates. Each well 
contained 5 ml cIMDM containing 2 x 106 DC plus 10 ng/mL GM-CSF and 20 ng/mL IL-4 
(352). Plates were incubated at 37 °C for 7 days. Cells were supplemented with nutrients on 
days 3 and 5 by removing 2 mL medium from each well and replacing with 2 mL fresh 
cIMDM containing of 10 ng/mL GM-CSF and 20 ng/mL IL-4. 
 
2.2.2.2 Activation of DC 
DC were activated by treating with 100 ng/mL LPS for the last 20 hr of culture. Non-adherent 
cells were harvested on day 7 by pipetting up the cell suspension and gently washing over the 
surface of the plate 2 or 3 times. 
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2.2.2.3 Loading of DC with α-Galactosylceramide (α-GalCer) 
DC were loaded with α-GalCer by treating with 100 ng/mL α-GalCer (IRL) for the last 40 hr 
of culture.  
 
 
2.2.3 Infection with influenza A viruses 
 
2.2.3.1 Preparation of influenza A virus stocks 
The A/HKx31 (HKx31) influenza A virus is a laboratory-generated recombinant with the 
external surface components of A/Aichi/2/34 (H3N2) and the internal components of A/Puerto 
Rico/8/34 (PR8, H1N1). Virus stocks were grown in allantoic cavities of 10-day-old 
embryonated chicken eggs and stored as infectious allantoic fluid at -80 °C. Virus stock was 
shown to be endotoxin free by Limulus amebocyte lysate assay (Sigma). Virus titre was 
determined by agglutination of human erythrocytes and is expressed as hemagglutinating units 
(HAU). Stock HKx31 (10 HAU/1 µL) was stored at -80 °C in 100 µL aliquots. Before use a 
fresh aliquot was diluted in sterile PBS to a concentration of 1 HAU/30 µL.  
 
Influenza virus PR8 was kindly provided by Dr. Margaret Baird (University of Otago, 
Dunedin, NZ) and prepared as described in Faulkner et al (353). Stock PR8 Virus (0.86 x108 
PFU/mL) was stored at -80°C in 1 mL aliquots. Before use a fresh aliquot was diluted in 
sterile PBS to a concentration of 5 x 107 PFU/mL. 
 
Both viral stocks were titrated and an optimal dose was determined by measuring weight loss 
and assessing the CD8+Db-NP366-374+ T cell response. Optimal viral doses chosen were able to 
induce a measurable a CD8+Db-NP366-374+ T cell response (with CD8+Db-NP366-374+ T cells being 
5-10 % of blood CD8+ T cells at day 8-11 after infection) and induced a weight loss that 
complied with the NZ ethical guidelines (see section 2.1.3.1).  
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2.2.3.2 Virus infections 
Mice were anaesthetised by receiving an intraperitoneal (i.p.) injection of anaesthetic 
containing ketamine and xylazine at 100 mg/kg and 3 mg/kg body weight respectively 
followed by an intranasal (i.n.) infection with of 1 HAU of HKx31 virus diluted in 30 µL of 
sterile PBS. Control mice were injected with 30 µL of sterile PBS. This i.n. route of 
administration was chosen as this the natural route of infection and generates a physiologically 
relevant immune response. To generate a secondary response, mice were initially primed by 
i.p. injection with 1 x 107 PFU PR8 virus in 200 µL sterile PBS 4 weeks before i.n. challenge 
with 1 HAU of HKx31 virus. The use of the i.p. route of administration for the PR8 virus was 
used based on the known virulence of the viral strain and previously published work (354-
357).  
 
 
2.2.4 Analysis of viral titre in lung tissue 
 
2.2.4.1 Collection of lung tissue 
Mice were euthanised with a lethal dose of anaesthetic containing ketamine and xylazine at 
400 mg/kg and 12 mg/kg body weight respectively and the lung cavity exposed. Lungs were 
harvested from mice at different time points after an i.n. infection of HKx31 and placed into a 
1.5 mL RNAse free microtube (Kontes glass company, Vineland New Jersey, USA) 
containing 500 µL of TRIzol reagent (Invitrogen). Samples were stored at -80 °C.  
 
2.2.4.2 RNA extraction 
Lung tissue was thawed and homogenised using an RNAse free pestle (Kontes glass 
company). Once the tissue was homogenised 500 µL of TRIzol reagent was added followed 
by centrifugation at 12000 g for 10 min at 4 °C. The supernatant was collected and transferred 
to a clean 1.7 mL microtube (Axygen Scientific Inc., Union City, CA, USA) and left at RT for 
5 min. Next, 200 µL chloroform was added followed by vigorous shaking for 15 sec, then left 
to incubate at RT for 2-3 min. After incubation, samples were centrifuged at 12000 g for 15 
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min at 4 °C and the colourless aqueous phase was transferred to a new microtube. To 
precipitate the RNA, 500 µL of isopropanol was added to the aqueous phase, mixed and 
incubated at RT for 10 min followed by centrifugation at 12000 g for 10 min. The supernatant 
was removed and the pellet washed twice in 1 mL of 75 % ethanol and centrifuged at 7500 g 
for 5 min. Ethanol was tipped out, and the pellet was left to air dry and resuspended in 20 µL 
DEPC/RNAse free dH2O. Contaminating DNA was removed using the DNA-free kit 
(Ambion, Foster City, CA, USA). 
 
2.2.4.3 Quantification of RNA 
RNA concentration was calculated according to the formula: 
RNA (mg/mL) = optical density (OD) at 260 nm x dilution factor x 40 
 
2.2.4.4 Generation of cDNA 
cDNA was synthesized from 5 µg RNA using the SuperScript III First-Strand Synthesis 
System for RT-PCR kit and random hexamer primers (Invitrogen) following the 
manufacturers instructions.  
 
2.2.4.5 Real time PCR (RT-PCR) 
Primers as described in Spackman et al (358) and 18S control primers were obtained from 
Sigma GenoSys (Sigma).  
 
Influenza A virus forward, AGA TGA GTC TTC TAA CCG AGG TCG, Influenza A virus 
reverse, TGC AAA AAC ATC TTC AAG TCT CTG, 18S forward, GTA ACC CGT TGA 
ACC CCA TT and 18S reverse, CCA TCC AAT CGG TAG TAG CG. For amplification 
reactions, cDNA, primers and SYBR Green PCR MasterMix (Applied Biosystems, Foster 
City, CA) were mixed and run on an ABI prism 7700 Sequence Detection System (Applied 
Biosystems) for 40 cycles of 15 sec at 95°C followed by 1 min at 62°C. The amplified 
products were homogeneous by Tm. For each sample the number of cycles required to reach a 
pre-determined ∆Rn was calculated, and the expression of Influenza A virus in treated mice 
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(Exp) relative to C57L/6 mice D8 treated control mice (Cont) was calculated as 2-∆∆Ct, where 
∆∆Ct = (No. cycles for influenza A virusExp – No. cycles for 18SExp) – (No. cycles for 
Influenza A virusCont – No. cycles for 18SCont). 
 
 
2.2.5 Treatment with glycolipids and ova protein 
 
2.2.5.1 Preparation of glycolipids 
NKT cell ligands α-GalCer and OCH (IRL) were resuspended in a 10:10:3 
methanol:chloroform:water solution and further diluted to a concentration of 200 µg/mL in 
PBS containing 0.5 % Tween 20 (Sigma). To ensure the solution was completely dissolved it 
was incubated at 80 °C for 5 min followed by sonication (Ultrasonic cleaner, Unisonics PTY 
LTD, Sydney, Australia) for 5 min, then repeated 3 times. A 1 X solution was prepared by 
diluting the 200 µg/mL stock solution in PBS to a final concentration of 2 µg/mL and stored at 
4 °C.  
 
α-GalCer from Alexis (Sapphire Bioscience, Redfern, Australia) was diluted to a 
concentration of 200 µg/mL in PBS containing 0.5 % Tween 20 (Sigma). To ensure the 
solution was completely dissolved it was incubated at 80 °C for 5 min followed by sonication 
for 5 min, then this was repeated 3 times. The solution was then stored at 4 °C overnight 
before CD1d tetramer loading the following day (see section 2.2.7.4).  
 
2.2.5.2 Preparation of chicken ovalbumin (ova) protein 
Chicken ova, kindly provided by Thomas Moran (Department of Microbiology, Mount Sinai 
School of Medicine, New York), was isolated endotoxin-free as described in Brimnes et al 
(359). The protein was diluted to a final concentration of 60 mg/mL at stored at -80 °C. Prior 
to use the 60 mg/mL stock solution was further diluted in PBS to the desired concentration.  
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2.2.5.3 Injection of glycolipids and ova protein 
Prior to treatment the glycolipid solution was sonicated to ensure no particles were present. 
When glycolipids were administered in combination with ova protein 1 mL insulin syringes 
were layered with 100 µL of glycolipid and ova protein to ensure simultaneous injection of 
both glycolipid and protein. Mice were immunised intravenously (i.v.) with 200 ng of 
glycolipid unless otherwise stated and 200 µg of ova protein in a total volume of 200 µL. 
Single administration of either glycolipid or ova protein was injected in a 100 µL volume.  
To boost the ova-specific response and create a secondary T cell response some mice received 
an i.v. boost of either 200 µg or 2 mg ova protein in a 100 µL volume 30 days after the initial 
treatment of α-GalCer and ova protein.  
 
 
2.2.6 Tissue Preparation 
 
2.2.6.1 Bronchoalveolar lavage (BAL) 
Mice were euthanised by a lethal dose of anaesthetic as described in section 2.2.4.1 and the 
trachea exposed. A small incision was made into the trachea and the catheter tube inserted. 1 
mL of sterile PBS was washed through the trachea and lung 3 times. The harvested BAL fluid 
was collected into FACS tubes and stored on ice. This was repeated 3 times until 
approximately 3 mL of BAL fluid was collected in total from each mouse. Cells were then 
centrifuged at 320 g for 4 min and pellets resuspended the appropriate buffer and stored at 
4°C. Before use samples were counted as described in section 2.2.6.6.  
 
2.2.6.2 Blood 
Mice were warmed for approximately 5 min under a heat lamp before placing them into 
restrainers. Once securely restrained, blood was collected by either gently cutting across the 
lateral tail vein or by tipping the end of the tail with a sterile scalpel blade. Approximately 10 
drops of blood was collected into 500 µL of Alsever’s Solution in a 1.7 mL microtube. 
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Pressure was applied to the cut site and, once bleeding had ceased, mice were returned to their 
cages.  
 
The blood samples were stored on ice until ready for processing. Samples were centrifuged at 
600 g for 2 min and the supernatant was removed by aspiration. The pellet was resuspended in 
1 mL ACT buffer and incubated at 37 °C for 5 min to lyse red blood cells. Samples were 
centrifuged at 600 g for 2 min, the supernatant was removed by vacuum and the pellets 
resuspended in FACS buffer. This was repeated to ensure all trace of ACT buffer was 
removed. Samples were then resuspended in the appropriate buffer and stored at 4 °C. 
 
2.2.6.3 Lymph Nodes (LN) 
Mesenteric lymph nodes (MesLN) were harvested from mice euthanised by CO2 asphyxiation, 
whereas mediastinal lymph nodes (MLN) were harvested from mice euthanised by a lethal 
dose of anaesthetic as described in section 2.2.4.1. Harvested LN were placed into cIMDM 
and stored on ice until they could be processed.  
 
LN were disrupted on a 70 µM cell strainer using a 1 mL syringe plunger and cells were 
washed with IMDM followed by centrifugation at 320 g for 4 min. LN cells were then 
resuspended in the appropriate buffer and stored at 4°C. Before use samples were counted as 
described in section 2.2.6.6.   
 
When stated, LN cells were digested to allow maximum release of cells. LN were pulled apart 
using 18 gauge needles and were incubated for 1 hr at 37 °C in 1 mL of IMDM containing 2.4 
mg/mL Collagenase II and 10 µg/mL DNase I. Cells were then forced repeatedly through a 
21-gauge needle to obtain a single cell suspension, passed through 70 µM gauze and collected 
into FACS tubes. Cells were then centrifuged at 320 g for 4 min and washed and resuspended 
in the appropriate buffer and stored at 4 °C. Before use samples were counted as described in 
section 2.2.6.6.  
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2.2.6.4 Spleen 
Spleens were harvested from mice euthanised by either asphyxiated in CO2 or cervical 
dislocation. Spleens were placed into cIMDM and stored on ice until they could be processed.  
 
Spleens were disrupted on a 70 µM cell strainer using a 1 mL syringe plunger and cells were 
washed with IMDM and centrifuged at 320 g for 4 min. Splenocytes were incubated in 3 mL 
ACT Buffer for 5 minutes at 37 °C to lyse red blood cells followed by centrifugation at 320 g 
for 4 min. Splenocytes were then resuspended in the appropriate buffer and stored at 4 °C. 
Before use samples were counted as described in section 2.2.6.6. 
 
When indicated spleens were digested to allow maximum release of splenocytes. 1 mL of 
IMDM containing 0.41 mg/mL liberase CI and 10 µg/mL DNase I was injected into the 
spleens using a 1 mL syringe and a 25-gauge needle. Spleens were placed into either a 24 well 
plate or 15 mL Falcon tubes and incubated for 25 min at 37 °C. EDTA was then added to a 
final concentration of 10 mM and spleens were incubated for a further 5 min at 37 °C. Spleens 
were then disrupted as above and treated with ACT buffer and resuspended in the appropriate 
buffer and stored at 4 °C. Before use samples were counted as described in section 2.2.6.6.  
 
2.2.6.5 Thymus 
Thymi were harvested from mice euthanised by asphyxiation in CO2 and placed into cIMDM 
and stored on ice until samples could be processed.  
 
Thymi were disrupted on a 70 µM cell strainer using a 1 mL syringe plunger and cells were 
washed with IMDM and centrifuged at 320 g for 4 min. Thymocytes were then resuspended in 
the appropriate buffer and stored at 4 °C. Before use samples were counted as described in 
section 2.2.6.6.  
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2.2.6.6 Cell counting 
All cell samples were counted, either by Trypan blue dye (GIBCO) exclusion using a 
haemocytometer (Weber Scientific International Ltd) or with the Z2 Coulter Particle Count 
and Size Analyzer (Beckman Coulter Inc., Fullerton, CA, USA).  
 
 
2.2.7 Fluorescent labelling of cells and analysis by flow cytometry 
 
2.2.7.1 Labelling of proteins and antibodies 
Purified antibodies or ova protein were labelled with Alexa Fluor 647 (Invitrogen), fluorescein 
isothiocyanate (FITC, Sigma) or NHS-Biotin (Biotin, Pierce, Rockford, IL, USA). The dyes 
were dissolved in DMSO to a concentration of 10 mg/mL and stored under oil at -80 ºC. 
Protein (0.25 – 0.5 mg) was transferred to a Vivaspin 500 column (Vivascience, Stonehouse, 
UK) and concentrated by centrifugation at 4700 g for 10 min. The protein was washed twice 
by adding 500 µL fresh 0.1 M sodium bicarbonate (Sigma, St Louis, MO, USA) diluted in 
dH2O, followed by centrifugation at 4700 g for 10 min and discarding of the flow through. For 
labelling, the protein was transferred to a clean 1.7 mL microtube, and diluted to 2.5 mg/mL in 
0.1 M sodium bicarbonate buffer. The dye at 0.1 µg per 1 µg protein was added while mixing. 
After 8 min incubation at RT the protein was transferred back to the column and washed once 
with 0.1 M Tris buffer (pH 8-9) and twice with PBS to remove any excess dye before 
transferring to a new tube. Labelled antibodies or ova protein were diluted to 0.5-1 mg/mL in 
PBS containing 0.1 % sodium azide for storage at 4 °C. Antibodies were then titrated to 
determine the optimal concentration for flow cytometric analysis.  
 
2.2.7.2 Detection of cell surface marker expression 
Single cell suspensions were prepared, washed once in FACS buffer and resuspended at 1-10 
x 107 cells/mL. The cell suspension was distributed to the wells of a round bottom 96 well 
plate in 100 µL aliquots. The plate was centrifuged at 240 g for 2 min and the supernatants 
were tipped off by flicking the plate once. Pellets were resuspended by vortexing. Fc receptor 
blocking antibody (2.4G2) was added at 10 µg/mL, and the plate was incubated at 4 °C for 10 
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min. Fluorescently-conjugated antibodies against surface markers of interest were then added 
at appropriate dilutions in a volume of 50 µL and incubated at 4 °C for a further 10 min. 
Following the incubation 100 µL of FACS buffer was added to each well and the plate 
centrifuging at 240 g for 2 min to remove any excess antibody. If required, second step 
reagents were added and incubated for a further 10 min at 4 °C. Cells were washed and 
resuspended in 200 µL of FACS buffer, containing PI at 0.25 µg/mL or 0.1 µg/mL DAPI, for 
analysis by flow cytometry. 
 
2.2.7.3 Detection of antigen specific TCR using MHC I pentamers 
Samples were prepared as described in section 2.2.6 and cells placed in the wells of a round 
bottom 96 well plate. As described in section 2.2.7.2 the Fc receptors were blocked using the 
2.4G2 antibody followed by the addition of 100 µL of FACS buffer to each well and 
centrifuged at 240 g for 2 min. After centrifugation the supernatants were tipped off by 
flicking the plate once.  
 
For single labelling with the unlabelled Db-NP366-374 pentamer an optimal concentration was 
added directly to the cells and incubated for 10 min at RT. Cells were then washed and the 
supernatants tipped off. 8 µL of the R-PE Fluorotag was added to the cells along with any 
other antibodies of interest at the appropriate concentration and incubated at 4 °C for 20 min. 
Cells were then washed and resuspended in 200 µL of FACS buffer, containing PI at 0.25 
µg/mL, for analysis by flow cytometry. 
 
If samples were to be labelled with both unlabelled Db-NP366-374 and biotin Db-PA224-233 
pentamers, cells were labelled as above with the Db-NP366-374. Then the biotin labelled Db-
PA224-233 pentamer was then added at 2.5 µL/sample for 10 min at RT. Cells were washed and 
supernatant flicked off. SA-APCy was added along with an anti-CD8 antibody at the 
appropriate concentration and incubated at 4°C for 20 min. Cells were then washed and 
resuspended in 200 µL of FACS buffer, containing PI at 0.25 µg/mL, for analysis by flow 
cytometry. 
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For single labelling with the PE conjugated Kb-ova257-264 pentamer, an optimal concentration 
was added directly to the cells and incubated for 10 min at RT. Cells were then washed and 
the supernatants tipped off. Other cell surface antibodies were then added at their optimal 
concentrations and incubated at 4 °C for 20 min. Cells were then washed and resuspended in 
200 µL of FACS buffer, containing PI at 0.25 µg/mL, for analysis by flow cytometry. 
 
2.2.7.4 Loading of CD1d tetramer with α-GalCer and detection of NKT cells with the 
CD1d tetramer 
The PE labelled mouse CD1d tetramer was loaded with α-GalCer (Alexis) by mixing with 12 
molar excess of α-GalCer that had been sonicated for 2 hr at 37 °C and incubated overnight at 
RT. Before labelling of other surface markers (see section 2.2.7.2), cells were incubated for 30 
min with the α-GalCer-loaded mouse CD1d tetramer (ProImmune) at 4 °C. Cells were then 
washed and resuspended in 400 µL of FACS buffer, containing DAPI at 0.1 µg/mL, for 
analysis by flow cytometry. 
 
2.2.7.5 Detection of intracellular IFN-γ after in vitro restimulation 
 
2.2.7.5.1 In vitro restimulation 
Prior to intracellular labelling of IFN-γ, cells were resuspended in cIMDM at 1-2 x 106 
cells/mL and placed into 6 or 24 well plates, with 1 µM NP366-374 or PA224-233 peptide. 
GolgiStop (Pharmingen, BD Biosciences) was added at the beginning of the restimulation at 1 
µg/mL, to prevent export of proteins from the Golgi bodies. Cells were incubated at 37 °C for 
4-6 hr. Cells were then harvested and washed in IMDM. 
 
2.2.7.5.2 Detection of intracellular IFN-γ 
After peptide stimulation, cells were labelled with antibodies for cell surface markers, before 
fixing for intracellular labelling. After surface labelling as described in section 2.2.7.2, cells 
were fixed and permeabilised using the BD Cytofix/Cytoperm Kit (Pharmingen, BD 
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Biosciences). Briefly, cells were washed in FACS buffer and fixed by incubating for 20 min 
with 200 µL of BD Cytofix/Cytoperm solution at RT. Cells were then washed twice with 1 X 
BD Perm/Wash buffer. The antibody for IFN-γ, or its respective isotype control antibody, was 
added in 50 µL Cytofix/Cytoperm solution and cells were incubated for 30 min at 4 °C. Cells 
were washed twice more in cold BD Perm/Wash Buffer, resuspended in 200 µL FACS buffer 
and kept at 4 °C before analysis by flow cytometry. 
 
2.2.7.6 Acquisition and analysis 
After surface labelling live cells were resuspended in FACS buffer containing PI or DAPI, for 
acquisition. Live cells were identified based on Forward Scatter (FSC) and Side Scatter (SSC) 
properties and the exclusion of PI+ or DAPI+ events.  
 
Fixed cells were resuspended in 200 µL of FACS buffer for acquisition. Intact, fixed cells 
were identified based on FSC versus SSC properties. Unlabelled samples and single labelled 
controls for each fluorochrome were included in all cases for calibration of voltages and 
compensation. Isotype control antibodies were used to control for background fluorescence 
caused by non-specific antibody binding as indicated.  
 
Data was acquired using either a BD FACSCalibur or BD LSRII SORP (both Beckton-
Dickinson, Mountain View, CA, USA) and analysed using FlowJo software (Tree Star, San 
Carlos, CA, USA).  
 
 
2.2.8 Cell purification by Magnetic Cell Separation (MACS) 
Single cell suspensions of OT-IxB6.congenic LN, filtered through nylon gauze to remove cell 
clumps, were enriched for CD8+ T cells using the AutoMACS system (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Ten million cells were resuspended in 90 µL Würzburger 
buffer with 10 µL MACS CD8α Microbeads (Miltenyi Biotec) per 100 µL. Cells and beads 
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were mixed well and incubated for 15 min at 4 °C. Cells were washed by adding 1 mL of 
Würzbuger buffer followed by centrifugation at 320 g for 4 min and scaled up as appropriate. 
Cells were then resuspended in 500 µL Würzbuger buffer per 1 x 108 cells and filtered through 
a 40 µm cell strainer before positive selection on the AutoMACS. Positively selected cells 
were resuspended in PBS for i.v. injection.  
 
 
2.2.9 Neutralisation of TNF-α 
Mice were treated i.p. with 10 mg/kg of anti-TNF-α (clone TN3-19.12, BioLegend, San 
Diego, CA, USA). Mice were treated i.v. with 200 ng α-GalCer 20 hr later. Then 48 hr after 
the α-GalCer treatment spleens were harvested, digested and processed as described in section 
2.2.6.4. To confirm that the anti-TNF-α treatment was effective, blood was collected at 3 hr 
after α-GalCer treatment, and the serum level of TNF-α measured using the Bio-Plex 
system (Bio-Rad Laboratories, Hercules, CA, USA) according to manufacturer’s instructions 
(see section 2.2.10). 
 
 
2.2.10 Detection of serum cytokines 
Blood was taken from mice by slicing the lateral tail vein and 5-8 drops collected in 1.7 mL 
microtubes. The blood was incubated at RT for 4-6 hr to allow blood clotting. After 
centrifugation at 14000 g for 5 min serum was transferred to a new microtube and stored at -
20 ºC until analysis. Serum levels of IL-4, IFN-γ, IL-12p70 and TNF-α were determined using 
a bead multiplex immunoassay (Bio-Plex systems, Bio-Rad Laboratories) according to 
manufacturer’s instructions. Briefly, the desired capture beads, 0.65 µL per cytokine were 
combined in a microtube in a total volume of 50 µL Bio-Plex assay buffer and transfer to 96 
well filter plates (L-Plate, Abacus ALS, Auckland, New Zealand). The plate was washed twice 
with Bio-Plex assay buffer by adding 100 µL buffer per well and removing by vacuum 
(Bio-Rad). Serum samples were diluted either 1:2 or 1:4 in Bio-Plex assay buffer to a final 
volume of 50 µL and added to the plate. The plate was then incubated with agitation for  
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30 min at RT and then washed twice as described above. Detection antibodies diluted 
appropriately in Bio-Plex assay buffer and 25 µL was added to the plate followed by 
washing and incubation with 50 µL of SA-PE for 10 min at RT. Samples were then washed 
and resuspended in 125 µL Bio-Plex assay buffer before analysis using the Bio-Plex 
system. Cytokine concentrations were determined against commercial standards (Bio-Rad) 
and calculated using the provided software (Bio-Rad, Bio-Plex systems). 
 
 
2.2.11 Detection of ova-specific antibodies by ELISA 
 
2.2.11.1 Generation of positive control serum 
A positive control was used to confirm that the ELISA was working correctly. Mice were 
primed i.p. with two doses of 2 µg ova protein (Sigma) in 100 µL alum (2 % Al(OH)3 
equivalent to 1.3 % Al2O3, Serva Electrophoresis GmbH, Heidelberg, Germany). Mice 
received the first dose of alum and ova protein then 14 days later boosted again. Then 10 days 
after the second dose of alum and ova protein cardiac puncture was performed and blood 
collected in 1.7 mL microtubes. Serum was then collected as described in section 2.2.10.  
 
2.2.11.2 Ova-specific IgG1 ELISA of murine serum 
Initially, Maxi sort immuno binding 96 Microwell plates were coated overnight at 4 °C with 
100 µL of ova protein diluted in ELISA coating buffer to a final concentration of 1 µg/well. 
After overnight incubation plates were inverted to remove excess solution. Wells were then 
washed 4 times with ELISA Wash Buffer and incubated with 150 µL of ELISA Blocking 
Buffer for 1 hr at RT to block non-specific protein binding.  
 
Serum samples were prepared while plates were blocking. Serum samples were thawed on ice 
and samples diluted in PBS. Samples were initially diluted 1:10 then 1:2 serial dilutions were 
carried out to a final dilution of 1:640. After blocking, plates were inverted to remove any 
excess solution and 50 µL of the appropriate samples were added to each well. Plates were 
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sealed, placed in the dark for 1 hr at RT. Plates were washed 6 times with ELISA Wash Buffer 
to remove any unbound serum proteins. For detection of ova-specific IgG1, 50 µL of biotin rat 
anti-mouse IgG1 antibody diluted 1:1000 in ELISA Buffer was added to each well and plates 
were incubated for 2 hr at RT in the dark. To remove excess unbound antibody plates were 
washed as described above. Then the second step reagent, streptavidin-horseradish peroxidase 
(HRP) was diluted 1:1000 in ELISA Buffer and 100 µL added to each well followed by 1 hr 
incubation in the dark at RT. After the 1 hr incubation plates were washed as described above 
to remove excess unbound streptavidin-HRP. Lastly, 100 µL of ELISA Substrate Buffer was 
added to each well for 5-10 min at RT until a gradient of colour was observed across the 
positive control sample, at which point 50 µL of ELISA Stopping Solution was added to all 
wells. After stopping the reactions, the absorbance of each well was read at 414 nm using a 
Versamax Microplate reader (Molecular Devices, Sunny Vale, CA, USA). Antibody titer was 
calculated using SOFTmax PRO (Molecular Devices). 
 
 
2.2.12 In vivo VITAL assay for cytotoxicity 
The VITAL assay provides a method for assessing antigen specific cytotoxicity by the 
analysis of elimination of fluorescently-labelled, antigen-loaded target cells compared to a 
control population of antigen-negative cells (360). 
 
2.2.12.1 Peptide loading of splenic targets 
Single cell suspensions were prepared from the spleens of C57BL/6 mice and separated into 4 
equal aliquots. One group of cells was incubated with α-GalCer at a final concentration of 6 
µM, the second group received 0.6 µM α-GalCer, while the third group received 60 nM α-
GalCer. The remaining group was left untreated. Cells were incubated at 37 °C for 2 hr, 
mixing every half hour by flicking or inverting tubes. Cells were then centrifuged at 320 g for 
4 min.  
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2.2.12.2 Labelling of cells with VITAL dyes 
Untreated cells were labelled with the dye CTO. Cells were counted and resuspended in pre-
warmed cIMDM at 5 x 106 cells/mL.  The CTO dye was added to the cells at a final 
concentration of 10 µM and incubated at 37 °C for 15 min followed by centrifugation at 320 g. 
To remove excess dye cells were resuspended in warmed cIMDM and incubated for 20 min at 
37 °C. The tube was then centrifuged at 320 g and resuspended in IMDM.  
 
Cells treated with α-GalCer were labelled with the dye CFSE. Cells were counted and 
resuspended in cold PBS at 5 x 106 cells/mL. CFSE was added to cells treated with 6 µM α-
GalCer at a final concentration of 4 µM, and cells treated with 0.6 µM and 60 nM α-GalCer 
were labelled with 0.8 µM and 0.16 µM CFSE respectively. Tubes were briefly vortexed to 
evenly distribute dye and incubated for 10 min at 37 °C. Five volumes of cold PBS were 
added to each tube to stop the labelling reaction and tubes were centrifuged at 320 g and 
resuspended in IMDM.  
 
All 4 tubes of cells were then washed 3 times in IMDM prior to i.v. injection. Each set of cells 
was counted and resuspended in IMDM at 6 x 107 cells/mL. The 4 groups of cells were then 
pooled together at equal ratios to give a final concentration of 6 x 107 cells/mL. 
C57BL/6, PKO and CD1 KO mice each received 200 µL i.v. of the target cell mixture. 
 
2.2.12.3 Analysis of NKT cell killing 
Killing was measured at 24 hr after administration of target cells. At this time point the 
MesLN were collected and made into a single cell suspension by straining through 70 µM 
gauze. Cells were then resuspended in 500 µL FACS buffer for analysis by flow cytometry. 
The amount of specific killing of α-GalCer-loaded target cells at each α-GalCer concentration 
was determined by calculating the ratio of surviving α-GalCer-loaded target cells (CFSE+) 
versus untreated target cells (CTO+) and adjusted by comparing to CD1 KO mice. The % 
specific killing was calculated as follows: 
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% specific killing = 100 – 100 x # CFSE+ cells (sample) / # CTO+ cells (sample) 
mean (# CFSE+ (control) / mean # CTO+ (control)) 
 
 
2.2.13 Challenge with B16.ova tumour cells 
Mice were injected s.c. in the left flank with 1 x 105 B16.ova tumour cells. Tumours in 
untreated control mice were palpable from ~8-10 days after tumour challenge. Once tumours 
were palpable they were checked 3 times a week. Bisecting diameters were measured using 
Mitutoyo callipers, with 1.5 mm being subtracted to account for the skin fold thickness. Mice 
were euthanised when tumour size reached 150-200 mm2. 
 
 
2.2.14 Statistical calculations 
All statistical analysis was carried out assuming that the data was sampled from populations 
that approximately followed a Gaussian bell-shaped distribution. Tests for normality were 
conducted on the number of CD8+ and CD8- DC subsets before and after α-GalCer treatment 
and the populations were found to be distributed normally. Parametric tests were chosen as 
when analysing biological data for which the sample size is small (< 12) they are more 
powerful than non-parametric tests which have little power to detect differences no matter 
how the values differ (361). The statistical significance of differences between 3 or more 
groups of data was calculated using either a one-way analysis of variance (ANOVA) followed 
by a Tukey post test to compare all groups of data or a two-way ANOVA followed by a 
Bonferroni post test to compare all groups of data. Statistical significance of differences 
between 2 groups of data was calculated using a Student’s t test using a 99 % confidence 
interval, as indicated. Statistical calculations were performed using the Graphpad Prism® 
Version 4 statistical package (Graphpad Software Inc., San Diego, CA, USA), and the 
companion statistics guide (361).  
 
 
Chapter 3: Characterisation of immune responses to influenza A virus in PKO mice 
 
89 
3  
Chapter 3: 
Characterisation of immune responses to influenza A 
virus in PKO mice 
Chapter 3: Characterisation of immune responses to influenza A virus in PKO mice 
 
90 
3.1  Introduction 
As discussed in detail in Chapter 1, DC are critical for the initiation of CD4+ and CD8+ T 
cell responses. It has been demonstrated that CTL-mediated DC elimination has a 
detrimental effect on T cell proliferation and tumour immunity (169). Improved DC 
survival through manipulation of the expression of anti-apoptotic molecules has been 
shown to enhance CD4+ and CD8+ T cell responses (144, 158, 160, 161) and improve 
tumour protection (160). However, not all situations of extended DC survival result in a 
more desirable outcome as reports have linked increased DC survival to chronic 
lymphocyte activation and associated immunopathology (158, 163, 164, 362, 363). 
Therefore it appears that carefully regulated DC survival is essential for the generation of 
effective T cell mediated immunity.  
 
Through the use of different experimental systems it has been proposed that DC presenting 
antigen are eliminated by responding CTL, thereby limiting the duration of antigen 
presentation and hence the magnitude of the immune response (153, 155, 336). Direct 
evidence supporting this has come from investigations demonstrating that DC loaded with 
antigen then injected into immune C57BL/6 mice are rapidly eliminated by TCR 
transgenic CD8+ T cells (155, 169, 345, 364). Furthermore, when antigen loaded BMDC 
were injected into immune PKO mice, whose CTL cannot kill target cells using the 
perforin/granzyme pathway, the BMDC could be recovered 24-96 hr later (155), indicating 
that CTL regulate DC survival in a perforin-dependent manner. However, it is important 
that these results are confirmed using a more physiologically relevant model.  
 
The murine influenza A virus model was chosen as a physiologically relevant model to 
assess how CTL regulate DC survival for several reasons. Firstly, infected mice represent a 
highly reproducible model for analysing CD8+ T cell mediated immunity (365). Secondly, 
the influenza A virus infection has been well characterised and a number of reagents are 
available to enable assessment of the influenza-specific immune response. Thirdly, this 
model allows the assessment of perforin in CTL-mediated killing as PKO mice are able to 
clear influenza A virus, albeit slightly more slowly than infected C57BL/6 mice (366). 
Finally, both primary and secondary immune responses can be easily assessed. This is 
important because both CTL and memory CD8+ T cells have been shown to kill DC, 
however, their relative contribution to DC elimination has not been shown in a 
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physiologically relevant setting (169, 344, 345). Therefore these features of the murine 
model of influenza infection make it an excellent physiologically relevant model to assess 
the role of CTL in DC killing.  
 
To investigate a secondary influenza-specific CD8+ T cell response two heterologous 
viruses were used, PR8 (H1N1) and HKx31 (H3N2). These viruses share the internal 
proteins; so prior infection with the PR8 virus generates populations of memory CD8+ T 
cells that are reactivated when mice are challenged with the HKx31 virus (354, 355, 357). 
In contrast, the external proteins differ between the two viruses, enabling a secondary 
infection to be established in mice that carry high titres of neutralizing antibodies. In this 
thesis two different routes of administration were used for the influenza viruses. Intranasal 
(i.n.) administration results in a productive viral infection in respiratory epithelial cells 
(367) correlating with an observed weight loss, whereas intraperitoneal (i.p.) 
administration leads to a robust influenza-specific CD8+ T cell response without the 
establishment of a productive viral infection and the consequent side effects. This route of 
administration is used preferentially for virulent isolates such as the PR8 virus.  
 
The influenza-specific immune response can be assessed by a number of parameters. 
Initially the weight loss of infected mice can be evaluated to determine the progression of 
the viral infection, while measuring the viral load in lung can be to determine the kinetics 
of viral clearance. Additionally, the kinetics of the influenza-specific CD8+ T cell response 
can be easily assessed. The percentage of antigen-specific CD8+ T cells was measured by 
two methods, firstly by using fluorescently-labelled MHC I pentamers, secondly by 
measuring the specific synthesis of IFN-γ. Two dominant CD8+ epitopes have been 
characterised in the murine influenza A virus model. The CD8+ epitope from the viral 
nucleoprotein (NP) NP366-374, is co-dominant with an epitope from the acid polymerase 
protein, PA224-233, during a primary influenza immune response (354, 356), while the Db-
NP366-374 epitope is the dominant epitope during a secondary response (354, 355, 357). 
Furthermore, the phenotype of antigen-specific CD8+ T cells can be evaluated by flow 
cytometry. The cell surface marker, CD62L, is primarily expressed on naive T cells and a 
subset of resting memory cells and its absence can be used as an indicator of an effector 
phenotype (197). Additionally, the marker Killer Cell Lectin-like Receptor G 1 (KLRG1) 
has been associated with terminally differentiated memory CD8+ T cells and T cell 
exhaustion (368-371). Thus evaluating the expression of KLRG1 and CD62L on 
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influenza-specific CD8+ T cells provides further insight into the phenotype and 
differentiation state of these cells.  
 
 
3.2 Aims 
The experiments described in this chapter were designed to characterise and compare 
antigen-specific immune responses in C57BL/6 and PKO mice. The murine influenza A 
virus was chosen as a physiologically relevant immune response to evaluate this in. It was 
hypothesised that compared to C57BL/6 mice, PKO mice would have an enhanced 
influenza specific CD8+ T cell response.  
 
The specific aims were: 
• To profile the progression of the influenza virus infection in C57BL/6 mice by 
measuring the severity of disease and the rate of viral clearance, and comparing it 
to that of PKO mice.  
 
• To determine whether PKO mice have an enhanced antigen-specific CD8+ T cell 
response. The influenza-specific CD8+ T cell response during both a primary and 
secondary infection in both C57BL/6 and PKO mice was investigated to address 
this aim.  
 
• To gain information about the phenotype and differentiation status of influenza 
specific T cells by comparing the expression of CD62L and KLRG1 on influenza-
specific CD8+ T cells in C57BL/6 and PKO mice at specific time points during 
both a primary and secondary influenza infection.  
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3.3 Results 
 
 
3.3.1 Influenza A virus establishes infections of comparable severity in 
C57BL/6 and PKO mice 
It has been previously published that PKO mice can clear the influenza A virus with 
almost similar kinetics to the C57BL/6 mice (366, 372); however, it was important to 
confirm this in our particular model setting. An initial primary indicator of influenza A 
viral infection is a decrease in body weight. To determine whether C57BL/6 and PKO 
mice might respond differently to a primary infection in the lung, the change in weight 
during the course of the infection was evaluated. Mice were weighed before the influenza 
infection followed by multiple weighings throughout the course of infection. The 
percentage weight loss was then determined. Maximal weight loss was observed seven 
days after the initial infection, where mice typically had lost 15-18 % of their initial body 
weight (Figure 3.1 A). This weight loss was observed in both C57BL/6 and PKO mice. 
However, PKO mice were slower to re-gain their original weight compared to C57BL/6 
mice. This delay in recovery was also observed in a repeat experiment (Figure 3.1 C), 
although the difference did not reach statistical significance. Throughout the later stages of 
the infection the C57BL/6 and PKO mice re-gained their weight at a similar rate (Figure 
3.1 A). No weight loss was only observed when the influenza virus, PR8 was administered 
i.p. indicating that weight loss was a consequence of a productive infection (Figure 3.1 B). 
This was consistent with previously published data that demonstrated the influenza virus 
was only able to establish a productive viral infection in the lung epithelia (367). Overall, 
these data indicate that the C57BL/6 and PKO mice have an almost similar recovery rate 
after a primary influenza A virus infection.  
 
Weight loss throughout a secondary influenza infection was also evaluated. Previously 
published data has demonstrated that PKO mice can clear a secondary viral challenge at a 
similar rate to C57BL/6 mice (372) but it was necessary to confirm this result in the 
current setting. To establish a secondary influenza infection mice were first primed with 
the PR8 virus i.p. and then 1 month later mice were challenged i.n. with the HKx31 virus. 
During the secondary influenza infection both mouse strains had a comparable maximal 
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weight loss (10-12 %), which was observed five days after infection (Figure 3.1 C). 
Furthermore, as they recovered, the C57BL/6 and PKO mice gained weight at a similar 
rate during the secondary influenza infection. Overall weight loss was comparable in both 
C57BL/6 and PKO mice during both a primary and secondary influenza viral infection. 
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Figure 3.1 Weight loss after primary and secondary influenza infection. 
C57BL/6 and PKO mice were infected as indicated with HKx31 and/or PR8 influenza virus and 
percentage weight loss relative to day 0 (pre-infection) was recorded at specific times after 
infection. (A) Mice were infected i.n. with HKx31 virus or mock-infected with PBS. Each data 
point represents mean + SD of 6 mice per group (B) Mice were infected i.p. with PR8 virus or 
mock-infected with PBS. Each data point represents mean + SD of 3-8 mice per group (C) Mice 
that had been infected i.p. with the PR8 virus 30 days earlier were re-infected i.n. with the HKx31 
virus (Secondary) or previously uninfected mice were infected i.n. with the HKx31 virus only 
(Primary). As a negative control mice were mock-infected with PBS. Each data point represents 
mean + SD of 3-5 mice per group. ∗: indicates the statistical difference in C57BL/6 and PKO 
HKx31 infected mice, p < 0.05 by a two-way ANOVA with a Bonferroni post test. The 
experiments were repeated two or more times with similar results. 
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3.3.2 Measurement of viral load in the lung tissue after a primary 
influenza infection 
In addition to measuring weight loss, the viral load present in the lung can also be assessed 
to determine the rate of viral clearance. Topham et al reported that PKO mice are able to 
clear influenza virus at a similar rate to C57BL/6 mice (366). To confirm this, semi-
quantitative real-time PCR was performed to investigate the level of viral RNA present in 
the lung tissue at various days after infection. Lung tissue was homogenised and RNA 
extracted using TRIzol and cDNA was prepared. Primers specific for the matrix protein 
(358), which is conserved across many influenza A virus strains, were used to determine 
the amount of viral RNA in the lung tissue. Five days after inoculation of the HKx31 virus 
i.n. both the C57BL/6 and PKO mice had a 100-fold higher lung viral RNA titer relative to 
the C57BL/6 mice that had been inoculated for eight days (Figure 3.2). This sample was 
chosen as the relative control because a sample that contained viral RNA was required. 
Eight days after HKx31 viral infection the PKO mice had a higher level of viral RNA 
present in the lung tissue compared to the C57BL/6 mice (Figure 3.2), although this 
difference did not reach statistical significance. Eleven and 14 days after virus infection 
both the PKO and C57BL/6 mice had barely detectable levels of virus in the lung tissue 
(Figure 3.2). These semi-quantitative RT-PCR results indicated that PKO mice are able to 
clear the HKx31 virus at an almost similar rate to C57BL/6 mice.  
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Figure 3.2 Clearance of the HKx31 virus from the lung tissue is slightly delayed in PKO mice 
compared to C57BL/6 mice.  
Lung tissue was collected from C57BL/6 and PKO mice at specific time points after i.n. infection 
with the HKx31 virus. Lung tissue was homogenized and RNA extracted using TRIzol and cDNA 
was prepared for quantitative real-time PCR. Primers specific for the matrix protein were used to 
determine the amount of influenza A virus present in the lung tissue. Each sample was normalised 
to 18S RNA. Data are shown as a fold increase relative to an arbitrarily chosen sample (C57BL/6 
D8). Bars show mean ± SD of 3 mice per group. No statistical difference between C57BL/6 and 
PKO mice was found by a one-way ANOVA.  
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3.3.3 Evaluation of the influenza-specific T cell response using MHC I 
pentamers in C57BL/6 and PKO mice during a primary infection  
The previous results illustrated that PKO mice could clear the virus at a comparatively 
similar rate to the C57BL/6 mice. Next the antigen-specific CD8+ T cell response was 
investigated to determine whether PKO mice had an increased immune response compared 
to C57BL/6 mice, indicating whether survival of antigen presenting DC is regulated in a 
perforin-dependent manner. Initially, the frequency of CD8+Db-NP366-374 + T cells was 
examined in multiple tissues 10 days after HKx31 i.n. infection using a MHC I pentamer. 
To control for specificity, samples were also labelled with an irrelevant pentamer. 
CD8+Db-NP366-374+ specific T cells were observed in all tissues examined, spleen, 
mediastinal lymph node (MLN) and bronchoalveolar lavage (BAL) (Figure 3.3 A-D and 
Figure 3.4). In both the MLN and spleen the percentage and number of CD8+Db-NP366-374+ 
T cells did not significantly differ between the PKO and C57BL/6 mice. However, in the 
BAL, C57BL/6 mice showed a statistically significant higher percentage and number of 
CD8+Db-NP366-374+ T cells compared to PKO mice (Figure 3.3 D and Figure 3,4 C). 
Overall these data indicate that there was no difference between the two mouse strains in 
the frequency of CD8+Db-NP366-374+ T cells in MLN and spleen, whereas in BAL the 
frequency of CD8+Db-NP366-374+ T cells was decreased in PKO mice compared to C57BL/6 
mice during a primary influenza infection.  
 
Although the percentage of CD8+Db-NP366-374+ T cells did not appear to be increased in 
PKO mice compared to C57BL/6 mice during a primary influenza infection, it was of 
interest to determine if the antigen-specific T cells in PKO mice had an activated 
phenotype and whether this was similar to the phenotype of cells from C57BL/6 mice. To 
assess this, cell surface expression of CD62L was analysed on antigen-specific CD8+ T 
cells. A decrease in CD62L expression is characteristic of effector cells. In the MLN, 
spleen and BAL, 80-100 % of the CD8+Db-NP366-374+ T cells expressed low levels of 
CD62L, demonstrating that they all had an effector phenotype (Figure 3.3 E). This effector 
phenotype was observed in both PKO and C57BL/6 mice indicating that the activation 
status of the CD8+Db-NP366-374+ T cells between the two mouse strains, as determined by 
CD62L expression, was similar.
Chapter 3: Characterisation of immune responses to influenza A virus in PKO mice 
 
100
Figure 3.3 C57BL/6 and PKO mice generate similar influenza-specific CD8+ T cells responses 
after infection with HKx31.  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus. BAL and tissues were harvested 
10 days later and processed into single cell suspensions. MLN samples were digested in a solution 
of collagenase II and DNase I to obtain a single cell suspension. Cell suspensions were labelled 
with anti-CD8, anti-CD62L and Db-NP366-374 pentamer or an irrelevant pentamer (Db-GP33-41). The 
percentage of antigen-specific cells was determined by flow cytometry. Dead (PI+) cells were 
excluded and lymphocytes were gated on the basis of their FSC vs. SSC properties. (A) Panels 
show dot plots of spleen CD8+ cells, Db-NP366-374+ cells are highlighted by an oval. The percentages 
of CD8+Db-NP366-374+ T cells from the indicated sources are shown in panels (B-D). (E) Percentages 
of CD8+Db-NP366-374+CD62Llo cells in various tissues. Each dot represents an individual mouse and 
lines represent the mean. ∗∗: 0.001 < p < 0.01, and ns: not significant by an unpaired Student’s t 
test. 
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Figure 3.4 The number of CD8+Db-NP366-374+ T cells found in MLN and spleen is comparable 
between C57BL/6 and PKO mice after a primary infection with HKx31.  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus. BAL and tissues were harvested 
10 days later and processed into single cell suspensions. MLN samples were digested in a solution 
of collagenase II and DNase I to obtain a single cell suspension. Cell suspensions were labelled 
with anti-CD8, anti-CD62L and Db-NP366-374 pentamer or an irrelevant pentamer (Db-GP33-41). The 
percentage of antigen-specific cells was determined by flow cytometry. Dead (PI+) cells were 
excluded and lymphocytes were gated on the basis of their FSC vs. SSC properties. The numbers 
of CD8+Db-NP366-374+ T cells from the indicated sources are shown in panels. Each dot represents 
an individual mouse and lines represent the mean. ∗: p < 0.05, and ns: not significant by an 
unpaired Student’s t test.
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The results obtained in Figure 3.3 and Figure 3.4 are specific to the time point analysed, 
therefore it was important to confirm these results by characterising the influenza-specific 
CD8+ T cell response over the course of a primary infection in C57BL/6 and PKO mice. 
To do this a time course experiment that tracked the percentage of CD8+Db-NP366-374+ T 
cells in the blood over time was performed (Figure 3.5). After a primary HKx31 i.n. 
infection the greatest percentage of CD8+Db-NP366-374+ specific T cells was observed 11 
days after infection. This corresponded to 5-10 % of CD8+ T cells in the blood being 
specific for the NP epitope (Figure 3.5 A). Following the peak of the observed T cell 
response the percentage of CD8+Db-NP366-374+ T cells declined dramatically to only 2.5 % 
of CD8+ T cells being specific for the NP epitope by day17 after the infection. At 103 days 
after infection the percentage of CD8+Db-NP366-374+ T cells was maintained at 
approximately 1 % (Figure 3.5 A). Similar results were observed in both C57BL/6 and 
PKO mice. Thus these data failed to reveal differences in the percentage of CD8+ Db-
NP366-374+ T cells between C57B/6 and PKO mice during a primary influenza infection and 
is consistent with the data reported in Figure 3.3.  
 
It was also of interest to determine if the phenotype of CD8+Db-NP366-374+ T cells differed 
between PKO and C57BL/6 mice over the course of the primary influenza infection. As 
already seen at day 10, 80-100 % of the CD8+Db-NP366-374+ T cells expressed a low level of 
CD62L throughout the course of the infection and no differences were seen between the 
PKO and C57BL/6 mice (Figure 3.5 B). Overall, the percentage and phenotype of the 
CD8+Db-NP366-374+ specific T cells in the blood during a primary infection were similar in 
both the C57BL/6 and PKO mice.  
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Figure 3.5 Similar percentages of CD8+Db-NP366-374+ T cells are found during an influenza 
infection in C57BL/6 and PKO mice.  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus and blood was collected from the 
tail vein at specific time points after infection. Blood cells were labelled with anti-CD8, anti-
CD62L and Db-NP366-374 pentamer. Blood from mock-infected mice was used as a negative control. 
Percentage of CD8+ Db-NP366-374+ cells was analysed by flow cytometry. Dead (PI+) cells were 
excluded and then lymphocytes were gated on the basis of their FSC vs. SSC properties. Graphs 
show the percentage of CD8+ Db-NP366-374+ cells (A) and CD8+Db-NP366-374+CD62Llo cells (B) in the 
blood at specific times after a primary infection with the HKx31 virus. Each data point represents 
mean ± SD of 3 mice per group. No statistical differences were found when the C57BL/6 and PKO 
infected mice were compared by a two-way ANOVA with a Bonferroni post test. These 
experiments were repeated twice with similar results. 
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It has been reported that in C57BL/6 mice the Db-NP366-374 epitope is co-dominant with 
another epitope, Db-PA224-233 during a primary infection (354, 355). Therefore it was 
important to determine if this co-dominance was maintained in the PKO mice. In a primary 
infection (Figure 3.6, left panels) the percentage of CD8+Db-NP366-374+ and CD8+Db-PA224-
233
+
 T cells was similar in both mouse strains. This confirms that PKO mice also exhibit 
co-dominance of the two CD8+ epitopes similar to what has previously been reported by 
other authors (354, 355). Taken together these data show that PKO mice do not have a 
greater percentage of antigen-specific CD8+ T cells compared to C57BL/6 mice after a 
primary influenza A infection. 
 
3.3.4 Evaluation of the influenza-specific T cell response using MHC I 
pentamers in C57BL/6 and PKO mice during a secondary infection 
Investigations into the primary influenza immune response only assess the frequency of 
CTL and not memory CD8+ T cells. However, there is evidence to suggest that memory 
CD8+ T cells can also be involved in DC elimination (169, 344, 345). To investigate 
whether perforin deficiency is associated with increased memory CD8+ T cells, a 
secondary influenza infection was established. Mice were first infected i.p. with the PR8 
virus followed by an i.n. challenge with the HKx31 virus 30 days later. Both the Db-NP366-
374
+
 and Db-PA224-233+ epitopes were investigated. It was found that both in C57BL/6 and 
PKO mice there was an increased percentage of CD8+Db-NP366-374+ T cells compared to 
CD8+Db-PA224-233+ T cells during the secondary response (Figure 3.5, middle panels and 
Figure 3.6 A). The frequency of antigen-specific T cells was highest 10 days after the 
secondary challenge in both the C57BL/6 and PKO mice (Figure 3.7 A). In addition, over 
the course of the secondary infection, C57BL/6 mice maintained a statistically significant 
3-fold higher percentage of CD8+Db-NP366-374+ T cells in the blood compared to PKO mice 
(Figure 3.7 A). In fact the percentage of CD8+Db-NP366-374+ T cells in PKO mice during a 
secondary infection did not significantly increase compared to the primary response 
(Figure 3.7 A). No difference was observed in the percentage of CD8+Db-PA224-233+ T cells 
between the two mouse strains (Figure 3.7 B). Furthermore, at the height of the observed 
response, day 10, the percentage of CD8+Db-PA224-233+ T cells did not differ between the 
primary and secondary influenza infections (Figure 3.7 B). Overall, these data indicate that 
during a secondary influenza infection the frequency of CD8+Db-PA224-233+ T cells was 
similar in PKO and C57BL/6 mice, while a markedly reduced percentage of CD8+Db-
NP366-374+ T cells was observed in PKO mice compared to C57BL/6 mice.  
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The effector phenotype of CD8+Db-NP366-374+ T cells during the secondary infection, was 
determined by measuring the cell surface expression of CD62L by flow cytometry. As in 
the primary influenza infection, 80-100 % of the CD8+Db-NP366-374+ T cells expressed low 
levels of CD62L (Figure 3.7 C). This was observed in both C57BL/6 and PKO mice 
throughout the course of the secondary infection (Figure 3.7 C). So, although the 
percentage of CD8+Db-NP366-374+ T cells was lower in PKO mice compared to C57BL/6 
mice the cells that were present were activated and expressed an effector phenotype similar 
to that seen in C57BL/6 mice.  
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Figure 3.6 Detection of Db-NP366-374+ and Db-PA224-233 CD8+ T cells during a primary and a 
secondary influenza infection.  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus (Primary) or were infected i.p. 
with the PR8 virus and 30 days later infected i.n. with HKx31 virus (Secondary). As a negative 
control mice were mock-infected with PBS. Blood was collected 10 days later from the tail vein 
and cells were labelled with anti-CD8, Db-NP366-374 and Db-PA224-233 pentamers. Percentage of 
antigen-specific cells was determined by flow cytometry. Dead (PI+) cells were excluded and then 
lymphocytes were gated on the basis of their FSC vs. SSC properties. Panels show representative 
dot plots of blood CD8+cells, Db-NP366-374+ and Db-PA224-233+ cells are highlighted by rectangle 
gates.
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Figure 3.7 A reduced percentage of CD8+Db-NP366-374+ T cells is observed in PKO mice 
compared to C57BL/6 mice during a secondary influenza infection.  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus (Primary) or were infected i.p. 
with the PR8 virus  and 30 days later infected i.n. with HKx31 virus (Secondary). As a negative 
control mice were mock-infected with PBS. At specific time points after infection blood was 
collected from the tail vein. Blood was labelled with anti-CD8, Db-NP366-374 and Db-PA224-233 
pentamers. The percentage of antigen-specific cells was determined by flow cytometry. Dead (PI+) 
cells were excluded and lymphocytes were gated on the basis of their FSC vs. SSC properties. The 
percentage of CD8+Db-NP366-374+ cells (A), CD8+Db-PA224-233+ cells (B) and CD8+ Db-NP366-374+ 
CD62Llo cells (C) in the blood was shown at specific time points after primary and secondary 
influenza infection. Each data point represents mean ± SD of 3 mice per group. The statistical 
analysis compares values for the C57BL/6 and PKO secondary infected mice. ∗∗∗: p < 0.001 by a 
two-way ANOVA with a Bonferroni post test. Experiment A, has been repeated twice with similar 
results.
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3.3.5 Evaluation of the influenza-specific T cell response by measuring 
the production of specific IFN-γ in C57BL/6 and PKO mice 
To further assess the influenza-specific immune response the number of antigen-specific 
CD8+ T cells was determined by calculating the number of cells producing IFN-γ after 
restimulation with a specific peptide. This method was commonly used before the 
availability of MHC I pentamers to evaluate the number of antigen-specific CD8+ T cells. 
This detection method of intracellular IFN-γ provides information not only about the cell 
number but also their effector function. To determine the number of influenza-specific 
CD8+ T cells producing IFN-γ, single cell suspensions from various tissues were 
restimulated for 4-6 hr with either the NP366-374 or PA224-233 peptide. Cells were then 
labelled with anti-CD8 and anti-IFN-γ mAbs. To control for non-specific intracellular 
antibody binding, control samples were labelled with an isotype control antibody.  
 
Initially, BAL cells were collected 13 days after primary infection with the HKx31 virus 
and restimulated with NP366-374 peptide (Figure 3.8 A). PKO mice had a slight increase in 
the percentage of NP366-374 responsive cells producing IFN-γ; 4.7 % compared with 3.2 % 
in the C57BL/6 mice. However, as pooled samples were used due to the low cell count in 
the BAL no statistical analysis could be carried out to determine if this difference was 
statistically significant. Next the percentage of NP366-374 responsive T cells producing IFN-
γ in the spleen and MLN 11 days after a primary infection was investigated. No statistical 
difference was seen in the frequency of NP366-374 responsive T cells producing IFN-γ in the 
PKO or C57BL/6 mice in either the MLN or spleen (Figure 3.8 B and Figure 3.9 A and B). 
This result correlated with the data in Figure 3.3 B and C and Figure 3.4 A and B, where 
no difference was seen in the percentage of CD8+Db-NP366-374+ T cells using the MHC I 
pentamer, and confirms previously published data showing that these two techniques 
produce comparable results (177, 354, 372). Furthermore, these data indicate that the 
CD8+Db-NP366-374+ T cells in both the C57BL/6 and PKO mice have a similar effector 
function. 
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Figure 3.8 Detection of intracellular IFN-γ in NP366-374+ responsive T cells in different tissues 
from C57BL/6 and PKO mice undergoing a primary influenza infection.  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus. Thirteen (A) or 11 days (B) after 
influenza infection tissues were collected and processed. MLN samples were digested in a solution 
of collagenase II and DNase I to obtain a single cell suspension. Cell suspensions were then 
restimulated for 4 hr with 1 µM NP366-374 peptide. Cells were labelled with anti-CD8 mAb, fixed 
and labelled intracellularly with anti-IFN-γ mAb or with a rat IgG1 isotype matched control 
antibody and examined by flow cytometry. Lymphocytes were gated on the basis of their FSC vs. 
SSC properties. Dot plots show the percentage of BAL (A), MLN and spleen (B) CD8+ IFN-γ 
producing cells in cultures stimulated with NP366-374 peptide. 
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It was next asked whether the number of CD8+ T cells producing IFN-γ after restimulation 
with the NP366-374 peptide was similar in the spleen and MLN between the two mouse 
strains over the course of a primary infection (Figure 3.9 A and B). Barely detectable 
numbers of NP366-374 responsive T cells were present five days after the primary infection, 
in the spleen and MLN of both C57BL/6 and PKO mice. Eight days after the primary 
infection, it was observed that the PKO mice had approximately 2-fold less NP366-374 
responsive T cells producing IFN-γ compared to C57BL/6 mice in both the spleen and 
MLN. However, this difference was not found to be statistically significant (Figure 3.9 A 
and B). Eleven and 14 days after infection PKO and C57BL/6 mice had a similar level of 
NP366-374 responsive T cells producing IFN-γ. Taken together these data indicate that 
during a primary influenza infection the number of NP366-374 responsive T cells producing 
IFN-γ in the MLN and spleen was similar in C57BL/6 and PKO mice.  
 
It was also of interest to determine the number of PA224-233 responsive T cells producing 
IFN-γ in the MLN and spleen at specific time points during a primary infection and verify 
the results found in the blood that were obtained using the MHC I pentamer. The number 
of PA224-233 responsive T cells producing IFN-γ in the MLN or spleen did not statistically 
differ between C57BL/6 and PKO mice at either 8 or 15 days after a primary influenza 
infection (Figure 3.9 C-F). This correlates with the data obtained using the MHC I 
pentamer (Figure 3.6). Overall, during a primary influenza infection there was no 
difference in the number or effector phenotype of the influenza-specific CD8+ T cells in 
C57BL/6 and PKO mice. 
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Figure 3.9 A similar number of influenza-specific T cells produce IFN-γ over the course of a 
primary infection in C57BL/6 and PKO mice  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus. At specific time points post 
infection (p.i.) the MLN (A, C and D) and spleen (B, E and F) were collected and processed. MLN 
samples were digested in a solution of collagenase II and DNase I to obtain a single cell 
suspension. Cell suspensions were restimulated for 4 hr with 1 µM NP366-374 (A and B) or PA224-233 
(C - F) peptide. Cells were labelled with anti-CD8 mAb, fixed and labelled intracellularly with 
anti-IFN-γ mAb and examined by flow cytometry. Lymphocytes were gated on the basis of their 
FSC vs. SSC properties. Each data point represents mean ± SD of 3 mice per group. (A and B) No 
statistical difference found between infected C57BL/6 and PKO mice using a two-way ANOVA 
with a Bonferroni post test. (C - F) ns: not significant by a one-way ANOVA with a Tukey post 
test. 
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The number of antigen specific CD8+ T cells producing IFN-γ after restimulation with the 
NP366-374 and PA224-233 peptides was examined during a secondary influenza infection. Six 
days after the secondary challenge the number of NP366-374 responsive T cells was 
statistically greater in the MLN but statistically lower in the spleen of C57BL/6 mice 
compared to PKO mice (Figure 3.10 A and Figure 3.11 A). However, these statistical 
differences in the number of NP366-374 responsive T cells between the two mouse strains in 
the MLN and spleen were no longer observed 10 days after secondary challenge (Figure 
3.10 B and Figure 3.11 B). These results differ from the data obtained from the blood 
using the MHC I pentamer, where C57BL/6 mice had a statistically significant increase in 
the percentage of CD8+Db-NP366-374+ T cells during the course of a secondary influenza 
infection (Figure 3.7 A). Thus it appears that during a secondary influenza infection the 
number of NP366-374 responsive T cells varied between C57BL/6 and PKO mice, but this 
was not consistent between different tissues.  
 
The Db-PA224-233 epitope is subdominant to the Db-NP366-374 epitope during a secondary 
infection and unlike the Db-NP366-374 epitope a similar number of CD8+Db-PA224-233+ T 
cells are seen during both a primary and secondary infection (354, 355, 357). The data 
obtained using the MHC I pentamer (Figure 3.7), confirmed these previously published 
data. Therefore it was next asked whether the technique of detecting antigen-specific CD8+ 
T cells by intracellular IFN-γ production would also reveal results similar to those seen in 
Figure 3.7, where the MHC I pentamer was used to detect the antigen-specific T cells 
during a secondary influenza infection. No statistical difference in the number of PA224-233 
responsive T cells in either the spleen or MLN was found between C57BL/6 and PKO 
mice during a secondary influenza infection (Figure 3.10 and Figure 3.11). These results 
obtained using the IFN-γ assay were consistent with the data acquired using the MHC I 
pentamer (Figure 3.7). Thus it appears that during a secondary influenza infection the 
number of PA224-233 responsive T cells was comparable between different tissues and did 
not differ between C57BL/6 and PKO mice.  
Chapter 3: Characterisation of immune responses to influenza A virus in PKO mice 
 
116 
Primary Secondary
C
D
8
+
IF
N
-γ
+
 c
e
ll
s
/
M
L
N
 (
x
1
0
4
)
C
D
8
+
IF
N
-γ
+
 c
e
ll
s
/
M
L
N
 (
x
1
0
4
)
C
D
8
+
IF
N
-γ
+
 c
e
ll
s
/
M
L
N
 (
x
1
0
4
)
C
D
8
+
IF
N
-γ
+
 c
e
ll
s
/
M
L
N
 (
x
1
0
4
)
A. 
B. 
Primary Secondary Primary Secondary
* ns
Primary Secondary
Day 6 p.i. + 1 µM NP
366-374 Day 6 p.i. + 1 µM PA224-233
Day 10 p.i. + 1 µM NP
366-374
Day 10 p.i. + 1 µM PA
224-233
ns
ns
ns
ns
ns
ns
ns
ns
Mock-
infected
C57BL/6 PKO C57BL/6 PKO
0
2
4
6
8
10
12
14
16
18
Mock-
infected
C57BL/6 PKO C57BL/6 PKO
0
2
4
6
8
10
Mock-
infected
C57BL/6 PKO C57BL/6 PKO
0
5
10
15
20
25
30
Mock-
infected
C57BL/6 PKO C57BL/6 PKO
0
1
2
3
 
Figure 3.10 The number of antigen-specific CD8+ T cells producing IFN-γ in the MLN after a 
secondary influenza challenge. 
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus (Primary) or were infected i.p. 
with the PR8 virus  and 30 days later infected i.n. with HKx31 virus (Secondary). As a negative 
control mice were mock-infected with PBS. At day 6 (A) and day 10 (B) after HKx31 virus 
infection the MLN were collected and processed. MLN samples were digested in a solution of 
collagenase II and DNase I to obtain a single cell suspension. Cell suspensions were restimulated 
for 4 hr with 1 µM NP366-374 or PA224-233 peptide as indicated. Cells were labelled with anti-CD8 
mAb, fixed and labelled intracellularly with anti-IFN-γ mAb and examined by flow cytometry. 
Lymphocytes were gated on the basis of their FSC vs. SSC properties. (A) The primary and mock- 
infected mice are pooled samples and each bar represents the data point, whereas in the secondary 
infected groups each bar represents mean ± SD or range of 2- 3 mice per group. (B) Each bar 
represents mean ± SD of 3 mice per group. (A) ∗: p < 0.05 and ns: not significant by a Student’s t 
test. (B) ns: not significant by two-way ANOVA with a Tukey post test.  
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Figure 3.11 The number of antigen-specific CD8+ T cells producing IFN-γ in the spleen after 
a secondary influenza challenge. 
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus (Primary) or were infected i.p. 
with the PR8 virus  and 30 days later infected i.n. with HKx31 virus (Secondary). As a negative 
control mice were mock-infected with PBS. At day 6 (A) and day 10 (B) after HKx31 virus 
infection the spleens were collected and processed. Cell suspensions were restimulated for 4 hr 
with 1 µM NP366-374 or PA224-233 peptide as indicated. Cells were labelled with anti-CD8 mAb, fixed 
and labelled intracellularly with anti-IFN-γ mAb and examined by flow cytometry. Lymphocytes 
were gated on the basis of their FSC vs. SSC properties. Each bar represents mean ± SD or range 
of 2-3 mice per group. ∗∗∗: p < 0.001, and ns: not significant by two-way ANOVA with a Tukey 
post test. 
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3.3.6 Expression of KLRG1 by influenza-specific CD8+ T cells 
After prolonged or repetitive antigenic stimulation CD8+ T cells can progress into a state 
of exhaustion where they lose their effector function and fail to develop into memory cells 
(373). Therefore, it was of interest to determine whether the decreased CD8+Db-NP366-374+ 
T cell response observed in the PKO mice during a secondary immune response was due to 
T cell exhaustion. KLRG1 has been found to be expressed on terminally differentiated 
CD8+ T cells but not on long lived memory cells (368-370). In addition, expression of 
KLRG1 has been associated with the presence of persistent antigen (371). This suggests a 
correlation between the expression of KLRG1 and T cell exhaustion. Therefore, the 
expression of KLRG1 on the influenza-specific CD8+ T cells in PKO and C57BL/6 mice 
was assessed to determine if the CD8+Db-NP366-374+ T cells from the PKO mice had a 
greater expression of KLRG1. The percentage of CD8+Db-NP366-374+ T cells that expressed 
KLRG1 was investigated in the blood 28 days after the secondary influenza challenge. 
After a viral infection the percentage of CD8+ T cells expressing KLRG1 increased in both 
the PKO and C57BL/6 mice (Figure 3.12 A). In addition, the PKO mice had a greater 
percentage of CD8+Db-NP366-374+ T cells expressing KLRG1, compared to the C57BL/6 
mice (29 % vs 19 %) (Figure 3.11 B). Thus this initial data would suggest that the reduced 
number of CD8+Db-NP366-374+ T cells in PKO mice during a secondary infection could be 
due to T cell exhaustion.  
 
Next it was of interest to determine the KLGR1 expression on CD8+Db-PA224-233+ T cells 
as the percentage and number of these antigen-specific T cells did not differ between the 
two mouse strains (Figures 3.7, 3.8 and 3.11). The expression level of KLRG1 on NP366-
374
+
 and PA224-233+ responsive T cells was investigated 10 days after either a primary or 
secondary infection. There were no significant differences in the expression of KLRG1 on 
either the NP366-374+ or PA224-233+ responsive T cells from the MLN or spleen of both PKO 
and C57BL/6 mice 10 days after either a primary or secondary influenza infection (Figure 
3.13). These data suggest that the inability of PKO mice to generate an increased CD8+ Db-
NP366-374+ T cell response compared to C57BL/6 mice was not due to an increased 
expression of KLRG1 on these T cells. 
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Figure 3.12 Expression of KLRG1 on CD8+Db-NP366-374+ blood T cells after a secondary 
influenza infection.  
C57BL/6 and PKO mice were infected i.p. with the PR8 virus and 30 days later infected i.n. with 
HKx31 virus. As a negative control mice were mock-infected with PBS. Twenty eight days after 
HKx31infection, blood was collected from the tail vein and labelled with anti-CD8, Db-NP366-374 
pentamer and anti-KLRG1. Dead (PI+) cells were excluded and lymphocytes were gated on the 
basis of their FSC vs. SSC properties. (A) Panels show representative dot plots of blood CD8+ 
cells, CD8+KLRG1+ cells are highlighted by an oval gate. (B) Panels show representative dot plots 
from 1 out of 2 mice, CD8+Db-NP366-374+ cells (top panel) and CD8+Db-NP366-374+KLRG1+  (bottom 
panel) are highlighted by an oval gate. The specificity of anti-KLRG1 labelling was verified by 
comparing to a rat IgG1 isotype matched control antibody.
Chapter 3: Characterisation of immune responses to influenza A virus in PKO mice 
 
120 
C57BL/6 PKO
CD8
D
b
-N
P
3
6
6
-3
7
4
 P
e
n
ta
m
e
r
K
L
R
G
1
CD8
Is
o
ty
p
e
 c
o
n
tr
o
l
1 10 100 1000 10000
1
10
100
1000
10000
1 10 100 1000 10000
1
10
100
1000
10000
1 10 100 1000 10000
1
10
100
1000
10000
0.48 %
1 10 100 1000 10000
1
10
100
1000
10000
1 10 100 1000 10000
1
10
100
1000
10000
19 % 29 %
3.29 % 1.42 %
CD8
1 10 100 1000 10000
1
10
100
1000
10000
1 10 100 1000 10000
1
10
100
1000
10000
1 10 100 1000 10000
1
10
100
1000
10000
1 10 100 1000 10000
1
10
100
1000
10000
Mock-infected C57BL/6 PKO 
1 10 100 1000 10000
1
10
100
1000
10000
0.17 %
1.31 % 10.8 % 11.5 %
0.33 %
CD8
CD8
K
L
R
G
1
Is
o
ty
p
e
 c
o
n
tr
o
l
A. 
B. 
C57BL/6
 
Chapter 3: Characterisation of immune responses to influenza A virus in PKO mice 
 
121
Figure 3.13 The percentages of influenza-specific CD8+ T cells expressing KLRG1 in 
C57BL/6 and PKO mice are similar.  
C57BL/6 and PKO mice were infected i.n. with the HKx31 virus (Primary) or were infected i.p. 
with the PR8 virus  and 30 days later infected i.n. with HKx31 virus (Secondary). As a negative 
control mice were mock-infected with PBS. Ten days after HKx31virus infection the MLN (A and 
B) and spleen (C and D) were collected. Tissues were processed and single cell suspensions made. 
MLN samples were digested in a solution of collagenase II and DNase I to obtain a single cell 
suspension. Cell suspensions were restimulated for 4 hr with 1 µM NP366-374 (A and C) or PA224-233 
(B and D) peptide. Cells were labelled with anti-CD8 and anti-KLRG1 mAbs, fixed and labelled 
intracellularly with anti-IFN-γ mAb and examined by flow cytometry. Lymphocytes were gated on 
the basis of their FSC vs. SSC properties. Graphs show the percentage of CD8+ IFN-γ+ cells that 
express KLRG1 on the cell surface in the MLN (A and B) and spleen (C and D) after restimulation 
with either NP366-374 (A and C) or PA224-233 peptide (B and D). Each data point represents an 
individual mouse and the line represents the mean. ns: not significant by a one-way ANOVA with 
a Tukey post test. 
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3.4 Discussion 
The aim of the experiments described in this chapter was to characterise and compare the 
influenza-induced immune response in both C57BL/6 and PKO mice. It was hypothesised that 
PKO mice would have an increased number of antigen-specific CD8+ T cells compared to the 
C57BL/6 mice, due to a possible increased number of DC surviving in the PKO mice. The 
percentage and phenotype of antigen-specific CD8+ T cells were examined in multiple tissues 
throughout primary and secondary influenza infections. The frequency of influenza-specific 
CD8+ T cells during a primary influenza infection was similar in C57BL/6 and PKO mice. 
However, during a secondary influenza infection PKO mice had a markedly reduced 
frequency of CD8+Db-NP366-374+ T cells compared to C57BL/6 mice, while the frequency of 
CD8+Db-PA224-233+ T cells was similar between the two mouse strains. Additionally, the 
influenza-specific CD8+ T cells from both mouse strains similarly expressed the markers 
CD62L and KLRG1.   
 
Similar to the findings of Liu et al and Topham et al, a slight delay in viral clearance in the 
PKO mice was found compared to C57BL/6 mice (366, 374). The delay in viral clearance 
correlated with a prolonged weight loss between 8 and 12 days after a primary infection in the 
PKO mice. This was in contrast with a more recent report where a similar rate of viral 
clearance was found in both the C57BL/6 and PKO mice (372). This difference from the 
earlier reports is not likely to be due to a variation in the detection system. Although, Price et 
al used an hemagglutination assay (372), this has been shown to have a similar sensitivity and 
specificity to the viral detection method used in this thesis (358). In contrast, the virus strain 
used in this study was the same used by Topham et al, whereas in the study by Price et al a 
different influenza virus strain of low virulence was used (366, 372). Consequently, subtle 
differences in the experimental system may account for the different results observed.  
 
Studies using either an influenza vaccine (375) or influenza A virus (374) have shown that 
PKO mice generated an increased antigen-specific immune response compared to C57BL/6 
mice. In addition, studies that used infection with LCMV or L. monocytogenes also reported 
that PKO mice had an increased antigen-specific CD8+ T cell response compared to WT mice 
(338, 339, 376-378). These reports are in contrast to the results presented in this thesis, where 
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no increase in percentage of antigen-specific CD8+ T cells was observed in PKO mice. 
Throughout a primary influenza infection the percentage of antigen-specific CD8+ T cells in 
the MLN, spleen and blood was similar between C57BL/6 and PKO mice. However, the 
majority of reports that demonstrated an enhanced immune response in the PKO mice used 
viral infections that required the presence of perforin for their clearance (338, 339, 376-378). 
When PKO mice were infected with vesicular stomatitis virus (VSV), which does not require 
perforin for viral clearance, no enhanced immune response was seen in the PKO mice (379). 
Therefore it is possible that the enhanced T cell response observed by others in PKO mice is 
due to increased viral load and an inability to clear the virus. However, in the absence of a 
viral infection an enhanced antigen-specific CD8+ T cell response could still be induced in 
PKO mice compared to C57BL/6 mice (155). In that study, mice were exposed to limited 
antigen presented by adoptively transferred antigen loaded BMDC. Thus an increased viral 
load and inability to clear the virus does not completely explain the enhanced T cell responses 
observed by others in PKO mice. This will be further discussed in the general discussion 
chapter.  
 
Throughout a secondary infection, C57BL/6 mice had a significant increase in the percentage 
of CD8+Db-NP366-374+ T cells compared to a primary infection. This was in contrast to PKO 
mice where the percentage of CD8+Db-NP366-374+ T cells did not significantly increase during 
the secondary immune response. Despite the fact that there was no significant increase in the 
percentage of CD8+Db-NP366-374+ T cells in PKO mice, the response elicited during a 
secondary immune response did differ from the primary response. Firstly, during the 
secondary response CD8+ T cells were initially more activated, as a greater percentage was 
CD62Llo. Secondly, the CD8+Db-NP366-374+ T cells in the secondary response did not contract 
as greatly as those from the primary response. Thus, even though the CD8+Db-NP366-374+ T 
cells in the PKO mice did not expand significantly more in the secondary response in 
comparison to the primary response, they still show characteristic features of memory cells.  
 
During secondary influenza infection the percentage of CD8+Db-NP366-374 + T cells in PKO 
mice did not increase to the extent seen in C57BL/6 mice. This could have been due to an 
increased expansion of CD8+ T cells specific for the Db-PA224-233 epitope. It has previously 
been shown that during a chronic viral infection the immunodominance hierarchy was altered, 
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with the subdominant epitopes becoming more dominant (380). The increased antigen 
presentation by DC in the PKO mice during a secondary influenza infection (156) could 
mimic a situation similar to chronic viral infection. However, previously published data have 
shown that the immunodominance hierarchy of the Db-NP366-374 and Db-PA224-233 epitopes was 
intact in PKO mice during primary and secondary influenza infections after an i.p. influenza 
administration (381, 382). This route of administration was in contrast to the i.n. infection 
route used in this study. Thus, it was important to examine the immunodominance hierarchy in 
this study where a viral infection was established, as the presence of viral antigens may have 
affected the response in PKO mice. Similar to these earlier studies (381, 382), results in this 
thesis discovered no difference in the percentage of CD8+Db-PA224-233+ T cells between the 
two mouse strains. Taken together, these data indicate that a difference in the dominance 
hierarchy of the epitopes does not account for the lack of expansion in the CD8+Db-NP366-374 + 
T cells observed in PKO mice. 
 
The frequency of antigen-specific T cells was assessed by the production of antigen-specific 
IFN-γ or by using MHC I pentamers. These two techniques have been shown to produce 
comparable results (177, 356, 372). In experiments described in this thesis the IFN-γ assay and 
MHC I labelling resulted in equivalent percentages of antigen-specific CD8+ T cells during a 
primary response, however, during a secondary response the number of IFN-γ producing 
CD8+ T cells and percentage of MHC I pentamer positive cells did not completely correlate. 
Using the MHC I pentamer it was found that the percentage of CD8+Db-NP366-374 + T cells was 
greater in C57BL/6 mice than PKO mice during a secondary response, whereas a significant 
difference in the number of CD8+Db-NP366-374 + T cells producing IFN-γ was detected only at 
an early time point. One reason for the difference in these two experimental results could be 
due to the different tissues examined. The MHC I pentamer data was obtained from the 
peripheral blood whereas the IFN-γ data was generated from lymphoid tissue. In contrast, 
other studies that showed the two techniques to be comparable directly assessed the techniques 
in the same tissue (177, 356, 372). Additional explanations for the lack of correlation in this 
experimental system could be that the CD8+Db-NP366-374 + T cells in C57BL/6 mice are not all 
fully functional and not producing IFN-γ or that the PKO mice produced more IFN-γ to 
compensate for the lack of perforin. However, if after the data has been repeated a similar 
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result is observed, this would suggest that the frequency of antigen-specific CD8+ T cells 
differs between peripheral and lymphoid tissues, which could arise from altered migration. 
Further investigations are required to determine why the results from the IFN-γ assay did not 
correlate with the data obtained using the MHC I pentamer.  
 
Situations of increased DC survival have resulted in increased T cell responses (144, 158, 160, 
161) and improved tumour protection (160). In addition, enhanced immune responses have 
been observed in PKO mice during a range of infections (338-340, 377). This enhanced 
immune response has been proposed to be due to the increased number of DC presenting 
antigen, as they are not eliminated by the CTL due to the lack of perforin (155). Thus it was 
hypothesised that during an influenza infection PKO mice would have an increased T cell 
response and that this would correlate with increased DC survival. However, an enhanced T 
cell response in PKO mice was not observed in experiments described in this thesis. In fact, 
during a secondary influenza infection PKO mice showed a markedly reduced CD8+Db-NP366-
374
+
 T cell response compared to C57BL/6 mice. These data would suggest that if there is a 
difference in DC survival in PKO mice during an influenza infection it is not reflected in the 
influenza specific T cell response.  
 
The next step in this study was to investigate the number of DC in both C57BL/6 and PKO 
mice, however, during the course of this study a report by Belz et al was published that also 
investigated whether CTL regulate antigen presentation in a perforin-dependent manner 
during an influenza infection (156). The experimental approach used in their study differed 
from the method used in this thesis. Belz et al examined the number of cells presenting NP366-
374 and PA224-233 epitopes in the MLN by using specific T cell hybridomas expressing LacZ. 
Cells taken from MLN at differing time points during the course of an influenza infection 
were cultured with specific LacZ+ T cell hybridomas, and the number of cells in MLN 
presenting influenza epitopes was determined by calculating the number of LacZ+ hybrids. 
Using this approach it was demonstrated that during a secondary influenza infection there was 
a greater number of cells presenting influenza-specific epitopes in the MLN of PKO mice 
compared to C57BL/6 mice (156), suggesting that memory CD8+ T cells eliminate DC in a 
perforin-dependent manner. This result is in complete contrast to the findings presented in this 
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thesis, where the absence of an enhanced T cell response in PKO mice implies that CTL do 
not eliminate DC in a perforin-dependent manner during an influenza infection.  
As the current study and the report by Belz et al (156) used alternative experimental 
approaches to address the same question it makes it difficult to directly compare the two 
studies as different parameters were measured. However, as the viral load was not examined 
in the study by Belz et al (156), it may have been increased in PKO mice, which could 
account for the opposing results between the two studies. In the steady state there is continual 
migration of lung DC to the draining LN and following a lung infection this migration of lung 
DC rapidly increases (383). It is feasible that prolonged presence of viral antigens could 
further increase the migration of lung DC to the draining LN, and account for the observed 
increase in cells presenting influenza antigens in the MLN of PKO mice (156). Since a 
delayed viral clearance in PKO mice has been observed during a primary influenza infection 
(366, 374), PKO mice might also have an increased viral load during a secondary influenza 
infection. Belz et al (156) did use the same viral strains as this thesis (PR8 and HKx31), and 
results described in Chapter 3 suggest that based on the similar weight loss between C57BL/6 
and PKO mice that the viral loads are comparable during a secondary influenza infection. 
However, the viral stocks of PR8 and HKx31 used by Belz et al may have been more virulent 
than those used in this current study, which could have impacted on the viral load in PKO 
mice. Therefore, it would have been valuable for Belz et al (156) to evaluate the viral load in 
the two mouse strains to confirm that viral load was not a factor in the observed findings. 
Nevertheless, it is possible that PKO mice do have an increased number of antigen presenting 
DC in the MLN, but this does not correlate with an increased T cell response, rather the 
prolonged antigen presentation is detrimental to an effective T cell response. Further 
investigations, such as assessing both the survival of DC presenting influenza antigens and the 
influenza-specific T cell response in the same experimental setting are necessary to ascertain 
whether DC survival and the magnitude of the T cell response correlate during an influenza 
infection.  
 
In situations of chronic infection and antigen persistence, antigen-specific CD8+ T cells have 
been found to become exhausted and die (373). The prolonged antigen presentation observed 
in PKO mice during a secondary influenza infection might result in the influenza-specific T 
cells becoming exhausted and dying. KLRG1 has been reported to be a marker of terminal 
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effector cells and of cell exhaustion (368-370). When expression of KLRG1 on the influenza-
specific CD8+ T cells in C57BL/6 and PKO mice was investigated, a trend towards increased 
expression during the secondary response compared to the primary response was observed. 
This was consistent with other published data (384), which investigated the expression of 
KLRG1 on CD8+ T cells during immunisation regimens with L. monocytogenes and VSV. 
However, studies in this thesis showed there was no statistical difference in the expression of 
KLRG1 between the PKO and C57BL/6 mice. This lack of statistical difference between the 
C57BL/6 and PKO mice could have arisen from not analysing the optimal time point. 
However, work by Masopust et al investigated the expression of KLRG1 on antigen-specific 
CD8+ T cells during a secondary infection and found that KLRG1 expression was maintained 
for the duration of the infection (384), suggesting that at the time points analysed in this thesis 
the influenza-specific CD8+ T cells should still be expressing KLRG1. Therefore this suggests 
the lack of difference in expression of KLRG1 between the C57BL/6 and PKO mice was a 
real effect. 
 
The use of the KLRG1 marker may not be enough to definitively identify terminally 
differentiated and exhausted CD8+ T cells. During an extensive analysis of markers expressed 
during T cell exhaustion, KLRG1 was found to be expressed at low levels on CD8+ T cells 
from mice infected with the chronic LCMV strain compared to those infected with the acute 
LCMV strain (385). This was in contrast to studies that found KLRG1 associated with 
repetitive antigen stimulation, cellular senescence, and terminal differentiation (369, 370, 384, 
386). Therefore, expression of KLRG1 by itself may not be sufficient to establish whether or 
not a T cell has an exhausted phenotype. PD-1, along with a number of other inhibitory cell 
markers, is also associated with T cell exhaustion (385, 387). Through kinetic analysis of a 
large array of markers it appears that CD8+ T cell exhaustion is a gradual process during 
chronic viral infection and that there are stages in the differentiation and development of 
exhausted CD8+ T cells (385). Thus further investigations are required to determine whether 
the CD8+ T cells in the PKO mice are in a state of exhaustion.  
 
The lung epithelium could play an inhibitory role leading to the lack of expansion of the CD8+ 
T cells in the PKO mice during a secondary influenza infection. Airway epithelial cells 
produce an array of regulatory mediators including a number of chemokines and cytokines 
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(388) that could have an inhibitory effect on both DC and CD8+ T cells after an influenza 
infection. As PKO mice are unable to kill target cells via the perforin/granzyme pathway, 
more infected epithelial cells would be present, potentially leading to an increased level of 
inhibitory factors. Thus in PKO mice the expansion of the CD8+Db-NP366-374+ T cells could be 
restricted by inhibitory mediators released from epithelial cells. Further investigation into the 
levels of regulatory chemokines and cytokines secreted by lung epithelial cells would be 
required to ascertain if this is a potential mechanism and determine why an effect is seen only 
during a secondary and not a primary immune response.  
 
The PKO and C57BL/6 mice were able to generate an effective primary influenza-specific 
immune response but the CD8+ T cell response specific for the dominant epitope during a 
secondary response was dramatically reduced in PKO mice. These data suggest that perforin 
may be involved in some aspect of CD8+ T cell memory response against influenza virus. 
Over the last few years many factors have been discovered to be significant in the generation 
of long-lived memory CD8+ T cells, such as the transcription factors T bet, Eomes and 
BLIMP-1 along with the cytokines IL-7 and IL-15 (389, 390). It is likely that over the coming 
years more factors will be discovered that are important for the generation of an effective 
CD8+ T cell response. Thus perhaps perforin is also important for the maintenance of CD8+ T 
cell memory. However, it has been demonstrated that PKO mice can clear a secondary 
influenza viral infection at a similar rate to the C57BL/6 mice (372), although this was shown 
using an influenza strain of low virulence, but it would suggest that under certain conditions 
memory CD8+ T cells that lack perforin are present and able to clear the viral infection. 
Further investigation is needed to determine how perforin would confer this improved 
memory CD8+ T cell response. 
 
 
3.4.1 Summary 
C57BL/6 and PKO mice have a similar disease progression during both a primary and 
secondary influenza virus infection. Throughout a primary influenza infection there was no 
evidence indicating that the percentages of CD8+Db-NP366-374+ or CD8+Db-PA224-233+ T cells 
was different between the two mouse strains. This was in contrast to the secondary infection 
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where C57BL/6 mice had a statistically significant 3-fold increase in the percentage of 
CD8+Db-NP366-374+ T cells compared to PKO mice. This lack of secondary T cell expansion in 
PKO mice did not appear to result from exhaustion as the expression of KLRG1 on the 
antigen-specific CD8+ T cells was similar in PKO mice and C57BL/6 mice. However, before 
T cell exhaustion can be ruled out completely other markers of T cell exhaustion need to be 
investigated. Furthermore, the antigen-specific CD8+ T cells in the two mouse strains had a 
similar expression of CD62L during both a primary and secondary infection, indicating a 
similar activation status. Overall, these data indicate that in this influenza model, PKO mice 
do not generate an enhanced influenza specific T cell response compared to C57BL/6 mice. 
This would suggest that the increased antigen presentation in PKO mice reported by others 
(156) does not correlate with an enhanced influenza-specific CD8+ T cell response.  
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4.1  Introduction 
 DC survival is important due to the central role DC play in the generation of effective 
immune responses. As discussed in section 1.4, investigations have demonstrated that CTL 
eliminate adoptively transferred antigen loaded BMDC (155) and endogenous DC 
presenting influenza antigen during a secondary influenza immune response (156) in a 
perforin-dependent manner. However, CTL are not the only cells that have the ability to 
eliminate target cells. A number of in vitro studies have demonstrated that both mouse and 
human NKT cells can kill tumour target cells (313-315, 318, 323), while human NKT cells 
can kill DC (150-152, 310, 313). In vitro investigations into the mechanism of DC killing 
revealed that NKT cells can kill DC in a perforin-dependent manner (310). Consequently, 
NKT cells might also regulate DC survival in vivo in a perforin-dependent mechanism 
similar to CTL.  
 
To assess whether NKT cells regulated DC survival in a perforin-dependent manner, an in 
vivo model was established that consisted of i.v. treatment of C57BL/6 and PKO mice with 
the glycolipid, α-GalCer, which is a potent activator of NKT cells. This enabled the 
evaluation of whether NKT cells eliminate DC in an in vivo setting and to determine 
whether the mechanism of elimination was dependent on perforin. Furthermore, α-GalCer 
administered in conjunction with the model protein antigen ovalbumin (ova) activates 
stronger ova-specific CD4+ and CD8+ T cell responses compared to ova protein alone 
(319, 320, 325, 326). Therefore, this α-GalCer/ova protein model also allowed us to 
investigate whether specific CTL can mediate DC elimination during a different immune 
response than those previously studied.  
 
Activation of NKT cells through the administration of α-GalCer also induces B cell 
activation, proliferation, antibody secretion and expansion of the B cell memory pool (327, 
330, 332, 335). Furthermore, treatment with α-GalCer together with either ova protein or 
particulate antigen has led to the production of IgM and class switched specific antibodies 
including ova-specific IgE (329, 331-333). Taken together, treatment with the NKT cell 
ligand, α-GalCer and ova protein elicits both antigen-specific T and B cell responses. The 
elimination of DC by NKT cells could have an impact on both these immune responses as 
DC are critical to NKT cell activation (391, 392).  
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4.2 Aims 
The experiments described in this chapter were designed to evaluate whether DC survival 
was regulated in a perforin-dependent manner after treatment of α-GalCer and ova protein.  
 
The specific aims were: 
• To determine whether the number of splenic DC decreased during treatment with 
α-GalCer and ova protein, and whether this decrease required perforin.  
 
• To determine whether PKO mice generated an enhanced ova-specific CD8+ T cell 
response after treatment with α-GalCer and ova protein compared to C57BL/6 
mice.  
 
• To determine whether DC survival is regulated in a perforin-dependent manner 
during an ova-specific secondary T cell response.  
 
 
4.3 Results 
 
 
4.3.1 CD8+ DC are depleted by treatment with α-GalCer and ova 
protein 
To determine whether DC were eliminated after i.v. administration of α-GalCer and ova 
protein, the number of DC in the spleens of C57BL/6 mice was examined 48 hr after 
treatment. DC were identified on the basis of cell surface expression of CD11c and MHC 
II, and quantified by flow cytometry (Figure 4.1). No significant difference in the total 
number of DC was observed when mice were treated with α-GalCer with or without ova 
protein compared to control groups (Figure 4.1).  
 
DC are a heterogeneous cell population and have been divided into subsets on the basis of 
the expression of a number of cell surface markers. Experimental evidence suggests that 
these DC subsets have different roles in immune responses (46) and express different TLR, 
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and thus are sensitive to different stimuli (49). The expression of the cell surface marker 
CD8 was used to differentiate between the CD8+ and CD8- DC subsets. It was observed 
that there was a decrease in the number of CD8+ DC after treatment with α-GalCer, and 
that this occurred in the absence or presence of ova protein (Figure 4.2 A and B). The 
number of CD8- DC did not change, though both CD8+ and CD8- DC subsets showed an 
increased cell surface expression of CD86 (Figure 4.2). This indicated that both DC 
subsets were activated upon treatment with α-GalCer and ova protein, and is consistent 
with previously published data (187). These results indicated that different DC subsets 
responded differently to treatment with α-GalCer; the CD8+ DC subset declined, while the 
CD8- DC subset did not change. The presence of ova protein along with α-GalCer did not 
alter the response compared to α-GalCer only, thus ova-specific T cells were not involved 
in the loss of CD8+ DC in this model. 
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Figure 4.1 Treatment with α-GalCer and ova protein does not affect the total number of 
splenic DC. 
C57BL/6 mice were injected i.v. with α-GalCer and/or ova protein as indicated. Spleens were 
harvested 48 hr later and the number of DC present in the spleen was analysed by flow cytometry. 
Dead (PI+) and B220+ cells were excluded. Lymphocytes were gated on the basis of their FSC vs. 
SSC properties. (A) Representative dot plots of spleen samples; the CD11c+ MHC II+ population is 
highlighted by an oval, the percentage of these cells in the total gated population is indicated. (B) 
Total number of DC in the spleen 48 hr after the indicated treatment. Bars represent mean ± range 
of 2 mice per group, except the PBS control group where only one mouse was examined. This 
experiment was repeated with similar results.  
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Figure 4.2 Treatment with α-GalCer induces a decrease in the number of splenic CD8+ DC.  
C57BL/6 mice were injected i.v. with α-GalCer and/or ova protein as indicated. Spleens were 
harvested 24 or 48 hr later and analysed as described in Figure 4.1. (A) Dot plots of representative 
spleen samples; the CD8- DC are indicated by a rectangle gate and the CD8+ DC are indicated by 
an oval, the percentage of these cells in the total gated population is indicated. (B) Total number of 
CD8- DC (left panel) and CD8+ DC (right panel) present in the spleen 48 hr after the indicated 
treatments. (C) The expression of CD86 on the splenic CD8- DC (left panel) and CD8+ DC (right 
panel) 24 hr after the indicated treatments. Bars represent mean ± SD of 3-4 mice per group. ∗∗∗: p 
< 0.001, ∗: p < 0.05, and ns: not significant by one-way ANOVA with a Tukey post test. These 
experiments were repeated with similar results.
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4.3.2  The decrease in the splenic CD8+ DC subset is not due to perforin-
dependent killing 
The results in Figure 4.2 indicated that loss of CD8+ DC after treatment with α-GalCer and 
ova protein was not due to the presence of ova-specific T cells. The loss of CD8+ DC was 
observed after treatment with the NKT cell ligand, thus it was considered likely that the NKT 
cells were mediating the loss of CD8+ DC. NKT cells have cytotoxic ability and are reported 
to kill DC presenting α-GalCer in vitro (150). Blocking perforin-mediated killing has been 
reported to significantly reduced the ability of NKT cells to kill tumour cell lines (312-315) 
and human DC in vitro (310). Therefore it was of interest to determine whether the observed 
decrease in CD8+ DC required the expression of perforin, especially as CTL have been shown 
to eliminate DC in vivo via a perforin-dependent mechanism (155, 156). To investigate this, 
PKO mice were treated with α-GalCer i.v., and the number of splenic CD8+ DC was 
determined 24 hr later. As shown in Figure 4.3, C57BL/6 and PKO mice treated with α-
GalCer had similar decreases in the number of CD8+ DC, while the number of CD8- DC was 
not affected in either strain of mice. Additionally, both C57BL/6 and PKO mice responded to 
the treatment of α-GalCer with similar increases in the expression of CD86 on both DC 
subsets (Figure 4.3). These data indicated that the loss of CD8+ DC subset after α-GalCer 
treatment was not due to perforin-dependent killing.  
 
Human in vitro experiments have demonstrated that NKT cells can kill DC in a perforin-
dependent manner (310), however, it has not been demonstrated if this occurs in vivo. Mouse 
NKT cells have been reported to kill α-GalCer loaded splenocytes in an antigen-specific 
manner, but the mechanism of this target cell lysis was not established (360). Therefore, it was 
next asked if mouse NKT cells could kill target cells in vivo in a perforin-dependent manner. 
To assess this splenocytes were loaded with or without α-GalCer, and labelled with the 
fluorescent dyes CFSE or CTO, respectively, to track the two splenocyte populations. These 
labelled splenocytes were injected i.v. into C57BL/6, PKO or CD1 deficient (CD1 KO) mice 
and MesLN were recovered 24 hr later to quantify the percentage of the remaining labelled 
splenocyte populations. CD1 KO mice, which lack NKT cells, were used as a control to 
establish a baseline for NKT cell specific killing, as any target cell loss in these hosts could 
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only be explained by non-specific cell loss. The percentage of antigen-specific killing in 
C57BL/6 and PKO mice was calculated by normalising the ratio of CFSE+ targets vs. CTO+ 
control cells against CD1 KO mice. As shown in Figure 4.4, 10-25 % of splenocytes were 
killed in both the C57BL/6 or PKO mice. Although killing was low, it must be noted that 
among splenocytes B cells also express CD1d and can bind α-GalCer, and could have been 
killed in an NKT cell specific manner. Therefore these results indicate that NKT cells could 
kill α-GalCer loaded splenocyte targets in vivo. This is consistent with previously published 
data (360). However, these data also demonstrated that the mechanism of NKT cell killing 
was not dependent on perforin. Nonetheless, the data in Figures 4.3 and 4.4 fail to provide 
evidence for NKT cell-mediated killing of endogenous DC via a perforin-dependent 
mechanism. 
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Figure 4.3 The decline in the CD8+ DC subset after α-GalCer treatment occurs in a perforin-
independent manner.  
C57BL/6 and PKO mice were injected i.v. with either α-GalCer or PBS. Spleens were harvested 20 or 
24 hr later and analysed as described in Figure 4.1. (A) Total number of CD8- DC (left panel) and 
CD8+ DC (right panel) present in the spleen 24 hr after the indicated treatment. (B) The expression of 
CD86 on the CD8- DC (left panel) and CD8+ DC (right panel) in the spleen 20 hr after the indicated 
treatment. Each bar represents mean ± SD of 3-4 mice per group.∗∗∗: p < 0.001, ns: not significant by 
one-way ANOVA with a Tukey post test. The experiment was repeated at least three times with similar 
results. 
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Figure 4.4 NKT cells can kill α-GalCer pulsed targets in a perforin-independent manner. 
Splenocytes from a C57BL/6 mouse were loaded with the indicated concentration of α-GalCer or left 
untreated, and labelled with CFSE and CTO, respectively. A total of 2.5 x106 labelled splenocytes 
were injected i.v. into C57BL/6, PKO and CD1 KO mice. MesLN were harvested 24 hr after the 
adoptive transfer and analysed by flow cytometry for the presence of labelled target cells. The 
percentage of antigen-specific killing was calculated from the ratio of CFSE+ targets vs. CTO+ control 
cells and normalized against the CD1 KO mice. Bars represent mean ± SD of 3-5 mice per group.  
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4.3.3 The decrease in CD8+ DC is not due to a Fas-dependent mechanism 
As shown in Figure 4.3, the decline in CD8+ DC occurred in a perforin-independent manner. 
However, NKT cells also express FasL (152), which has been shown to be important for 
killing DP thymocytes (317) and certain tumour cell lines (315). To investigate if the 
reduction in CD8+ DC occurred in a Fas-FasL dependent manner, mice lacking expression of 
Fas (B6.lpr) were utilised. However, some reports have described that lpr mice have a 
deficiency in NKT cell numbers and function (393, 394), while another has reported no 
significant difference (395). Thus, before the B6.lpr mice could be used it was necessary to 
determine whether they had comparable numbers of NKT cells to C57BL/6 mice.  
 
In preliminary experiments, the number of NKT cells in B6.lpr and C57BL/6 mice was 
assessed using a CD1d tetramer loaded with α-GalCer in conjunction with an anti-CD3 mAb. 
The number of thymic NKT cells was comparable in C57BL/6 and B6.lpr mice, while a 
statistically significant increase in the number of spleen NKT cells was observed in B6.lpr 
mice compared to C57BL/6 mice (Figure 4.5). These results illustrated that the B6.lpr mice 
did not have a deficiency in the number of NKT cells. Thus further investigations were carried 
out using the B6.lpr mice. 
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Figure 4.5 The number of NKT cells in the thymus and spleen of C57BL/6 and B6.lpr mice was 
comparable.  
Spleens and thymi from untreated C57BL/6 and B6.lpr mice were harvested and processed into single 
cell suspensions. Cells were labelled with anti-CD3 mAb and CD1d tetramer loaded with α-GalCer 
followed by examination of NKT cell numbers by flow cytometry. Dead (DAPI+) cells were excluded 
and lymphocytes were gated on the basis of their FSC vs. SSC properties. (A) Representative dot plots 
from 1 out of 3 mice show thymocytes (top) and splenocytes (bottom). CD1d tetramer+CD3+ cells are 
highlighted by polygonal gates, the percentage of these cells in the total gated population is indicated. 
(B) Total number of CD1d tetramer+CD3+ cells in the spleen (left) and thymus (right) from C57BL/6 
and B6.lpr mice. Bars represent mean ± SD of 3 mice per group. ∗: p < 0.05 and ns: not significant by 
an unpaired Student’s t test. 
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To establish whether the Fas-FasL pathway played a role in the decline of CD8+ DC after 
treatment with α-GalCer, C57BL/6 and B6.lpr mice were treated with α-GalCer and 24 hr 
later the spleens were harvested and the number of DC examined by flow cytometry. The 
number of CD8+ DC in B6.lpr mice treated with α-GalCer was significantly decreased 
compared to the control group, though not as profoundly as in C57BL/6 mice (Figure 4.6 A). 
This would suggest that Fas played a small role in the decrease of the CD8+ DC. The 
activation status of DC from C57BL/6 and B6.lpr mice was also assessed by the expression of 
cell surface marker CD86 (Figure 4.6 B). After α-GalCer treatment DC from B6.lpr mice did 
not significantly upregulate expression of CD86 compared to the PBS treated group. This was 
in contrast to the C57BL/6 mice, in which a significant increase in the expression of CD86 
was observed after α-GalCer treatment (Figure 4.6 B). Thus it would appear that Fas 
signalling is important for the activation of CD8+ DC, but has only a small effect on the loss of 
CD8+ DC in the spleen after α-GalCer treatment.  
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Figure 4.6 Fas deficiency has a minor effect on the loss of CD8+ DC after α-GalCer treatment. 
C57BL/6 and B6.lpr mice were injected i.v. with either PBS or α-GalCer. Spleens were harvested 24 
hr later and analysed as described in Figure 4.1. (A) Total number of CD8- DC (left panel) and CD8+ 
DC (right panel) present in the spleen 24 hr after the indicated treatment. (B) The expression of CD86 
on the CD8- DC (left panel) and CD8+ DC (right panel) in the spleen 24 hr after the indicated 
treatment. Bars represent mean ± SD of 5 mice per group. ∗∗∗: p < 0.001, ∗∗: 0.001 < p < 0.01, ∗: p < 
0.05, and ns: not significant by one-way ANOVA with a Tukey post test. 
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4.3.4 Assessing the ova-specific CD8+ T cell response after treatment with 
α-GalCer and ova protein 
In some infection models PKO mice have been reported to generate an enhanced immune 
response (338, 339, 374-376, 378). Therefore, it was of interest to investigate whether there 
was a difference in the percentage of antigen-specific CD8+ T cells after treatment with α-
GalCer and ova protein. Seven days after α-GalCer and ova protein administration, CD8+ T 
cells specific for the dominant CD8 epitope, ova257-264 were detected in the blood using an 
MHC I pentamer by flow cytometry (Figure 4.7). This day 7 time point was chosen based on 
previous studies using the same α-GalCer and ova model (320). No statistical difference in the 
percentage of CD8+Kb-ova257-264+ T cells was found between C57BL/6 and PKO mice (Figure 
4.7 B). These data suggest that in this model the PKO mice do not generate an enhanced CD8+ 
T cell response in response to ova administered with α-GalCer.   
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Figure 4.7 C57BL/6 and PKO mice treated with α-GalCer and ova protein generate comparable 
ova-specific CD8+ T cell responses.  
C57BL/6 and PKO mice were injected i.v. with α-GalCer and ova protein and seven days later blood 
was collected from the tail vein and examined by flow cytometry for the presence of CD8+Kb-ova257-
264
+
 T cells. Dead (PI+) cells were excluded and lymphocytes were gated on the basis of their FSC vs. 
SSC properties. (A) Panels show dot plots of CD8+ cells, the oval highlights the CD8+Kb-ova257-264+ 
cells. The percentage of these cells in the total gated population is indicated. (B) Percentages of 
CD8+Kb-ova257-264+ T cells seven days after administration of α-GalCer and ova protein. Each point 
represents an individual mouse and the lines represent the mean. ∗∗: 0.001 < p < 0.01 and ns: not 
significant by one-way ANOVA with a Tukey post test. 
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4.3.5 Assessing DC survival after a boost of ova protein  
So far experiments did not reveal perforin-mediated DC elimination during a primary ova-
specific CD8+ T cell response. However, as discussed in chapter 1, there is evidence indicating 
that memory CD8+ T cells can eliminate DC. To determine whether DC might be eliminated 
during a secondary ova-specific CD8+ T cell response, mice were primed with α-GalCer and 
ova protein as described previously, followed by an i.v. injection of ova protein 30 days after 
the original treatment. Initially the ova-specific CD8+ T cell response was assessed to 
determine whether a secondary T cell response was being generated using this boosting 
method. There was no clear increase in the percentage of CD8+Kb-ova257-264+ T cells in mice 
that received the secondary ova injection compared to those that only received the primary 
treatment (Figure 4.8), indicating that a secondary immune response was not induced.  
 
Although no secondary ova-specific T cell response was detected, two and seven days after 
the boost of ova protein the total number of DC (CD11c+MHC II+) and CD8+ DC was 
assessed in the spleen (Figure 4.9). At both time points no significant difference was observed 
in total number of DC or CD8+ DC in C57BL/6 mice across all groups (Figure 4.9). Similar 
results were also observed in PKO mice (Figure 4.9). These data indicate that in the absence 
of a secondary ova-specific T cell response DC are not eliminated.   
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Figure 4.8 A boost of ova protein did not induce an increased percentage of CD8+Kb-ova257-264+ T 
cells. 
C57BL/6 mice were injected i.v. with α-GalCer and ova protein or left untreated. Mice were then 
treated 30 days later with 2 mg ova protein i.v. or left untreated. Blood was collected five days after 
boosting and analysed as described in Figure 4.7. The percentages of CD8+Kb-ova257-264+ cells are 
shown. Each point represents one individual mouse and lines represent the mean. ∗: p < 0.05, and ns: 
not significant by one-way ANOVA with a Tukey post test.  
 
 
 
Chapter 4: Differential survival of splenic DC subsets after treatment with α-GalCer 
 
151
C57BL/6 PKOC57BL/6 PKO
C
D
1
1
c
+
M
H
C
 I
I+
 D
C
/
s
p
le
e
n
 (
x
1
0
5
)
Day 2 after Boost
C57BL/6 PKO C57BL/6 PKO
C
D
8
+
 D
C
/s
p
le
e
n
 (
x
1
0
5
)
C
D
8
+
 D
C
/s
p
le
e
n
 (
x
1
0
5
)
C
D
1
1
c
+
M
H
C
 I
I+
 D
C
/
s
p
le
e
n
 (
x
1
0
5
)
CD11c+MHC II+ DC
CD11c+MHC II+ DC
CD8+ DC
CD8+ DC
Day 7 after Boost
A. 
B. 
PBS
PBS
PBS
α-GalCer + ova ova 
ova 
Treatment BoostKey:
0
5
10
15
20
25
0
10
20
30
40
50
60
70
80
90
0
5
10
15
20
25
30
35
40
45
0
2
4
6
8
10
12
14
 
Figure 4.9 Boosting with ova protein does not lead to a change in the number of spleen DC. 
C57BL/6 and PKO mice were injected i.v. with either PBS or α-GalCer and ova protein. Mice were 
boosted 30 days later with either an i.v. injection of PBS or 200 µg ova protein. Then two (A) or seven 
days (B) after the boost of ova protein the spleens were harvested and the number of CD11c+MHC II+ 
and CD8+ DC were analysed as described in Figure 4.1. Bars represent mean ± SD of 3-4 mice per 
group. No statistical differences between groups were found using a one-way ANOVA. 
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4.3.6 IgG1 levels, and number of basophils are similar in PKO and 
C57BL/6 mice 
While endeavouring to induce a secondary ova-specific T cell response it was observed that 
after the boost of ova protein all the mice became unresponsive within seconds. These 
symptoms are suggestive of systemic anaphylactic shock, which is a rapid-onset, life 
threatening allergic reaction (396, 397). Of interest PKO mice were more severely affected by 
the boost of ova protein than C57BL/6 mice, as PKO mice never recovered from the state of 
unresponsiveness and had to be culled for ethical reasons. Thus, it was of interest to 
investigate why PKO mice reacted more severely than t C57BL/6 mice to the second dose of 
ova protein.  
 
It is well known that IgE is crucially involved in systemic anaphylaxis (398) and more 
recently IgG1 has been shown to also play an important role (399-401). The more severe 
anaphylactic-like symptoms observed in PKO mice might have been due to an increased 
amount of circulating ova-specific antibodies. To assess the level ova-specific IgG1 and IgE, 
ELISAs were performed using serum samples collected 30 days after the α-GalCer and ova 
protein treatment. This time point was chosen because this was when the boost of ova protein 
had been administered. No statistically significant difference in the serum levels of ova-
specific IgG1 was found between the PKO mice and C57BL/6 mice (Figure 4.10). The levels 
of ova-specific IgE in both C57BL/6 and PKO mice treated with α-GalCer and ova protein 
were greater than in the PBS treated mice but still very low and below the level of sensitivity 
of the assay. Thus these data suggest that the observed increased unresponsiveness in the PKO 
mice was not directly related to an increase in ova-specific antibodies.  
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Figure 4.10 The levels of ova-specific IgG1 in the serum of C57BL/6 and PKO mice were similar.  
C57BL/6 and PKO mice were injected i.v. with α-GalCer and ova protein or PBS. Serum was 
collected 30 days later via cardiac puncture. To generate a positive control mice were treated twice i.p. 
with alum and ova protein (see methods). ELISA specific for ova IgG1 was performed. Each bar 
represents mean ± SEM of 4-5 mice per group. Numbers represent the mean antibody titer. The PBS 
groups are marked < 10 as the antibody titer was below the detection limit of the assay, whereas the 
positive control is marked as > 1000 as the antibody titer was greater than the highest serum dilution. 
The dotted line indicates the detection limit. ns: not significant by an unpaired Student’s t test. The 
experiment was repeated three times with similar results.  
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The severity of systemic anaphylactic shock is also related to the number of cells present that 
mediate the symptoms. Recently, it was discovered that basophils are important in IgG-
mediated anaphylaxis (402). Unlike mast cells that reside in tissue, basophils are found in the 
bloodstream (403). Since the ova protein was administered i.v., it was more likely that the 
boost of ova protein would be more accessible to basophils than mast cells. Consequently, the 
number of basophils was investigated to verify if this accounted for the increased 
unresponsiveness observed in the PKO mice. Mice were bled 30 days after α-GalCer and ova 
protein treatment, and basophils were identified as CD45intFcεR1+ by flow cytometry (Figure 
4.11 A). The percentage of basophils in the blood of PBS treated mice was approximately 0.3 
% and this corresponded to previously published work (403). However, the percentage of 
basophils did not change after treatment with α-GalCer and ova protein (Figure 4.11 B). 
Furthermore, PKO mice did not have an increased number of basophils compared to C57BL/6 
mice (Figure 4.11 B). This result indicated that an increased percentage of basophils was not 
the explanation for the increased mortality observed in PKO mice.  
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Figure 4.11 C57BL/6 and PKO mice show a similar percentage of basophils present in the 
peripheral blood after treatment with α-GalCer and ova protein.  
C57BL/6 and PKO mice were injected i.v. with α-GalCer and ova protein or PBS. Blood was collected 
30 days later and analysed by flow cytometry for the percentage of basophils. Dead (PI+) cells were 
excluded and lymphocytes were gated on the basis of their FSC vs. SSC properties. (A) Representative 
dot plots show CD45+ cells in the rectangle gate and CD45intFcεRI+ basophils are indicated by an oval, 
the percentage of these cells in the total gated population is indicated. (B) Percentage of basophils in 
peripheral blood after the indicated treatment. Each point represents an individual mouse and lines 
represent the mean. ns: not significant by one-way ANOVA.  
Chapter 4: Differential survival of splenic DC subsets after treatment with α-GalCer 
 
156
4.4 Discussion  
The aim of this chapter was to determine whether DC survival was regulated in a perforin-
dependent manner after treatment with α-GalCer and ova protein. The use of α-GalCer and 
ova protein enabled the assessment of both NKT cells and CD8+ T cells in the role of 
regulating DC survival. Treatment with α-GalCer and ova protein led to a decrease only in the 
CD8+ DC subset, which did not require the presence of ova-specific CD8+ T cells, and thus is 
likely to be mediated exclusively by NKT cells. The disappearance of CD8+ DC occurred in a 
perforin- and Fas-independent manner.  
 
Similar to CTL, NKT cells are capable of cytotoxic function. NKT cells express perforin and 
the ligands for a number of cell death receptors such as FasL and TRAIL (152, 235, 311-313, 
318). Perforin-, FasL- and TRAIL-mediated cytotoxicity by human and mouse NKT cells 
have been demonstrated to be important for killing DC and tumour cell lines (152, 310, 312-
315, 318). However, during this study it was found that after α-GalCer treatment the decline 
in CD8+ DC occurred in a perforin-independent manner. Furthermore, experimental evidence 
suggests that the loss of splenic CD8+ DC was independent of Fas expression. An earlier 
report showed that mice lacking Fas expression had reduced NKT cells numbers and function 
(394). Contrary to this, results in this chapter confirmed that the B6.lpr used in this thesis had 
comparable numbers of α-GalCer reactive NKT cells to C57BL/6 mice, which was also 
supported by another published study that assessed the percentage of NK1.1+TCRαβ+ NKT 
cells in the spleen (395). However, functional capacity of the NKT cells from B6.lpr mice 
used in this thesis was not assessed. Since the study which found reduced functional capacity 
correlated this with a reduced number of NKT cells (394), it is likely that the NKT cells from 
the B6.lpr mice are functionally equivalent to those from C57BL/6 mice. As it would appear 
that neither perforin nor FasL directly mediated the decrease of the CD8+ DC it would suggest 
that the decrease was not mediated by direct interaction with the NKT cell. However, other 
death receptors such as TRAIL would need to be investigated before this can be formally 
concluded.  
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It has been reported that murine DC are resistant to Fas induced apoptosis (404). This 
resistance is due to an increased expression of the molecule FLIP, which inhibits apoptosis 
induced by both Fas and TNFR ligation (404). However, in an earlier study, blood derived 
human DC were sensitive to Fas-induced apoptosis unless they received signalling through 
CD40 (146). CD40 ligation of DC has been shown to enhance DC survival (123, 128, 147). It 
is thought that this enhanced survival is partly due to the DC upregulating anti-apoptotic 
proteins such as Bcl-xL (132). NKT cells express CD40L upon activation (122) and interact 
with CD40 on the DC after α-GalCer treatment (122, 187, 320, 405). Therefore it would be 
expected that CD40 ligation would be occurring in the model presented in this thesis and that 
the DC would upregulate anti-apoptotic proteins leading to enhanced cell survival. This is in 
contrast to the observed decline in CD8+ DC after α-GalCer treatment. However, it is possible 
that some protection is being mediated by CD40 ligation as well as resistance to Fas mediated 
cell death by the upregulation of FLIP. Nevertheless, this protection is not sufficient to prevent 
a significant decrease in the CD8+ DC subset of the spleen from occurring.  
 
The results described in this chapter suggest that presence of CTL did not cause the observed 
loss of DC that occurred after treatment with α-GalCer and ova protein. However, memory 
CD8+ T cells have also been shown to eliminate DC (156, 169, 344); thus a secondary ova 
response was also studied. To assess this, mice were treated with α-GalCer and ova protein 
followed by administration of a second dose of ova protein 30 days later. α-GalCer was not 
administered during the boost as it has been reported that NKT cells become hyporesponsive 
after an initial treatment of α-GalCer (406, 407). However, boosting with ova only did not 
successfully generate a secondary ova-specific T cell response. This could be due to the 
presence of ova-specific antibodies clearing the antigen. Consequently, a different system is 
required to create secondary ova-specific T cell response to evaluate whether ova-specific 
memory CTL regulate DC survival. The use of α-GalCer and ova protein followed by 
treatment with recombinant vaccinia virus expressing full length ova protein is an effective 
method to prime and boost ova-specific CD8+ T cell response (320) and would be a potential 
model system to evaluate DC survival in the presence of ova-specific memory CD8+ T cells.  
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After the second dose of ova protein (2 mg) the mice became unresponsive within minutes and 
did not recover for a long time. The rapidity of this response suggested an antibody-mediated 
response. An IgE-mediated type I immediate hypersensitivity reaction can occur within 
minutes of allergen exposure (408). Systemic anaphylaxis is a type I immediate 
hypersensitivity where IgE bound to FcεRI on mast cells and basophils is cross-linked by 
allergen, resulting in the release of chemical mediators such as histamine and release platelet 
activating factor  (PAF). Release of these chemical mediators ultimately leads to the 
characteristic symptoms of anaphylaxis (408), such as hypotension, hypothermia, decreased 
mobility, and scratching (400). An assessment criteria has been described to quantitatively 
assess the anaphylactic symptoms with a score 0 indicating no symptoms and a score 5 
indicating death. According to this assessment criteria, mice injected with the second dose of 
ova protein immediately went to a score 4 which is classified as no activity after prodding or 
tremor and convulsion (409). Therefore, rather than the intended secondary ova-specific CD8+ 
T cell response, the second injection of ova protein resulted in symptoms with characteristics 
similar to systemic anaphylaxis.  
 
Administration of α-GalCer leads to B cell activation and antibody secretion (327-331, 333-
335). Mice treated with particulate α-GalCer produced IgM and early class switched specific 
antibodies (333). Additionally, systemic treatment with α-GalCer or ova in Complete 
Freund’s Adjuvant has previously been found to lead to high levels of total and ova-specific 
IgE compared to control (332). Furthermore, a report that gave repeated low doses of α-
GalCer and protein followed by a recall treatment of protein alone weeks later showed that the 
specific Ig titer was enhanced in the recall response compared to protein alone (335). In this 
thesis antibody titers were also measured in mice treated with α-GalCer and ova protein and 
found the presence of ova-specific IgG1 and low levels of IgE after treatment with α-GalCer 
and ova protein. Taken together these results might account for why the mice pre-treated with 
α-GalCer and ova protein became unresponsive upon administration of a second dose of ova 
protein. 
 
It was observed that PKO mice reacted more severely to the second dose of ova protein 
compared to C57BL/6 mice, as none of the PKO mice recovered. This suggests that perforin 
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might play a role in the development of the observed anaphylactic shock-like symptoms, 
which is a novel finding. As the level of IgE and IgG1 has been directly correlated with the 
severity of the anaphylactic shock (410), it was asked if PKO mice had higher serum antibody 
titers. PKO mice have already been reported to generate a stronger antibody response 
compared to C57BL/6 mice (375). Investigations into the levels of ova-specific IgE and IgG1 
found no evidence that PKO mice had an enhanced level of ova-specific antibodies present in 
the serum compared to C57BL/6 mice. However, the ELISA technique used to determine the 
level of ova-specific antibodies, only measures free circulating antibodies present in the serum 
and not cell bound antibodies. Though, 30 years ago a correlation between serum IgE levels 
and the amount of IgE bound to basophils was observed (411). More recently, in vivo studies 
have shown that IgE increases the cell surface expression of FcεRI on basophils (412), 
indicating that IgE itself is a major regulator of the amount of cell surface bound IgE. Thus it 
is unlikely that PKO mice would have an increased level of cell surface bound IgE if they did 
not have a significant increase in serum IgE. Therefore, increased levels of ova-specific 
antibodies in PKO mice do not appear to account for the increased reaction to the second dose 
of ova protein observed in these mice.  
 
Severity of anaphylactic shock is also influenced by the number of mast cells, macrophages 
and basophils present (400). Basophils have recently been shown to be important in IgG 
mediated anaphylaxis (402). IgG mediated anaphylaxis closely resembles the classical 
pathway that involves mast cells and IgE antibodies (400). In allergen-sensitised mice, 
antigen-specific IgG antibodies form antigen-IgG immune complexes that are immediately 
captured by circulating basophils through Fc receptors for IgG (FcγRs). Basophils become 
activated by the immune complexes and PAF, which in turn increases vascular permeability 
by acting on endothelial cells, thereby leading to systemic anaphylaxis (413). Thus an 
increased number of basophils in PKO mice could have explained the enhanced severity in 
anaphylaxis due to increased degranulation and presence of chemical mediators. However, a 
similar percentage of basophils was observed in both C57BL/6 and PKO mice. Further 
investigations into the effector functions of the basophils from the two mouse strains would 
need to be performed to establish whether increased basophil reactivity might be a mechanism 
for the enhanced anaphylaxis in PKO mice. One approach to examine this would be to use a 
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PAF antagonist to assess the role of PAF released by basophils and whether this differs 
between WT and PKO mice. Additionally, a mAb has recently been described that binds to 
CD200R3 and upon in vivo injection it causes the depletion of basophils from the peripheral 
blood and spleen of mice (414, 415). Thus, this depleting antibody could be used in 
combination with PKO mice to assess whether basophils play a role in the generation of the 
observed severe anaphylactic reaction. 
 
It was not determined which pathway of anaphylaxis was occurring, either IgE or IgG 
mediated or a combination of the two, therefore investigations into other cell types such as 
mast cells may provide evidence and clarify why PKO mice presented with increased 
anaphylactic shock-like symptoms. In addition, although this study observed that PKO mice 
had a more severe reaction to the second dose of ova protein this was not assessed in a 
quantitative manner. Thus before further analysis is performed to evaluate whether PKO mice 
respond differently to the second dose of ova protein compared to C57BL/6 mice a 
quantitative method needs to be established, such as measuring changes in body temperature 
or measuring the levels of serum derived factors.  
 
 
4.4.1 Summary 
This chapter reports that treatment with α-GalCer and ova protein induced a decrease in the 
number of splenic CD8+ DC. Through the use of knockout mice it was shown that the 
mechanism of this decline was independent of both perforin and Fas. NKT cells, which 
become activated in the presence of α-GalCer, are the likely mediators of this decrease in 
CD8+ DC. Responses induced with α-GalCer and ova protein could not be boosted in vivo 
using a second dose of ova protein, thus preventing the study of DC elimination during a 
secondary ova-specific CD8+ T cell response. Instead, the second dose of ova protein elicited a 
response that shared some characteristics of anaphylaxis that could be due to the presence of 
ova-specific antibodies generated after the initial treatment with α-GalCer and ova protein. 
Upon treatment with the second dose of ova protein it was also observed that PKO mice 
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reacted more severely than C57BL/6 mice. This would be an interesting area for future studies 
as a role for perforin in anaphylaxis has not been previously demonstrated.  
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5.1 Introduction 
It has been proposed that DC killing is one of the immune regulatory functions of NKT 
cells, to prevent excessive antigen stimulation (151, 152) and to regulate the Th1/Th2 
balance by removing DC that are a major source of IL-12 (310). However, it is yet to be 
determined whether NKT cells mediate DC killing in vivo, and how.  
 
Results described in Chapter 4, demonstrated that after α-GalCer treatment, loss of DC 
occurred in a perforin- and FasL-independent manner, suggesting that NKT cells must use 
a different mechanism to mediate loss of DC. NKT cells express a wide variety of cell 
death-inducing effector molecules that could contribute to DC killing; as well as perforin 
(235, 311, 313) and FasL (152, 317) they express TRAIL (318). Furthermore, NKT cells 
also secrete the cytokines, IFN-γ and TNF-α that could contribute to cell lysis (266, 270). 
TNF-α binds its receptor to activate the classical caspase dependent apoptosis pathway, 
whereas IFN-γ can promote NK and CD8+ T cell activation resulting in cell lysis. This 
chapter assessed whether IFN-γ and TNF-α are involved in NKT cell-mediated killing of 
DC.  
 
Experiments described in Chapter 4 showed that 24-48 hr after i.v. injection with α-GalCer 
the splenic CD8+ DC subset was reduced, whereas no change in number of the CD8- DC 
was observed. The splenic CD8+ and CD8- DC are distinct DC subsets as they have 
differential gene expression (64), are found in different anatomical locations (44, 61, 62) 
and the CD8+ DC preferentially secrete more IL-12 (44, 63). The CD8+ DC subset has 
been found to be important for CD8+ T cell mediated immunity. CD8+ DC are more 
efficient at cross presenting antigen than the CD8- DC subset (100, 101) and they are the 
principle DC in priming naïve CD8+ T cell during viral infections (416). Recently, 
selective depletion of the CD8+ DC was reported to profoundly abrogate CD8+ T cell 
proliferation and reduced subsequent tumour challenge (417). Additionally, a role in 
tolerance induction has been proposed, as CD8+ DC selectively phagocytose apoptotic 
cells (102, 418, 419) and decreased numbers of CD8+ DC led to reduced tolerance 
induction resulting in increased onset of experimental autoimmune encephalomyelitis 
(420). Therefore, the lack of this specific DC subset after α-GalCer treatment could impact 
on subsequent immune responses. Thus it was of particular interest to determine the 
mechanism of DC loss after α-GalCer treatment.  
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5.2 Aims 
The experiments described in this chapter were designed to identify the mechanism of the 
loss of CD8+ DC after treatment with α-GalCer, and to assess whether the decrease in 
CD8+ DC affected immune responses against protein antigen.  
 
The specific aims were: 
• To characterise the kinetics of the decrease in the CD8+ DC subset. 
 
• To determine if the loss of CD8+ DC required cognate interaction with NKT cells.   
 
• To determine whether the decline in CD8+ DC after α-GalCer and ova protein 
treatment affected ova-specific CD8+ T cell responses.   
 
 
5.3 Results 
 
 
5.3.1 The decrease in CD8+ DC is not due to the down regulation of CD8 
expression 
As described in Chapter 4, the number of splenic CD8+ DC was decreased 24-48 hr after 
treatment with α-GalCer (Figure 4.2). Firstly, it was important to establish whether the 
CD8+ DC subset was decreased because of cell loss or a loss of the CD8 molecule on the 
DC surface. To assess this the Langerin-EGFP mice were utilised. Langerin-EGFP mice 
express enhanced green fluorescent protein (EGFP) under the control of the Langerin 
promoter (57). Langerin is expressed on splenic CD8+ DC, whilst CD8- DC have little to 
no expression (421-423). As reported in the literature (57) the CD11c+EGFP+ DC 
expressed CD8 and DEC 205, while CD11c+EGFP- DC had low expression of these 
markers (Figure 5.1 A and B). Furthermore, both CD11c+EGFP+ DC and CD8+ DC from 
C57BL/6 mice expressed DEC 205 (Figure 5.1 B). To determine whether the CD8+ DC 
subset was decreased after α-GalCer treatment the Langerin-EGFP mice were treated i.v. 
with α-GalCer, then 24 hr later the spleens were harvested and the number of CD8+ DC 
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examined by flow cytometry. Langerin-EGFP mice treated with α-GalCer showed a 
significant decrease in the number of CD11c+EGFP+ cells compared to the control mice 
(Figure 5.2). This indicated that the splenic CD8+ DC subset was lost after α-GalCer 
treatment rather than down regulating the CD8 molecule.  
 
 
 
1 10 100 1000 10000
0
20
40
60
80
100
1 10 100 1000 10000
0
20
40
60
80
100
DEC 205 CD8
%
 o
f 
M
a
x
%
 o
f 
M
a
x
A. 
B. 
CD11c+EGFP+ CD11c+EGFP-Key:
M
F
I 
D
E
C
 2
0
5
M
F
I 
D
E
C
 2
0
5
C57BL/6 Langerin-EGFP
CD8
+
CD8
-
0
20
40
60
80
EGFP
+
EGFP
-
0
20
40
60
80
100
120
 
Figure 5.1 EGFP+ splenic DC from the Langerin-EGFP mice are phenotypically similar to 
splenic CD8+ DC from C57BL/6 mice.  
Spleens were harvested from naïve C57BL/6 and Langerin-EGFP mice, digested and processed 
into single cell suspensions. The number of DC present was then determined by flow cytometry. 
Dead (PI+) and B220+ cells were excluded and lymphocytes were gated on the basis of their FSC 
vs. SSC properties. (A) Histograms show the expression of DEC 205 (left panel) and CD8 (right 
panel) from representative Langerin-EGFP mice. (B) Expression of DEC 205 from C57BL/6 (left 
panel) and Langerin-EFP mice (right panel). Bars represent mean ± SD of 3 mice per group.
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Figure 5.2 The number of splenic DC expressing Langerin is reduced after treatment with α-
GalCer.  
C57BL/6 and Langerin-EGFP mice were injected i.v. with PBS or α-GalCer. Spleens were 
harvested 24 hr later and analysed as described in Figure 5.1. (A) Dot plots show expression of 
EGFP on spleen cells from C57BL/6 and Langerin-EGFP mice treated with α-GalCer or left 
untreated. The EGFP+ population is indicated by an oval gate and the EGFP- population is 
indicated by a rectangular gate. (B) Total number of CD11c+EGFP- cells (left panel) and 
CD11c+EGFP+ cells (right panel) present in the spleen 24 hr after the indicated treatments. (C) 
Expression of CD86 on CD11c+EGFP- cells (left panel) and CD11c+EGFP+ cells in the spleen 24 
hr after the indicated treatment. Bars represent mean ± SD or range of 2-3 mice per group. ∗∗∗: p < 
0.001, and ns: not significant by an unpaired Student’s t test. These experiments were repeated with 
similar results.
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To obtain additional evidence on whether the CD8+ DC were lost after α-GalCer treatment 
rather than downregulating expression of the CD8 molecule, the marker CD24 was also 
assessed, as splenic CD8+ DC express high levels of CD24 (58, 424). Indeed, 24 hr after α-
GalCer treatment the number of CD11c+CD24hi DC was decreased in C57BL/6 mice, 
while CD11c+CD24lo cells remained stable (Figure 5.3). Together, these data strongly 
suggest that the CD8+ DC subset in the spleen decreases after α-GalCer treatment.  
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Figure 5.3 The number of CD11c+CD24hi cells declines after α-GalCer treatment.  
C57BL/6 mice were injected i.v. with either PBS or α-GalCer. Spleens were harvested 24 hr later 
and analysed as described in Figure 5.1. Total number of CD11c+CD24lo cells (left panel) and 
CD11c+CD24hi cells (right panel) present in the spleen 24 hr after the indicated treatments. Bars 
represent mean ± SD or range of 2-3 mice per group. ∗:  p < 0.05, and ns: not significant by an 
unpaired Student’s t test. 
 
 
 
There are additional cell surface markers that are routinely used to distinguish the CD8+ 
DC from the CD8- DC subset. DEC 205 is highly expressed on steady state CD8+ DC, but 
not on CD8- DC (59). However, it was found that CD8- DC upregulate expression of DEC 
205 upon treatment with α-GalCer (Figure 5.4 B). This is consistent with previously 
published data (319). Thus, DEC 205 was not a suitable marker to identify CD8+ DC after 
α-GalCer treatment.  
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CD11b is an additional cell surface marker that is highly expressed on CD8- DC (59). A 
marginal increase in the cell surface expression of CD11b was found on the CD8+ DC 
subset after α-GalCer treatment (Figure 5.4 C). Increased expression of CD11b on the 
CD8+ DC has also been observed after overnight culture (59). Therefore it was decided not 
to use CD11b as an additional marker to establish whether the CD8+ DC subset was 
decreased. Altogether, the data from the Langerin-EGFP mice and the use of the cell 
surface marker CD24 provided convincing evidence that the splenic CD8+ DC subset was 
decreased after α-GalCer treatment rather than downregulating the expression of CD8.  
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Figure 5.4 DEC 205 is a marker of steady state but not activated splenic CD8+ DC.  
C57BL/6 mice were injected i.v. with either PBS or α-GalCer. Spleens were harvested 24 hr later 
and analysed as described in Figure 5.1. (A) Histograms show the expression of DEC 205 (left 
panel) and CD11b (right panel) on CD8- DC and CD8+ DC from representative mice treated with 
PBS. (B) Dot plot show total CD11c+ cells and percentage of cells expressing DEC 205 and CD8 
are indicated from representative mice treated with either PBS (left panel) or α-GalCer (right 
panel). (C) Dot plot show total CD11c+ cells and percentage of cells expressing CD11b and CD8 
are indicated from representative mice treated with either PBS (left panel) or α-GalCer (right 
panel). These experiments were repeated with similar results.
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5.3.2 The decrease in CD8+ DC requires the presence of CD1d and/or 
NKT cells 
Since evidence presented in Figures 5.2 and 5.3 supports the possibility that CD8+ DC are 
lost after α-GalCer treatment, it was of interest to determine the mechanism of this loss. To 
establish whether NKT cells were mediating CD8+ DC loss, it was next assessed whether 
the decrease in CD8+ DC was dependent on the presence of NKT cells. To evaluate this 
CD1 KO mice, which lack NKT cells, were treated with α-GalCer and 24 hr later the 
number of splenic CD8+ DC was examined by flow cytometry. As seen in Figure 5.5 A, no 
change in the number of either CD8+ or CD8- DC was observed in CD1 KO mice. In 
addition, treatment of CD1 KO mice with α-GalCer resulted in no increase in the 
expression of CD86 on either the CD8+ or CD8- DC compared to the PBS control group 
(Figure 5.5 B). This was in contrast to C57BL/6 mice where an increase in the expression 
of CD86 was seen after α-GalCer treatment (Figure 4.3 B). These data illustrate that the 
decline in CD8+ DC required the presence of NKT cells, which is a novel finding, and it 
confirmed, as reported by others (319, 320, 425) that CD1d is necessary for the activation 
of DC after α-GalCer treatment.  
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Figure 5.5 The decrease in CD8+ DC after α-GalCer treatment requires NKT cells.  
CD1 KO mice were injected i.v. with PBS or α-GalCer. Spleens were harvested 24 hr later and 
analysed as described in Figure 5.1. (A) Total number of CD8- DC (left panel) and CD8+ DC (right 
panel) present in the spleen 24 hr after the indicated treatment. Bars represent mean ± SD of 4 mice 
per group. (B) Expression of CD86 on the CD8- DC (left panel) and CD8+ DC (right panel) in the 
spleen 24 hr after the indicated treatment. Bars indicate CD86 MFI in individual mice. This 
experiment was repeated with similar results.  
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5.3.3 The reduction in CD8+ DC after α-GalCer treatment occurs in a 
dose dependent manner 
To further characterise the effect of α-GalCer, the dose required to induce loss of CD8+ 
DC was determined. Administration of 1 ng of α-GalCer caused no significant decrease in 
the number of CD8+ DC, while an intermediate dose (8 ng) resulted in a significant decline 
but not as dramatic as the high dose (200 ng) of α-GalCer (Figure 5.6 A). None of these 
doses of α-GalCer affected the number of splenic CD8- DC. However, at low doses of α-
GalCer, the expression of CD86 on CD8+ and CD8- DC was lower than in mice treated 
with 200 ng α-GalCer (Figure 5.6 B). The decrease in CD8+ DC numbers and the 
increased cell surface expression of CD86 were both observed at the same dose of α-
GalCer (Figure 5.6), suggesting that DC activation and loss of the CD8+ DC subset may be 
triggered in the same conditions, and might be related events.  
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Figure 5.6 The decrease in the number of CD8+ DC occurs in a dose dependent manner.  
C57BL/6 mice were injected i.v. with PBS or the indicated amount of α-GalCer. Spleens were 
harvested 24 hr later and analysed as described in Figure 5.1. (A) Total number of CD8- DC (left 
panel) and CD8+ DC (right panel) present in the spleen 24 hr after the indicated dose of α-GalCer 
or PBS. (B) Expression of CD86 on the CD8- DC (left panel) and CD8+ DC (right panel) in the 
spleen 24 hr after the administration of α-GalCer or PBS. Bars represent mean ± SD of 3 mice per 
group. ∗∗∗: p < 0.001, ∗∗: 0.001 < p < 0.01, ∗:  p < 0.05, and ns: not significant by one-way 
ANOVA with a Tukey post test. This experiment was repeated with similar results. 
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5.3.4 The decline in CD8+ DC after α-GalCer treatment is transient 
The results presented so far demonstrated that the decrease in CD8+ DC 24 hr after α-
GalCer treatment required NKT cells and occurred in a dose dependent manner. Next it 
was sought to characterise the kinetics of the decrease in the CD8+ DC subset. A time 
course of the loss of CD8+ DC was determined by treating mice with α-GalCer and at 
specific time points after treatment harvesting the spleens and determining the number of 
DC by flow cytometry. There was a modest but not statistically significant decrease in the 
number of CD8+ DC 10 hr after α-GalCer treatment (Figure 5.7 A), however, a significant 
decline in CD8+ DC was apparent as early as 15 hr after α-GalCer treatment with the 
greatest reduction occurring 24 hr after treatment (Figure 5.7 B and C). Seven days after α-
GalCer treatment the number of CD8+ DC was similar to the control group (Figure 5.7 B). 
After α-GalCer treatment the activation status of the DC was assessed by investigating the 
cell surface expression of CD86 (Figure 5.7 D). Similar to what was observed previously 
in Figure 5.6 B, the expression of CD86 was increased in both CD8+ and CD8- DC subsets 
after α-GalCer treatment (Figure 5.7 D). These results indicate that the loss of CD8+ DC 
occurred early after α-GalCer treatment but that this loss was only transient. 
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Figure 5.7 The loss of CD8+ DC after α-GalCer treatment is transient.  
C57BL/6 mice were injected i.v. with either PBS or 200 ng α-GalCer. At 10 hours (A) or the 
indicated time point after treatment the spleens were harvested and analysed as described in Figure 
5.1. (A-C) Total numbers of CD8+ DC present in the spleen at the indicated times after treatment 
with α-GalCer. (D) Expression of CD86 on CD8- DC (left panel) and CD8+ DC (right panel) in the 
spleen at the indicated time points after treatment with α-GalCer. Bars represent mean ± SD of 3-4 
mice per group. (A) ns: not significant by an unpaired Student’s t test. (B-D) ∗∗∗: p < 0.001, ∗∗: 
0.001 < p < 0.01, and ∗: p < 0.05 by one-way ANOVA with a Tukey post test. These experiments 
were repeated with a similar result. 
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5.3.5 CD8+ DC express higher levels of CD1d  
These data presented so far show that the CD8+ DC subset was preferentially decreased by 
α-GalCer treatment. It is not clear why only the CD8+ DC subset was lost after α-GalCer 
treatment as both DC subsets were activated by the treatment. One possible explanation is 
that the CD8+ DC express a higher amount of CD1d on their cell surface, which might 
promote greater interaction with NKT cells. Expression of CD1d was examined by flow 
cytometry. Steady state CD8+ DC were found to express 2-fold higher levels of CD1d 
compared to CD8- DC (Figure 5.8). A similar result was also reported by others using a 
global gene analysis of the DC subsets using Affymetrix microarrays (64). Thus it is 
possible that the CD8+ DC are preferentially involved in the presentation of glycolipids to 
NKT cells.  
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Figure 5.8 CD8+ DC express higher levels of surface CD1d than CD8- DC.  
Spleen DC were obtained from untreated C57BL/6 mice. (A) Histograms show the expression of 
CD1d on total CD11c+ cells (dashed line), CD8- DC (grey line) and CD8+ DC (black line) from the 
spleen of untreated C57BL/6 mice. (B) Expression of CD1d on CD8+ DC and CD8- DC. Bars 
represent mean ± range of 2 mice per group. This experiment was repeated with a similar result.  
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5.3.6 Treatment with the α-GalCer analogue OCH induces a decrease in 
the number of spleen CD8+ DC 
A number of synthetic analogues of α-GalCer have been produced, which induce distinct 
functional responses from NKT cells. The analogue OCH has a substantially shorter 
sphingosine chain compared to α-GalCer, and when injected into mice it induces the 
preferential secretion of IL-4 (305-307) with kinetics similar to α-GalCer (305, 307). In 
addition, OCH has a reduced binding affinity to CD1d compared to α-GalCer (306, 426) 
and is less potent at activating NKT cells (305, 307). Thus it was of interest to determine 
whether treatment with OCH also resulted in a decrease in the splenic CD8+ DC. Mice 
were treated i.v. with OCH and 24 hr later the number of splenic CD8+ DC was assessed. 
As shown in Figure 5.9 A, after treatment of C57BL/6 mice with OCH the number of 
CD8+ DC was significantly decreased. Comparable doses of α-GalCer and OCH were 
required for this effect (Figure 5.9). Similar results were also observed in PKO mice and 
no significant change in the number of CD8- DC was observed in either C57BL/6 or PKO 
mice (Figure 5.9 A). A titration of OCH was carried out and the decrease in CD8+ DC was 
found to occur in a dose dependent manner (Figure 5.9 B) and require doses similar to α-
GalCer treatment (Figure 5.6 A). These data would indicate that in this mouse system the 
loss of CD8+ DC was not affected by the different NKT cell ligands and their different 
binding affinity for CD1d.  
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Figure 5.9 Treatment with the α-GalCer analogue OCH induces a decline in the number of 
CD8+ DC. 
C57BL/6 and PKO mice were injected i.v. with either PBS, α-GalCer or OCH as indicated. 
Spleens were harvested 48 hr later and analysed as described in Figure 5.1. (A) Total number of 
CD8- DC (left panel) and CD8+ DC (right panel) present in the spleen after the indicated 
treatments. (B) Total number CD8- DC (left panel) and CD8+ DC (right panel) present in the spleen 
after treatment with the indicated dose of OCH. Bars represent mean ± SD of 3-5 mice per group. 
∗∗∗: p < 0.001, ∗∗: 0.001 < p < 0.01, ∗:  p < 0.05 and ns: not significant by one-way ANOVA with 
a Tukey post test. These experiments were repeated with similar results.  
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5.3.7 The decline in CD8+ DC may not be mediated through a direct 
interaction with NKT cells 
To determine whether a direct cell-cell contact mechanism was required for the decline in 
CD8+ DC after α-GalCer treatment, an adoptive transfer method was used. BMDC were 
loaded with α-GalCer in vitro and adoptively transferred into naïve mice. Since it was 
assumed that in this experimental set up only the adoptively transferred BMDC were 
presenting α-GalCer on their cell surface, no direct interaction would be required between 
NKT cells and CD8+ DC.  
 
The number of resident splenic CD8+ DC was similarly reduced in mice treated with 
BMDC loaded with α-GalCer and mice treated i.v. with α-GalCer (Figure 5.10 A), 
suggesting that the loss of CD8+ DC was not mediated by a direct interaction with the 
NKT cells. However, when CD1 KO BMDC, which are able to take up α-GalCer but not 
present it on their cell surface, were loaded with α-GalCer and injected into mice, a 
decrease in the splenic CD8+ DC was also observed (Figure 5.10 B). This result suggested 
that host cells were taking up the adoptively transferred CD1 KO BMDC and presenting 
the α-GalCer on their cell surface. Again it was possible that this host population was the 
CD8+ DC, as these cells are known to be able to efficiently take up and cross present 
soluble antigen and apoptotic cells in blood.  
 
The activation status of the host splenic DC was also assessed by determining the 
expression level of CD86 (Figure 5.10 C and D). Interestingly, DC from mice that received 
either C57BL/6 or CD1 KO BMDC loaded with α-GalCer expressed lower CD86 
compared to DC from mice treated i.v. with α-GalCer, but greater than mice that had 
received unloaded BMDC (Figure 5.10 C and D). Since CD86 expression on DC from 
mice injected with either C57BL/6 and CD1 KO BMDC loaded with α-GalCer was 
similar, it is likely that the same mechanism was leading to DC activation. Since the 
number of splenic CD8+ DC was reduced after adoptive transfer of either C57BL/6 or CD1 
KO BMDC, no conclusion could be made as to whether a direct interaction between the 
NKT cell and DC was required for the decrease in splenic CD8+ DC. 
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Figure 5.10 The decrease in the number of CD8+ DC may not require a direct interaction 
with NKT cells.  
C57BL/6 mice were injected i.v. with 3 x 106 BMDC from either C57BL/6 (A, B, left panel and C) 
or CD1 KO (B, right panel and C) mice, which were untreated or loaded with α-GalCer. As a 
positive control, mice were treated with α-GalCer alone. Spleens were harvested 24 hr later and 
analysed as described in Figure 5.1. (A) Total number of CD8- DC (left panel) and CD8+ DC (right 
panel) present in the spleen after the indicated treatments. (B) Total number of CD8+ DC in the 
spleen 24 hr after adoptive transfer of either C57BL/6 BMDC (left panel) or CD1 KO BMDC 
(right panel). (C) Representative histograms from 1 out of 3 mice show the expression of CD86 on 
CD8+ DC 24 hr after the indicated treatment. (D) The expression of CD86 on CD8+ DC 24 hr after 
the indicated treatment. Bars represent mean ± SD or range of 2-3 mice per group. ∗∗∗: p < 0.001 
and ns: not significant by one-way ANOVA with a Tukey post test. These experiments were 
repeated with similar results.
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5.3.8 IFN-γ does not mediate the decrease in CD8+ DC after treatment 
with α-GalCer 
Adoptive transfer of BMDC did not provide direct evidence as to whether the decrease in 
CD8+ DC required a direct cell-cell contact between NKT cells and the CD8+ DC (Figure 
5.10). Additionally, as described in Chapter 4, neither perforin nor FasL are required for 
the observed decrease in CD8+ DC, further supporting the possibility that the decrease in 
CD8+ DC does not require a cell contact dependent mechanism (Figure 4.3 A and 4.6 A). 
Therefore the loss of CD8+ DC after treatment with NKT cell ligands could be cytokine 
dependent. A possible candidate was IFN-γ, which is rapidly produced by NKT cells after 
treatment of α-GalCer. To determine if IFN-γ played a role in the decrease of CD8+ DC, 
mice lacking the ability to produce IFN-γ (IFN-γ KO) were utilised. As in C57BL/6 mice, 
a significant decrease in the number of CD8+ DC was observed in IFN-γ KO mice 24 hr 
after α-GalCer treatment. Furthermore, no significant change in the number of CD8- DC 
was observed in the IFN-γ KO mice (Figure 5.11 A). Interestingly, DC from α-GalCer 
treated IFN-γ KO mice did not upregulate the expression of CD86 as profoundly as DC in 
C57BL/6 mice (Figure 5.11 C). This result is consistent with previously published work 
reporting that IFN-γ was required for the increase in CD86 after α-GalCer treatment (187). 
In addition, CD86 upregulation was especially weak on the CD8- DC subset suggesting 
that CD8+ and CD8- DC subsets may respond differentially to α-GalCer dependent 
stimulation. These data indicate that IFN-γ does not mediate the loss of CD8+ DC after α-
GalCer treatment.  
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Figure 5.11 IFN-γ does not mediate the loss of CD8+ DC after α-GalCer treatment.  
C57BL/6 and IFN-γ KO mice were injected i.v. with PBS or α-GalCer. Spleens were harvested 24 
hr later and analysed as described in Figure 5.1. (A) Dot plots show flow cytometric analysis of 
spleen cells, CD8- DC are indicated by a rectangle gate, and CD8+ DC are indicated by an oval 
gate. (B) Total number of CD8- DC (left panel) and CD8+ DC (right panel) present in the spleen 24 
hr after the indicated treatment. (C) Expression of CD86 on the CD8- DC (left panel) and CD8+ DC 
(right panel) in the spleen 24 hr after the indicated treatment. Bars represent mean ± SD of 3 mice 
per group. ∗∗∗: p < 0.001, ∗∗: 0.001 < p < 0.01, ∗:  p < 0.05, and ns: not significant by one-way 
ANOVA with a Tukey post test. These experiments were repeated three times with similar results.
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5.3.9 TNF-α plays a role in the reduction of CD8+ DC after α-GalCer 
treatment 
Another possible candidate for cytokine mediated loss of the CD8+ DC was TNF-α, which 
is produced by NKT cells (263) and DC (187) early after injection of α-GalCer. In 
addition, TNF-α is also known to induce cell death (427). To investigate whether TNF-α 
was mediating the decrease in CD8+ DC a TNF-α neutralising antibody was used.  
 
Firstly, it was important to confirm that the dose of TNF-α neutralising antibody used 
successfully blocked TNF-α. To evaluate this C57BL/6 mice were given TNF-α 
neutralising antibody 20 hr before α-GalCer treatment, then 3 hr after α-GalCer treatment 
blood was collected and the level of serum TNF-α determined using the Bio-Plex 
system. Undetectable serum levels of TNF-α were found in mice treated with the TNF-α 
neutralising antibody (Figure 5.12 A). These data indicated that this method successfully 
blocked TNF-α, at least transiently.  
 
To determine if blocking TNF-α affected the loss of CD8+ DC, mice were treated with 
anti-TNF-α followed by α-GalCer treatment 20 hr later. Forty-eight hr after α-GalCer 
treatment splenocytes were assessed for the number CD8+ DC by flow cytometry. A 
greater number of splenic CD8+ DC were recovered in C57BL/6 mice treated with the 
TNF-α neutralising antibody compared to the control treated mice (Figure 5.12 B and C). 
No change in the number of CD8- DC was seen after treatment with the TNF-α 
neutralising antibody (Figure 5.12 B and C). The cell surface expression of CD86 was also 
assessed to determine the activation status of the DC (Figure 5.13). In mice treated with 
the TNF-α neutralising antibody expression of CD86 on both DC subsets was markedly 
reduced compared to the controls (Figure 5.13). This is consistent with previously 
published data (187), where treatment of TNF KO mice resulted in reduced expression of 
CD86 on both CD8+ and CD8- DC subsets. These results suggested that TNF-α played a 
role in the activation and the decrease of the splenic CD8+ DC subset after α-GalCer 
treatment.  
 
Chapter 5: Study of the mechanism of CD8+ DC loss after treatment with α-GalCer 
 
189
Figure 5.12 TNF-α plays a role in the decrease of CD8+ DC after α-GalCer treatment.  
C57BL/6 mice were injected i.p. with PBS or 10 mg/kg of anti-TNF-α, treated i.v. with α-GalCer 
20 hr later, and 48 hr after α-GalCer treatment spleens were harvested and analysed as described in 
Figure 5.1. (A) Levels of serum TNF-α 3 hr after α-GalCer treatment. TNF-α concentrations were 
determined using the Bio-Plex system. ND: not detectable. (B) Dot plots show flow cytometric 
analysis of spleen cells 48 hr after α-GalCer treatment, CD8- DC are indicated by a rectangle gate 
and the CD8+ DC are indicated by an oval gate. (C) Total number of CD8- DC (left panel) and 
CD8+ DC (right panel) in the spleen 48 hr after α-GalCer treatment. Bars represent mean ± range 
of 2 mice per group. These experiments were repeated with similar results. 
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Figure 5.13 Treatment with a TNF-α neutralising antibody reduced the upregulation of 
CD86 on DC after α-GalCer treatment.  
C57BL/6 mice were injected i.p. with anti-TNF-α and treated i.v. with α-GalCer as described in 
Figure 5.12. Expression of CD86 on CD8- DC (left panel) and CD8+ DC (right panel) was 
examined in the spleen 24 hr after α-GalCer treatment. Bars represent mean ± range of 2 mice per 
group. ∗∗∗: p < 0.001, ∗∗: 0.001 < p < 0.01, and ∗: p < 0.05 by one-way ANOVA with a Tukey 
post test. This experiment was repeated with similar results. 
 
 
 
5.3.10 Reduced numbers of CD8+ DC after α-GalCer treatment do not 
affect ova-specific immune responses 
Studies have reported that α-GalCer acts as an adjuvant for T cell responses, as treatment 
with α-GalCer and ova protein activated larger numbers of ova-specific CD8+ and CD4+ T 
cells compared to ova protein only (319, 320, 325, 326). DC are important for the adjuvant 
effect of α-GalCer (187), thus a reduced number of CD8+ DC could affect the generation 
of CD8+ T cell responses. To assess whether the decrease in the CD8+ DC subset after α-
GalCer treatment impacted on the CD8+ T cell response to protein antigen, C57BL/6 mice 
were treated with either 200 ng or 1 ng of α-GalCer in conjunction with ova protein. The 
low α-GalCer dose of 1 ng was chosen because it caused no significant decrease in the 
number of CD8+ DC compared to 200 ng α-GalCer but still induced some DC activation 
(Figure 5.6 A). To evaluate the ova-specific CD8+ T cell response after treatment with the 
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different doses of α-GalCer, the percentage of CD8+Kb-ova257-264+ T cells in the blood was 
examined 7 and 12 days after α-GalCer treatment using a MHC I pentamer. The results 
showed that on day 7 the percentage of CD8+Kb-ova257-264+ T cells was greater in mice 
treated with 200 ng α-GalCer than in those treated with only 1 ng α-GalCer and ova 
protein (Figure 5.14). However, 12 days after treatment the percentage of CD8+Kb-ova257-
264
+
 
T cells was similar in mice treated with 200 ng or 1 ng α-GalCer (Figure 5.14). These 
data indicated that the activation status of DC during the initial priming of CD8+ T cells is 
more important than their numbers. Later responses did not appear to be as sensitive to the 
activation status of the DC compared to the requirement for the earlier responses.  
 
Chapter 5: Study of the mechanism of CD8+ DC loss after treatment with α-GalCer 
 
193
Figure 5.14 The lower dose of α-GalCer only affects the early ova-specific CD8+ T cell 
response.  
C57BL/6 mice were injected i.v. with either 1 ng or 200 ng of α-GalCer and 200 µg ova protein. 
Blood was collected from the tail vein 7 and 12 days later and labelled with anti-CD8 and Kb-
ova257-264 pentamer. Blood from mice injected with PBS was used as a negative control. The 
percentage of CD8+Kb-ova257-64+ cells was examined by flow cytometry. Dead (PI+) cells were 
excluded and lymphocytes were gated on the basis of their FSC vs. SSC properties. (A) Dot plots 
show total CD8+ cells, CD8+Kb-ova257-64+ cells are highlighted by an oval gate and their percentage 
is shown. (B) Percentages of CD8+Kb-ova257-64+ cells on day 7 (left panel) and 12 (right panel) after 
administration of α-GalCer and ova protein. Each point represents an individual mouse and lines 
represent the mean. ∗∗: 0.001 < p < 0.01 and ns: not significant by one-way ANOVA with a Tukey 
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The use of α-GalCer in conjunction with soluble ova has been shown to improve tumour 
immunity compared to ova alone (187, 319, 320, 325). To investigate whether the use of 
different doses of α-GalCer impacted on tumour immunity, C57BL/6 mice were treated 
s.c. with the B16.ova melanoma tumour 30 days after treatment with either 1 ng or 200 ng 
α-GalCer and ova protein. Tumour growth was then monitored over time. Mice treated 
with either 1 ng or 200 ng α-GalCer along with ova protein developed tumours 
approximately 25 days later compared to the control group (Figure 5.15). This reflects the 
results reported in Figure 5.14, where the percentages of ova-specific T cells were similar 
in mice treated with 1 ng or 200 ng α-GalCer on day 12. Thus in this prophylactic setting 
the different doses of α-GalCer did not affect tumour protection.  
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Figure 5.15 Administration of ova together with low or high doses of α-GalCer elicits similar 
tumour protection. 
C57BL/6 mice were injected i.v. with either 1 or 200 ng α-GalCer and  200 µg ova protein. As a 
negative control mice were injected i.v. with PBS. Thirty days later mice were injected s.c. with     
1 x105 B16.ova tumour cells in the left flank and tumour growth was monitored. A tumour was 
scored as positive when the product of bisecting diameters exceeded 4 mm2. Each point represents 
the percentage of tumour free animals with 4-5 mice per group.  
 
 
 
Chapter 5: Study of the mechanism of CD8+ DC loss after treatment with α-GalCer 
 
196 
Administration of a TNF-α neutralising antibody maintained a higher number of CD8+ DC 
after α-GalCer treatment. To determine if administration of a TNF-α neutralising antibody 
impacted on the ova-specific CD8+ T cell response, C57BL/6 mice were adoptively 
transferred with purified OT-IxB6 congenic CD8+ LN cells, treated with anti-TNF-α 
antibody 2 hr later, and treated with α-GalCer and ova after a further 20 hr. At specific 
time points after treatment the number of transferred cells in the blood was determined 
using a MHC I pentamer. Seven days after treatment, mice that were treated with the TNF-
α neutralising antibody before α-GalCer treatment had a statistically greater number of 
transferred cells present in the blood (Figure 5.16). However, this increase in transferred 
cells was not maintained over time. At the last time point measured mice treated with the 
TNF-α neutralising antibody showed a significant decrease in the number of transferred 
cells compared to the control treated group (Figure 5.16 B). These data indicated that 
treatment with the TNF-α neutralising antibody improved the early but not the late CD8+ T 
cell response. Furthermore, these results suggest that low doses of α-GalCer or anti-TNF-α 
treatment, which maintained a higher number of CD8+ DC, and resulted in less activated 
DC, did not lead to improved CD8+ T cell responses.  
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Figure 5.16 Blocking TNF-α during treatment with α-GalCer and ova improves the early but 
not the late CD8+ T cell response.  
CD8+ cells were purified from the LN of a OT-IxB6 congenic mouse using magnetic separation 
and 5 x103 cells were adoptively transferred into C57BL/6 mice. Two hr later mice were injected 
i.p. with 10 mg/kg Rat IgG or anti-TNF-α, then treated i.v. with α-GalCer 20 hr later. At the 
specific time points indicated blood was collected from the tail vein and examined by flow 
cytometry for the presence of transferred cells (CD8+CD45.1+). Dead (PI+) cells were excluded and 
lymphocytes were gated on the basis of their FSC vs. SSC properties. (A) The percentage of 
CD8+CD45.1+ cells in the blood 7 days after treatment with α-GalCer and ova protein. Each point 
represents an individual mouse and lines represent the mean. (B) Time course of the percentages of 
CD8+ CD45.1+ cells in blood after treatment with α-GalCer and ova protein. Each point represents 
mean ± SD of 4-5 mice per group. The statistical analyses in (B) refer to the α-GalCer and ova 
protein treated groups ∗∗: 0.001 < p < 0.01, ∗: p < 0.05 and ns: not significant by two way ANOVA 
with a Tukey post test.
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5.3.11 Neutralisation of TNF-α leads to reduced NKT cell activation  
In mice treated with the TNF-α neutralising antibody, DC were less activated and 
expressed lower levels of CD86 (Figure 5.13). To determine whether NKT cell activation 
was affected by TNF-α neutralisation, the serum level of cytokines associated with NKT 
cell activation were measured. Treatment with the TNF-α neutralising antibody led to 
significantly reduced serum levels of IL-4, IFN-γ and IL-12p70 (Figure 5.17 A and C-D). 
These cytokines are produced by different cell populations, with IL-4 being produced by 
NKT cells, IL-12p70 by DC, while IFNγ is produced by both NKT cells and NK cells. 
Thus the presence of TNF-α seems to be critical in the activation of NKT cells, DC and 
NK cells.  
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Figure 5.17 Treatment with anti-TNF-α leads to reduced serum cytokine levels after α-
GalCer treatment.  
C57BL/6 mice were injected i.p. with anti-TNF-α and treated i.v. with α-GalCer and ova protein as 
described in Figure 5.12. Three and six hr after α-GalCer and ova protein treatment the levels of 
serum TNF-α, IL-4, IL-12p70 and IFN-γ were determined using the Bio-Plex system. Bars 
represent mean ± SD of 5 mice per group. This experiment was repeated with similar results.  
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5.4 Discussion  
The aim of this chapter was to determine the mechanism of the loss of CD8+ DC after α-
GalCer treatment, and its potential effects on immune responses. It was discovered that the 
decrease in CD8+ DC was transiently induced by both α-GalCer and its analogue OCH, 
and required the presence of NKT cells. Neutralisation of TNF-α provided evidence that 
TNF-α was a key mediator in the reduction of CD8+ DC after α-GalCer treatment. DC 
depletion was intimately linked to activation, and preventing the loss of CD8+ DC also 
decreased DC activation, and did not improve the generation of CD8+ T cell response to a 
co-administered protein antigen.  
 
Firstly, it was established that loss of splenic CD8+ DC after α-GalCer treatment was due 
to cell loss, and not to down regulation of the CD8 molecule. This was determined by 
using cell markers other than CD8 to indirectly establish the presence of CD8+ DC in α-
GalCer treated mice. In the steady state, CD8+ DC express DEC 205 and lack expression 
of CD11b (59). Unfortunately, DEC 205 was found not to be suitable to the study of α-
GalCer treatment. Upon treatment with α-GalCer CD8- DC appeared to upregulate 
expression of DEC 205, a finding also reported by other authors (187). Similarly, 
expression of DEC 205 and CD11b on CD8- and CD8+ DC, respectively, are increased 
after overnight culture, indicating that DEC 205 and CD11b are not stable DC lineage 
markers (59). Other markers that gave more reliable results were Langerin (421, 423), and 
CD24, which are both reported to be expressed on CD8+ DC (58, 424). The results 
described in Figures 5.2 and 5.3, where the expression of Langerin and CD24 was 
investigated after α-GalCer treatment, showed a decrease in the CD8+ DC subset after α-
GalCer treatment, indicating that the DC subset was depleted after α-GalCer treatment. 
 
It has been recently recognised that the CD8+ DC are a heterogenous cell subset. They 
have been divided based on the expression of Langerin (CD207) and integrin αE (Itgae) 
also known as CD103, into two groups, either CD207+CD103+ or CD207-CD103-. It was 
observed that the CD207+CD103+ DC are superior in their ability to cross present soluble 
antigen and phagocytose apoptotic bodies (420). These data are consistent with an earlier 
report that demonstrates that not all the CD8+ DC can cross present cellular antigen 
indicating heterogeneity within the population (417). Furthermore, TLR ligand stimulation 
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caused disappearance of only the CD103+ DC in vivo, which resulted in reduced tolerance 
induction (420). Additionally, another recent paper showed that the CD8+CD207+ 
population disappeared after in vivo TLR ligand stimulation (428). Similar results were 
observed when Langerin-EGFP mice were treated with α-GalCer, as only the CD8+EGFP+ 
DC declined in cell number compared to the CD8+EGFP- DC (data not shown). Thus it 
would be of interest to further characterise the CD8+ DC that are lost after α-GalCer 
treatment by investigating the expression of CD103.  
 
As discussed in section 1.1.3, there is evidence indicating that the different murine splenic 
cDC subsets are functionally distinct. In particular, CD8+ DC express a different TLR 
repertoire from all other murine spleen DC subsets (65), and reduced levels of the anti-
apoptotic molecule Bcl-2 (429), suggesting that after recognition of certain stimuli CD8+ 
DC may be more sensitive to apoptosis than CD8- DC. In support of this, data presented in 
this thesis demonstrated that CD8+ DC were selectively decreased after treatment with α-
GalCer. Loss of CD8+ DC has also been reported during a range of different infections 
(430-433). Taken together these data suggest that CD8+ DC are more sensitive and 
possibly more prone to apoptosis than CD8- DC.  
 
It is possible that the differential response of CD8+ and CD8- DC to α-GalCer treatment is 
due to DC receiving multiple signals, some of which lead to activation of all DC, while 
others lead to the survival or death of specific DC subsets. Experiments attempted to 
separate the activation and survival/death signals by injecting decreasing doses of α-
GalCer, and by using the α-GalCer analogue OCH, which has a lower binding affinity for 
mouse NKT cells (434) and induces a differential cytokine response compared to α-GalCer 
(305). Conditions where DC activation and depletion were separated could not be 
identified in C57BL/6 mice, suggesting that CD8+ DC loss was most consistent with 
activation-induced cell death, as already described by others in DC responding to LPS (61, 
420). Against this hypothesis, a-GalCer injection induced weak upregulation of CD86 in 
B6.lpr mice, but some CD8+ DC loss was still observed. This suggests that DC activation 
and CD8+ DC loss can be dissociated at least in some cases. No further studies were 
carried out to characterize the response of B6.lpr mice to a-GalCer, and determine whether 
additional aspects of this response might also have been defective.  
 
Chapter 5: Study of the mechanism of CD8+ DC loss after treatment with α-GalCer 
 
203 
CD8+ DC express more CD1d and could preferentially interaction with NKT cells. To 
establish if direct contact between CD8+ DC and NKT cell was required for the decline in 
CD8+ DC, C57BL/6 mice were injected with BMDC loaded with α-GalCer. It was 
assumed that in this set-up the only DC able to present α-GalCer to the NKT cells were the 
adoptively transferred BMDC. Thus if a reduction in the number of resident splenic CD8+ 
DC was observed this would indicate that the loss of CD8+ DC was not mediated by direct 
NKT cell contact. However, a decrease in resident splenic CD8+ DC was also observed 
when CD1 KO BMDC were loaded with α-GalCer and adoptively transferred into 
C57BL/6 mice. Since CD1 KO BMDC cannot directly present α-GalCer, this result must 
be due to cross presentation of the injected BMDC, or of released α-GalCer, by resident 
splenic DC (Figure 5.18), presumably the CD8+ DC. Other reports have found that lipids 
can be cross-presented. Tumour cells loaded with α-GalCer and injected into mice can be 
taken up by host DC to induce activation of NKT cells (435). Similarly, when human 
melanoma cells that lack expression of any isoform of human CD1 and express the 
ganglioside, GD3, were injected into mice, activated GD3 reactive NKT cells were found, 
indicating cross-presentation of GD3 by murine APCs in vivo (436). In conclusion, the use 
of α-GalCer on BMDC did not provide any firm evidence on whether the decrease in 
CD8+ DC involved the formation of direct contacts between NKT cells and DC. 
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Figure 5.18 A schematic diagram of the mechanisms of α-GalCer presentation after adoptive 
transfer of BMDC loaded with α-GalCer.  
A schematic diagram of the possible mechanisms that lead to decrease in splenic CD8+ DC after 
adoptive transfer of BMDC. BMDC can directly present α-GalCer to NKT cells, or alternatively 
resident splenic DC can take up the BMDC and present α-GalCer presented on their CD1d molecules. 
The uptake of BMDC by splenic DC allows NKT cells to directly interact with them. NKT cells can 
then directly target the DC through cell mediated contact pathways (1), or alternatively, the NKT cells 
can release cytokines that then act directly on the DC or through other cell types (2). 
 
 
 
Since no strong experimental evidence was generated to suggest that the decline in CD8+ DC 
was mediated by a contact dependent mechanism, the possibility that a soluble mediator was 
causing the loss of CD8+ DC was considered. One possible candidate was the cytokine IFN-γ. 
NKT cells rapidly produce high levels of IFN-γ upon stimulation with α-GalCer (263). 
However, a decrease in CD8+ DC was also seen after treatment with the glycolipid OCH, 
which preferentially induces IL-4 production by NKT cells and little IFN-γ (305-307), 
suggesting that IFN-γ was not involved in the loss of the CD8+ DC. This conclusion was also 
supported by experiments where IFN-γ KO mice treated with α-GalCer showed a decline in 
the number of CD8+ DC in spleen, as observed in C57BL/6 mice. Thus these data 
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demonstrated that IFN-γ was not the soluble mediator involved in the decrease of the CD8+ 
DC after α-GalCer treatment.  
 
Another possible candidate for mediating the decline in CD8+ DC was TNF-α. TNF-α is a 
highly pleiotropic, pro-inflammatory cytokine that affects cellular proliferation and 
differentiation, as well as activation of apoptosis (220, 437). A study by Smyth and Sedgwick 
showed that TNF-α released from antigen activated CD8+ T cells was an important soluble 
mediator of bystander lysis (438). Furthermore, both NKT cells (263) and DC (187) have been 
shown to produce TNF-α within a few hours of α-GalCer stimulation. Consequently, high 
levels of TNF-α after α-GalCer treatment could lead to cell death. When TNF-α was blocked 
using a neutralising antibody the number of CD8+ DC did not decline as dramatically as in the 
control group. This is consistent with previously published data where CD8+ DC were 
selectively lost after an oral Salmonella infection in WT mice, but were resistant to cell death 
in TNFR1 deficient mice (433). Furthermore, TNF-α can only induce apoptosis in cells with 
low levels of anti-apoptotic proteins (439), which is consistent with the lower mRNA levels of 
Bcl-2 present in CD8+ DC (429). Taken together these data suggest that TNF-α selectively 
mediates the disappearance of CD8+ DC during different immune responses. 
 
The loss of CD8+ DC after α-GalCer treatment involved the cytokine TNF-α. TNF-α is 
primarily produced as a type II transmembrane protein arranged in stable homotrimers. This 
membrane intregrated form (mTNF) can then be proteolytic cleaved to release the soluble 
homotrimeric cytokine (sTNF) (220). There is evidence to suggest that mTNF has a role in 
cytotoxicity (440, 441). In the experiments described in this Chapter, it is not possible to 
distinguish whether it is mTNF or sTNF that contributes most significantly to the loss of CD8+ 
DC. Thus until this can be accurately assessed it is possible that the loss of CD8+ DC is at 
least partly mediated by direct cell contact with the NKT cells. However, as the administration 
of a TNF-α neutralising antibody inhibited the activation of both CD8+ and CD8- DC, it would 
point towards sTNF, rather than mTNF being involved in the loss of CD8+ DC. Though, if the 
depletion of CD8+ DC observed after α-GalCer treatment was due to the direct effects of 
sTNF, it is somewhat surprising that other subsets of DC, such as the CD8- DC subset, were 
not similarly depleted.  
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The involvement of TNF-α in the loss of the CD8+ DC would suggest that the DC are dying 
by apoptosis induced by TNF signalling, however, no DC death could be directly 
demonstrated in our studies. Studies of LPS-treated mice observed upregulation of 
CD80/CD86 and MHC II on splenic DC (61), followed by their death by apoptosis (145). Ex 
vivo labelling of DC with the viability dyes Annexin V and PI was conducted to verify 
whether apoptosis of CD8+ DC was occurring, however, the data was not informative due to 
high background labelling in the control group (data not shown). New technology now exists 
where dyes can be injected in vivo followed by flow cytometric analysis to evaluate the level 
of early stage apoptotic cell death. These experiments would clarify whether CD8+ DC are 
dying by apoptosis after α-GalCer treatment. 
 
Since no direct experimental evidence was available to show that the CD8+ DC were 
undergoing cell death after α-GalCer treatment, it was possible that the observed loss was due 
to DC migration out of the spleen into other tissues. However, an extensive literature search 
did not find any reports of DC migrating out of the spleen. In fact, it has been reported that 
after LPS treatment CD11c+ DC migrated from the marginal zone to the T cell zone within the 
spleen and then rapidly died by apoptosis within the T cell zone (61, 145). More recently, it 
has been reported that after treatment with poly(I:C) or LPS Langerin expressing CD8+ DC 
redistribute from the marginal zone to the T cell zone. This was followed by the disappearance 
of Langerin staining, which was presumed to be cell death of the Langerin expressing DC 
(428). Thus these data would provide support that perhaps the CD8+ DC are not migrating out 
of the spleen after α-GalCer treatment but instead dying by apoptosis.  
 
As well as TNF-α playing a role in the decrease of CD8+ DC after α-GalCer treatment, it 
appears that TNF-α was also important for the interaction between DC and NKT cell. 
Administration of a TNF-α neutralising antibody resulted in reduced expression of CD86 and 
IL-12p70 production by DC, while reduced serum levels of IFN-γ and IL-4 indicated reduced 
NKT cell activation. This reduced activation of both DC and NKT cell confirms that the 
activation of NKT cells leads to reciprocal activation of DC (319, 320, 425). There is evidence 
to suggest that TNF-α can help enhance IL-12p70 production by DC, which is important for 
the generation of effective CD8+ T cell responses (179) and is required for the production of 
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IFN-γ by NKT cells (405). Treatment with TNF-α has shown to induce a small antigen 
specific CD8+ T cell response in the presence of CD40 signalling (187) and TNF signalling 
was required for the production of IL-12p70 during DC-NK cell interactions (442). Thus these 
data illustrate that TNF-α plays a role in enhancing IL-12p70 production by DC and is 
important for the interaction between DC and NKT cell. 
 
DC are critical to the adjuvant effect of α-GalCer (187). Thus a reduced number of DC could 
reduce the adjuvant effect of α-GalCer. Recently, others have shown that the loss of CD8+ DC 
affected tolerance induction and T cell immunity (417, 420). In contrast, methods used in this 
study to retain a greater number of CD8+ DC did not improve the CD8+ T cell response after 
treatment with α-GalCer and ova protein, suggesting that the loss of the CD8+ DC does not 
profoundly affect the CD8+ T cell response. This result is consistent with the requirement for 
only a brief period of antigenic stimulation for the generation of strong CD8+ T cell responses. 
However, the methods employed in this study to retain a greater number of CD8+ DC after α-
GalCer treatment also led to a reduced activation status of the DC. Co-stimulation through 
CD28:CD86/CD80 signalling has been shown to be important for T cell activation and 
differentiation (110), thus reduced expression of CD86 on the DC would result in reduced co-
stimulation provided to the CD8+ T cells. This is likely to explain why a greater number of 
CD8+ DC did not improve the CD8+ T cell response and illustrates that the DC activation 
status is at least as important as absolute number. Thus perhaps if a greater number of CD8+ 
DC could be retained after α-GalCer treatment along with an activated phenotype then an 
improved CD8+ T cell response might be generated.  
 
The powerful adjuvant effect of α-GalCer comes from the activation of NKT cells rapidly 
producing a large array of cytokines leading to the trans-activation of many cell types, 
including DC and B cells. Studies in this Chapter focused on the activation of DC after α-
GalCer treatment, but as discussed in Chapter 1, B cells also express CD1d and can present α-
GalCer on their cell surface (91-93). Reports have demonstrated that NKT cell activation 
results in B cells proliferation and antibody secretion (327-333). However, others discovered 
that B cells poorly activate NKT cells to produce only Th2 cytokines (391) and were shown to 
be responsible for the induction of anergic NKT cells (406). Additionally, B cells appeared to 
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have a suppressive role in DC mediated NKT cell activation (391). Though, more recently it 
has been suggested that marginal zone B cells play a role in NKT cell activation (333, 334, 
443) and were found to amplify the DC mediated activation of NKT cells (443). Thus, perhaps 
B cells affect the decline of CD8+ DC after α-GalCer treatment. Therefore, it would be of 
interest to carry out further investigations using a mouse model deficient in B cells to assess 
whether B cells have a role in the loss of this DC subset after α-GalCer treatment. 
 
 
5.4.1 Summary 
Treatment α-GalCer results in the NKT cell-dependent depletion of splenic CD8+ DC. The 
precise mechanism leading to the decline of CD8+ DC was not definitively established, but 
appeared to involve the cytokine TNF-α. The loss of CD8+ DC was transient and 
administration of the NKT cell ligand OCH also resulted in a decrease of CD8+ DC, which 
occurred with comparable kinetics to α-GalCer. DC activation and depletion were tightly 
linked, with DC activation almost always correlating with a decline in the CD8+ DC subset. 
This loss has similar characteristics to activation induced cell death.  
 
Treatment with low doses or α-GalCer or anti-TNF-α reduced the loss of CD8+ DC, but did 
not lead to significant improvements in CD8+ T cell responses to ova protein. This result is 
likely to be due to a reduced activation status of the DC that occurred during the process of 
retaining the number of CD8+ DC. Improving responses would require that DC activation and 
loss be separated. 
 
Taken together, these data provides further insights into the physiology of DC during the 
immune response to α-GalCer and will hopefully help to improve future α-GalCer based 
cancer immunotherapies. 
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The main aim of this thesis was to establish whether CD8+ T cells and NKT cells eliminate DC 
in vivo in a perforin-dependent manner, and whether this elimination results in reduced T cell 
responses due to limited antigen presentation. 
 
At the time this study was initiated there was evidence indicating that CTL mediate DC killing 
in a perforin-dependent manner. However, this evidence arose from experiments that were 
conducted using immunised mice and BMDC loaded with peptide antigen (155). There are a 
number of limitations to this approach, such as the mice were injected with TCR transgenic T 
cells and the BMDC were loaded with a high concentration of a specific peptide, which is an 
artificial mode of antigen loading and presentation that does not reflect the physiological 
situation. Furthermore, the BMDC used in that study were an in vitro generated population 
that lacks an in vivo equivalent (155). Additionally, at the commencement of this study there 
was no in vivo data demonstrating whether NKT cells can eliminate DC. It was of interest to 
assess whether NKT cells have a role in DC killing as they express perforin and, like other 
perforin-expressing innate cells such as NK cells, may regulate DC survival and the outcome 
of immune responses (148). Therefore, two different experimental models were established to 
assess whether CD8+ T cell and NKT cells eliminate DC in vivo.  
 
The first in vivo model established was a murine influenza A viral infection. As discussed in 
Chapter 3, this model was chosen because influenza infection elicits a robust specific CD8+ T 
cell response. Furthermore, as clearance of the influenza A virus does not require perforin 
(366), antigenic viral load in PKO mice is not expected to differ significantly from C57BL/6 
mice. Among the drawbacks of this model are that, the antigen load is difficult to control 
experimentally, and that many CTL specific for numerous influenza antigens are present. To 
address some of these limitations, a second in vivo model was established which used 
immunisations with controlled amounts of antigen. The NKT cell ligand α-GalCer and the 
protein antigen ova were administered to elicit NKT cell activation and an ova-specific CD8+ 
T cell response, respectively, allowing the assessment of whether CD8+ T cells and NKT cells 
eliminated DC in a perforin-dependent manner. In both the influenza and the α-GalCer model, 
DC are loaded with antigen in vivo, and endogenous T cell responses are assessed without the 
requirement for TCR transgenic CTL. The results of these studies indicated that during an 
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influenza infection PKO mice did not generate an enhanced CD8+ T cell response compared to 
C57BL/6 mice. Furthermore, investigations in this thesis did not provide evidence for 
perforin-dependent elimination of DC by NKT cells, but instead revealed a loss of splenic 
CD8+ DC partly mediated by the cytokine TNF-α.  
 
Others have found that PKO mice generate enhanced immune responses after a range of 
infections (338, 339, 374-378) leading to the proposal that increased DC survival was driving 
increased T cell expansion in these mice (155). Furthermore, increased T cell responses were 
observed in other systems where DC were genetically manipulated to prolong their survival 
(144, 157-162), providing additional support that increased DC survival correlates with an 
improved T cell response. The studies described in this thesis demonstrated that the primary 
CD8+ T cell response to influenza was not enhanced in PKO mice compared to C57BL/6 
mice. These results are consistent with a published study showing that during a primary 
influenza infection the numbers of DC presenting influenza antigens were similar in the two 
mouse strains (156). Investigations into primary CD8+ T cell responses after treatment with α-
GalCer and ova protein revealed similar T cell expansion in C57BL/6 and PKO mice, but 
were inconclusive as to whether ova-specific CD8+ T cells could mediate killing of splenic 
DC. Loss of splenic CD8+ DC was observed but appeared to be due to the administration of α-
GalCer on NKT cells rather than the presence of ova-specific CTL, suggesting that the α-
GalCer model was not suitable for the study of CTL mediated DC elimination. Altogether, on 
the basis of these results it was not possible to conclude on a role of T cell derived perforin in 
regulating DC survival in vivo. It is likely that other experimental systems may be better suited 
to addressing this question. 
 
As discussed in Chapter 1, there is evidence suggesting that memory CD8+ T cells can kill 
DC, while naïve T cells are unable to do so. Thus secondary immune responses were induced 
to determine whether memory CD8+ T cells killed DC, using the two model systems studied in 
this thesis. The advantage of the influenza A virus infection is that there is a well established 
method for eliciting a secondary influenza-specific immune response (354, 355, 357). The 
results from these secondary influenza infection experiments revealed that, compared to 
C57BL/6 mice, PKO mice generated specific CD8+ T cell response that were not greater, or 
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were even smaller, than the responses in C57BL/6 mice. This was surprising considering that 
data published during the course of this study showed that, during a secondary influenza 
infection, the numbers of DC presenting influenza antigen in the MLN are much larger in 
PKO mice than C57BL/6 mice (156). These data are at odds with the observation reported in 
this thesis that the Db-NP366-374+CD8+ T cell response in peripheral blood was in fact reduced 
in PKO mice. Recent publications have reported that release of granzyme A by CTL induces 
the production of pro-inflammatory cytokines (444), which could lead to immunopathology. 
Granzyme A would be expected to be released in greater amounts in PKO mice, as a 
consequence of increased antigen presentation. This pro-inflammatory response could result in 
poor T cell proliferation and survival, and reduced expansion. Additionally, as a result of 
increased antigen presentation in PKO mice there is likely to be increased IFN-γ production, 
which is important for antigen-specific CD8+ T cells homeostasis (338) and could also play a 
part in the decreased T cell response observed in PKO mice during a secondary influenza 
infection. To assess whether enhanced immunopathology or increased IFN-γ plays a role in 
the reduced T cell response observed in PKO mice immunohistological staining of the lung 
tissue could be carried out and serum levels of IFN-γ could be examined. Taken together, 
these data indicate that, during an influenza virus infection, increased antigen presentation by 
DC does not correlate with an enhanced influenza-specific CD8+ T cell response, and may 
even result in reduced responses possibly through increased inflammation and 
immunopathology.  
 
Unfortunately, efforts to generate a secondary ova-specific CD8+ T cell response using the α-
GalCer and ova model were unsuccessful, and no information could be obtained on whether 
perforin regulates DC survival and T cell immune responses in this system.  
 
Studies in PKO mice demonstrate that the perforin pathway is involved in defence against 
viral pathogens and transformed cells (236). Perforin was also shown to be important in 
controlling immune responses in several experimental systems (339, 375, 378, 445-447). In 
support of these studies, the human disorder Familial Hemophagocytic Lymphohistiocytosis 
(FHL), which is caused by mutations in perforin and the perforin/granule pathway (341, 448), 
is characterised by uncontrolled expansion of antigen-specific CD8+ T cells and macrophages, 
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and a fatal outcome (341). An FHL-like syndrome is observed in PKO mice infected with 
LCMV (339). The lymphoproliferation observed in FHL patients and PKO mice infected with 
LCMV may be due to increased DC survival, resulting in continuous antigen presentation to T 
cells (153, 155, 336). Hemophagocytic syndromes are associated with a viral trigger (449), 
and the requirement of perforin for clearance of LCMV raises the question of whether the 
observed lymphocyte expansion in FHL patients and PKO mice is due to an inability to clear 
the infectious agent itself. Support for this view comes from a study that used VSV, which 
does not require perforin for viral clearance, and found that C57BL/6 and PKO mice generated 
similar T cell responses (379), suggesting that enhanced immune responses observed by others 
(339) is due to the requirement for perforin in viral clearance. Similarly, the findings in this 
thesis and by others (372), demonstrated that PKO mice infected with influenza virus did not 
have enhanced CD8+ T cell responses compared to WT. Nevertheless, it seems that the 
lymphoproliferation observed in the absence of a functional perforin/granule pathway cannot 
simply be a consequence of increased viral load, as PKO mice injected with peptide antigen 
under limiting conditions also showed enhanced T cell responses (155, 378). These 
discrepancies in T cell expansion between model systems might be linked to defects in 
perforin expression in other cell populations such as T regulatory (T reg) cells and NK cells. 
However, there is no evidence to indicate that defects in T reg cells affect T cell expansion in 
PKO mice injected with peptide antigen under limiting conditions (155), and it is not likely 
based on the similar rate of viral clearance between PKO and C57BL/6 mice that deficiency in 
perforin expression in either T reg or NK cells would affect immune responses during an 
influenza infection. Taken together there is evidence to suggest that perforin has an important 
role as an effector molecule in the clearance of certain viral infections, but as well there is data 
to suggest that perforin also has an immunoregulatory function. Thus, it is not yet fully 
understood the extent of the role perforin plays in immune responses. However, the ability of 
perforin to elicit its immunoregulatory function seems to depend on the nature of the stimulus, 
including pathogen virulence or strength of stimulation, and these requirements appear to 
differ between FHL patients and PKO mice. Though, the variation between FHL patients and 
PKO mice might reflect the clean environmental conditions the mice live in or be due to the 
immunologic differences between mouse and human. 
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In this thesis, the loss of splenic CD8+ DC that was observed in the presence of activated NKT 
cells did not depend on perforin expression. This was in contrast to the in vitro assays that 
have demonstrated that human NKT cells can kill DC (150, 151, 296, 310) and tumour cell 
lines (152, 313-315, 323) in a perforin-dependent manner (310, 312-315). However, perforin 
is differentially expressed in human NKT cell subsets with CD4- NKT cells expressing higher 
levels of perforin than CD4+ NKT cells (235). CD4- NKT cells are also less activated based on 
cell surface expression of CD69 and CD25 compared with CD4+ NKT cells (Nina Dickgreber, 
personal communication). These results are consistent with recent human studies 
demonstrating that the CD4 co-receptor is important for NKT cell activation and cytokine 
production (450, 451). Thus, these results suggest that NKT cells affect DC survival in vivo in 
a perforin-independent manner, which could be due to the differential expression of perforin 
in the NKT cell subsets.   
 
Published evidence suggests that CTL can regulate DC survival by perforin (155, 156). 
However, CTL and NKT cells also express molecules such as FasL and TRAIL that are also 
involved in mediating death of target cells (152, 225, 317, 318, 452). Recently, studies using 
mice that specifically lacked Fas expression on DC showed that Fas-FasL mediated killing of 
DC is an important regulatory mechanism to prevent systemic autoimmunity (453). This was 
consistent with a previous report showing that systemic autoimmunity develops in transgenic 
mice where DC accumulated due to a defect in apoptosis (164). In addition, it has been 
demonstrated that influenza-specific CD8+ T cells utilise TRAIL to mediate the death of 
influenza infected cells (454). DC killing was not directly assessed but it is possible that CTL 
could kill DC in a TRAIL specific manner. As well as other receptor-mediated cell death 
mechanisms, CTL and NKT cells also secrete the cytokine TNF-α, which is known to induce 
cell death (427). Consistent with this, studies in this thesis revealed that in the presence of 
NKT cell activation, TNF-α mediated the selective loss of the CD8+ DC. However, although 
other mechanisms could be used to regulate DC survival, there is clear evidence that perforin 
plays an important role in DC survival during an influenza infection (156). Thus, DC can 
potentially be eliminated through multiple pathways but it appears that the predominant 
pathway used to eliminate DC varies between different immune responses. 
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DC killing may be one active means of controlling and regulating the magnitude of immune 
responses, however, alternative mechanisms exist. T cells express CTLA-4 upon activation, 
which binds to CD80/CD86 on DC. Signalling through CTLA-4 blocks T cell proliferation 
and cytokine production (109, 112, 117). Activation of T cells also leads to co-expression of 
the death receptor Fas and its ligand, FasL, resulting in activation induced cell death, via 
neighbouring T cells or DC (455). T reg cells may act directly on DC to prevent antigen 
presentation and cause incomplete activation of T cells. T reg cells may also be able to directly 
suppress T cell activity (456). Multiple T cell subsets can exert negative immunoregulatory 
functions by producing immunomodulatory cytokines such as IL-10 and TGF-β. In support of 
this, CD4+ and CD8+ T cells were recently shown to produce IL-10 during an influenza 
infection. IL-10 is thought to act directly on CD4+ and CD8+ T cells to dampen the immune 
response and reduce lung inflammation (457). Any of these mechanisms might be acting to 
prevent increased T cell proliferation in influenza infected PKO mice. 
 
DC are being used as the basis of anti-cancer vaccines, however, after multiple clinical trials 
only a small number of positive clinical outcomes have been observed (167, 168, 170). The 
aim of DC vaccine strategies is to improve anti-cancer T cell responses. As discussed in 
section 1.1.5.2, prolonging the survival of DC has been demonstrated to increase T cell 
responses (144, 157-162). However, extended DC survival has also been correlated with 
systemic autoimmunity (163, 164). Data in Chapter 3 also revealed that in situations where 
increased DC survival was reported (156) an enhanced T cell response does not always occur. 
This would suggest that ensuring the survival of the DC vaccine is important (170) but not 
enough to guarantee that the corresponding T cell response will be improved. Therefore, 
understanding which other mechanisms may be acting to limit the size of the T cell response 
will be an important goal of future studies. Together with an understanding of the mechanisms 
that regulate the size of the T cell response, other aspects of DC biology need to be the focus 
of DC vaccine research to enable the next generation of DC vaccines to be more effective. 
Results in chapter 4 and 5 indicate that DC subsets behave differently to certain stimuli, 
consequently it is likely that the DC subset used for anti-cancer vaccines is important. 
Furthermore, as mentioned in chapter 1, migration to the LN and the activation status of 
injected DC is critical to the generation of an effector CD8+ T cell response. Thus, with further 
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research into these areas of DC biology it is hopeful that a successful DC vaccine will be 
produced in the near future.  
 
In recent years the NKT cell ligand α-GalCer has been used as an adjuvant in clinical trials in 
conjunction with DC vaccines as an anti-cancer treatment (458-462). Similar to DC vaccines 
without an adjuvant, the addition of α-GalCer in the vaccine regime has generated few 
positive clinical outcomes (463). The DC-NKT cell interaction is central to the adjuvant 
effects of α-GalCer. Studies in this thesis provide further insights into the physiology of DC 
during the immune response to α-GalCer. It was found that after α-GalCer treatment CD8+ 
DC, which are important for CD8+ T cell responses, were selectively lost. Nevertheless, loss 
of CD8+ DC did not prevent an antigen-specific CD8+ T cell response being generated. Thus, 
while the precise consequence of the loss of CD8+ DC requires further characterisation, this 
should not prevent the use of α-GalCer as a powerful adjuvant for cancer immunotherapies. 
 
Overall, it appears that multiple cell types, such as CTL and NKT cells, regulate the duration 
of antigen presentation, through several mechanisms including perforin- and cytokine-
dependent pathways. Depending on the model studied, the duration of antigen presentation 
may have a profound effect on the T cell response elicited. Furthermore, the studies conducted 
in this thesis highlight the need to use the appropriate in vivo experimental models to gain a 
greater understanding of the cell types that regulate DC survival and antigen presentation.  
 
 
6.1 Summary  
The major findings reported in this thesis can be summarised as follows: 
 
• C57BL/6 and PKO mice generated similar frequencies of antigen-specific CD8+ T 
cells during a primary influenza infection.  
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• C57BL/6 and PKO mice generated different frequencies of antigen-specific CD8+ T 
cell during a secondary influenza infection.  
 
• T cell exhaustion, evaluated as expression of the marker KLRG1, did not explain the 
diminished antigen-specific CD8+ T cell response in PKO mice during a secondary 
influenza infection.  
 
• Treatment with the NKT cell ligands α-GalCer and OCH induced a transient loss of 
splenic CD8+ DC, which was dose dependent and correlated with the induction of DC 
activation. 
 
• The loss of CD8+ DC in α-GalCer treated mice did not require expression of perforin, 
Fas or IFN-γ, but was prevented by treatment with an anti-TNF-α neutralising 
antibody, indicating that TNF-α played a role in CD8+ DC loss.  
 
 
Taken together, these results suggest that increased DC survival does not necessarily correlate 
with an increased T cell response. Thus there appears to be a fine balance between DC 
survival, increased T cell responses and immunopathology with many factors influencing the 
ultimate outcome of the host immune response.  
 
In addition, this thesis also showed that NKT cells play a role in the regulation of DC survival 
in vivo, which is at least in part mediated by the production of the cytokine TNF-α. 
Furthermore, the different splenic DC subsets are differentially regulated with the CD8+ DC 
being more susceptible to NKT cell mediated reduction than the CD8- DC subset. These 
findings provide additional knowledge about the regulation of DC survival and will hopefully 
assist in improving DC vaccines in the future.  
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6.2 Future Directions 
The work described in this thesis has raised a number of questions that will require detailed 
experimentation to be resolved.  
 
The experiments in Chapter 3 revealed that during a secondary influenza infection PKO mice 
had a significantly reduced CD8+Db-NP366-374+ T cell response compared to C57BL/6 mice. 
This result was inconsistent with the increased DC survival and hence antigen presentation 
observed by others (156). Expression of KLRG1 was investigated to assess whether the T cells 
in the PKO mice were exhausted and terminally differentiated, but no significant difference 
was found between PKO and C57BL/6 mice. As well as KLRG1 there are many other markers 
that have been associated with T cell exhaustion and a terminally differentiated phenotype, 
such as PD1 (385). Therefore investigation into the expression level of other markers on 
influenza-specific CD8+ T cells in C57BL/6 and PKO mice may reveal phenotypic differences 
that affect the functional capacity of the cells, possibly accounting for the observed difference 
in the expansion of influenza-specific CD8+ T cells in C57BL/6 and PKO mice during a 
secondary influenza infection.  
 
CD8+ DC appear to have a specialised role in viral immunity (416) and are the only DC subset 
that can induce the proliferation of memory CD8+ T cells during an influenza infection (464). 
Consequently, selective elimination of CD8+ DC during infections could be a mechanism to 
regulate memory T cells expansion thereby reducing immunopathology and limiting T cell 
expansion. It would therefore be of interest to determine if memory influenza-specific CD8+ T 
cells, which have been shown to eliminate DC (156), selectively eliminate a specific DC 
subset in the influenza model. These experiments would provide additional insights into DC 
elimination by memory CD8+ T cells as a mechanism of immune regulation. 
 
During this study the generation of a secondary ova-specific CD8+ T cell response was 
attempted, to address the question of whether CTL kill DC in a non-infectious setting. 
Unfortunately a secondary ova-specific CD8+ T cell could not be successfully generated using 
the experimental model chosen. It would be of interest to investigate this question using an 
different method. Another model system shown to generate an effective secondary ova-
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specific CD8+ T cell response, is the use of ova protein followed by recombinant vaccinia 
virus expressing full-length ova protein. Experiments using this model to assess a secondary 
ova-specific CD8+ T cell response could provide information on the role of CTL elimination 
of DC other than in the murine influenza A virus model used here. 
 
A possible avenue for future research is to elucidate the role membrane bound TNF in the 
decline of CD8+ DC after treatment with α-GalCer. As discussed in Chapter 5, mTNF has 
cytotoxic effects and could also be involved in the loss of the CD8+ DC after α-GalCer 
treatment. To evaluate the contribution of mTNF and sTNF in the loss of CD8+ DC after α-
GalCer treatment, knockout mice of each form of TNF could be used. Furthermore, it would 
be of interest to determine the cellular source of the TNF that mediates the loss of CD8+ DC, 
and to assess if CD8+ DC express higher levels of TNFR compared to CD8- DC, resulting in 
increased sensitivity to TNF-α after α-GalCer treatment. These results would provide 
additional information about the mechanism of the loss of CD8+ DC after α-GalCer treatment. 
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